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Abstract 
 
Over 10 million people in the UK suffer from allergic rhinitis. The majority have 
symptoms caused by grass pollen exposure. Phl p 1 and Phl p 5 are the major grass 
pollen allergens in Timothy grass (Phleum pratense). Specific grass pollen 
immunotherapy using whole extract is an effective disease-modifying treatment, but it 
is associated with severe, life-threatening systemic IgE-mediated side-effects. One 
strategy to improve safety and clinical efficacy is to develop peptide immunotherapy for 
grass pollen allergy.  
 
The aim of this thesis was to identify HLA-DR1-restricted CD4
+
 T cell epitopes of Phl 
p 1 and Phl p 5 by complementary approaches of epitope mapping: in silico prediction, 
tetramer guided epitope mapping and human HLA-DR1 transgenics. I investigated 
recognition of HLA-DR1-restricted CD4
+
 T cell epitopes in allergic and non-allergic 
individuals and characterised epitope-specific CD4
+
 T cells, according to cell surface 
markers and cytokine production. 
 
HLA-DR1 transgenics were primed with either Phl p 1 or Phl p 5b protein and the T cell 
lines generated were screened using a panel of overlapping peptides in 
3
H-thymidine 
incorporation assays. HLA-DR1-tetramers loaded with Phl p 1 or Phl p 5b peptides 
were used in tetramer guided epitope mapping studies using PBMC from HLA-DR1
+
, 
grass-allergic, seasonal allergic rhinitis patients. Tetramer-positive populations were 
detectable in PBMC of >75% of patients studied. Epitope-specific CD4
+
 T cells were 
detectable immediately ex vivo in allergic and non-allergic individuals. Data suggest 
that epitope-specific CD4
+
 T cells from allergic individuals exhibit an effector memory, 
Th2-like phenotype.  
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This study identified HLA-DR1-restricted CD4
+
 T cell epitopes for Phl p 1 and Phl p 5b 
and characterised epitope-specific CD4
+
 T cell responses. The epitopes identified may 
be used in peptide-based vaccines for grass pollen immunotherapy. 
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1. Introduction 
1.1. Allergy and allergic disease 
Allergic rhinitis, atopic asthma, atopic eczema, food allergies and anaphylaxis are 
collectively amongst the commonest causes of chronic disease in the developed world 
(Galli et al., 2008). Originally the term “allergy” was by adopted by von Pirquet to 
describe the concept of “changed reactivity” occurring when the immune system 
recognises foreign material but is unable to distinguish between protective immunity 
and destructive hypersensitivity (Kay, 2006). Today, however, the term is more widely 
used to describe the clinical manifestation of immunoglobulin (Ig) E-mediated 
hypersensitivity (Kay, 2001). Allergic diseases arise due to an abnormal immune 
response directed against allergens. Allergens are usually soluble proteins derived from 
ubiquitous environmental substances such as grass and tree pollens, animal danders, 
house dust mite faecal particles, foods, latex and insect venoms, although sensitisation 
may occur to non-proteinaceous substances such as drugs (Galli et al., 2008). IgE 
sensitisation, known as atopy, is necessary but not sufficient for the expression of 
allergic disease. Atopy shows a strong element of heritability and not all individuals 
exposed to an allergen (which may be ubiquitous in the environment) will mount an IgE 
response (Kay, 2001). However, in addition to genetic predisposition, environmental 
factors also play a major factor in the development of atopy. Environmental factors may 
include the route, timing and level of allergen exposure or co-factors such as microbial 
components (which may be protective) or pollutants. Many of these factors are now 
believed to impact at the level of the dendritic cell during initial immune sensitisation to 
allergen (Galli et al., 2008). Allergic responses in vivo may be categorised into three 
chronological phases: 1) the early phase, induced within minutes of allergen exposure, 
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2) the late phase, manifesting several hours after allergen exposure and 3) chronic 
allergic inflammation where inflammation persists due to repeated allergen exposure 
(Galli et al., 2008).  
 
1.2. Allergic rhinitis 
Allergic rhinitis is the most prevalent of the allergic disorders, affecting up to 25% of 
the Western population (Bousquet et al., 2008). It is characterised by an IgE-mediated, 
type 1 hypersensitivity reaction in the nose, in response to aeroallergens such as house 
dust mites, pollens, moulds and animal danders. Allergic rhinitis is characterised by 
rhinorrhoea, nasal obstruction, itch, sneeze and ocular symptoms (Bousquet et al., 
2008). Symptoms occur within minutes of allergen exposure with some patients 
exhibiting additional late phase nasal symptoms 4-24 hours post exposure (Durham, 
1998). Allergic rhinitis is often associated with asthma, conjunctivitis, rhinosinusitis and 
otitis (Bousquet et al., 2001; Nathan, 2007). Initially defined as „perennial‟ or „seasonal‟ 
according to the temporal pattern of symptoms experienced, allergic rhinitis has been 
reclassified based upon the severity and duration of symptoms as part of the Allergic 
Rhinitis and its Impact on Asthma (ARIA) initiative (Bousquet et al., 2001). Allergic 
rhinitis symptoms in sensitised individuals induced by grass, tree or weed pollens are 
found in approximately one quarter of the UK population (Bauchau and Durham, 2005).  
Allergic rhinitis can be associated with reduced quality of life and has major socio-
economic implications due to medication costs together with lost work and school days 
(Bousquet et al., 2001; Nathan, 2007; Meltzer and Bukstein, 2011). 
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1.3. Grass 
1.3.1. Classification and distribution 
Grass pollen is a major airborne allergen believed to account for up to 40% of extrinsic 
allergic disease (D‟Amato et al., 2007). More than 2000 grass species have been 
identified within the Poaceae family of flowering plants (Jaeger, 2008), of which 
approximately 20 have been linked with IgE sensitisation, particularly those within the 
Pooideae subfamily (Andersson and Lidholm, 2003; Mohapatra et al., 2005; Jaeger, 
2008). Pooideae species are widely distributed across Europe, although the local 
prevalence varies according to temperature, humidity conditions and soil composition 
(Jaeger, 2008). A number of such species are distributed across the UK and are 
associated with IgE sensitisation in grass allergic subjects (Figure 1.1). However, the 
relative contribution of each species to the airborne grass pollen burden and allergic 
disease in the UK is unknown. 
  27 
 
Timothy 
(Phleum pratense)
Smooth Meadow 
(Poa pratensis)
Cock’s-Foot 
(Dactylis glomerata)
Bermuda 
(Cynodon dactylon)
Meadow Fescue 
(Festuca pratensis)
Yorkshire Fog 
(Holcus lanatus)
Sweet Vernal 
(Anthoxanthum odoratum)
Perennial Rye 
(Lolium perenne)
 
Figure 1.1: The distribution of grass species within the United Kingdom. 
The UK distribution of common grass species associated with IgE sensitisation. Data 
were obtained from the National Biodiversity Network (http://data.nbn.org.uk). Each 
square represents 10 km area where the species is present. 
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1.3.2. Grass pollen 
Grasses rely on wind pollination for reproduction, releasing large quantities of pollen 
grains to be dispersed over wide areas (Andersson and Lidholm, 2003; Jaeger, 2008). 
Pollen grains from Pooideae exhibit a similar morphology thus making microscopic 
differentiation between them impossible (Peltre et al., 1987). The pollen grains have a 
small diameter (15-55 µm), are spheroid to ovoid in shape, with a single circular pore 
surrounded by a thickening of the outer and inner walls and are enveloped by a thin 
lipoid structure (Figure 1.2) (Jaeger, 2008). Grass pollen release is seasonal and 
regulated by temperature, humidity and luminosity (Jaeger, 2008). In the UK, the grass 
pollen season occurs between May and August, with exact timing of the peak showing 
some degree of annual variation (Figure 1.3). During this time pollen grains from 
different species are believed to be present in the air at high concentrations. 
Concomitant exposure to multiple species is therefore inevitable and onset of symptoms 
cannot be attributed to pollen release from individual species. 
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Figure 1.2: Scanning and transmission electron microscopy images of Phleum 
pratense grass pollen grains. 
A) Scanning electron micrograph of a Phleum pratense grass pollen grain, taken from 
(Diethart et al., 2007).  B) Transmission electron micrograph of the cross section of a 
dehydrated Phleum pratense grass pollen grain. Original magnification x2100, bar = 5 
µm. E, exine; I, intine; P, polysaccharide particle; ST, starch, taken from (Grote et al., 
1994). Copyright for images obtained from publishers.  
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Figure 1.3: Pollen index, London Summer 2007. 
Pollen counts for London 2007 (reproduced with kind permission of Professor J 
Emberlin at The National Pollen and Aerobiology Research Unit, University of 
Worcester). Counts are displayed as a „pollen index‟ which was calculated as the pollen 
count/5. The pollen count itself is the average of the number of certain types of pollen 
grains per cubic metre of air sampled in a 24 hour period.  
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1.3.3. Grass pollen allergens 
Charles Blackley first identified grass pollen as the causal agent of hay fever in 1873. In 
addition he undertook a series of experiments establishing a link between environmental 
pollen counts and the severity of hay fever symptoms (Comtois, 1995). Grass pollen 
allergens include a number of proteins rapidly released from pollen grains upon 
hydration (Vrtala et al., 1993a; Grote et al., 1994, 2000; Esch, 2008). Allergens can be 
grouped according to protein sequence and biochemical similarities. Currently, 13 
different groups have been defined (Andersson and Lidholm, 2003; Mohapatra et al., 
2005; Esch, 2008), with each group comprising a number of highly homologous and 
immunologically cross-reactive isoforms known as isoallergens. Isoallergens are 
proposed to exist as a result of either multiple gene products or post-translational 
modifications such as glycosylation or removal of sections of the polypeptide chain or a 
combination of both (Andersson and Lidholm, 2003).   
 
Allergen groups may be classified as „major‟ or „minor‟ with major allergens defined to 
bind IgE in greater than 50% of sensitised individuals (Alvarez-Cuesta et al., 2006). 
Furthermore, major allergens induce high specific IgE titres in the allergic populations 
and are present in a high concentration within the allergen source (Hrabina et al., 2008). 
Group 1 and group 5 are the major allergen groups and have been shown to dominate 
the immunological response to grass pollen extract. Using a range of 
immunoelectrophoretic techniques, SDS-PAGE immunoblot and luminescence 
immunoassay inhibition experiments the Phleum pratense group 5 allergen, Phl p 5, 
was isolated and characterised (Matthiesen and Løwenstein, 1991). Phl p 5 was shown 
to account for approximately three quarters of the Phleum pratense-specific IgE within 
a grass serum pool and comprises two isoforms with different molecular sizes but 
similar immunochemical properties (Matthiesen and Løwenstein, 1991). The Group 1 
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Phleum pratense grass pollen allergen, Phl p 1, was also identified and characterised 
from Phl p 5-depleted Phleum pratense extracts and shown to comprise a number of 
immunologically similar isoallergens (Petersen et al., 1993). The overwhelming 
majority of grass pollen allergic subjects show IgE reactivity to Phl p 1 and/or Phl p 5 
(Valenta et al., 1992; Laffer et al., 1994b; Vrtala et al., 1993b). The majority of studies 
of T cell responses to Phleum pratense allergens have also focussed on Phl p 1 and/or 
Phl p 5 allergens (Schenk et al., 1995; Müller et al., 1998b; Würtzen et al., 1999a, 
1999b; Oseroff et al., 2010). Due to sequence and structural similarities amongst grass 
species, considerable IgE and T cell cross-reactivity is observed between grass pollen 
isoforms and species (Müller et al., 1998b; Würtzen et al., 1999a, 1999b). 
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1.4. Allergic disease in the context of allergic rhinitis 
1.4.1. Allergen sensitisation 
Sensitisation to inhalant allergens like grass pollen is believed to occur as a result of 
respiratory mucosal exposure. Following inhalation, allergen from airborne allergenic 
particles is sampled from the airway lumen by dendritic cells. Allergen may enter into 
tissue through disrupted epithelium or perhaps through the inherent protease activity 
common to many allergens that cleaves epithelial cell tight junctions (KleinJan, 2011). 
Following allergen uptake, mature dendritic cells migrate to the draining lymph node 
where they present allergen-derived peptide in the context of major histocompatibility 
complex (MHC) molecules to naïve T cells (Godthelp et al., 1996; KleinJan et al., 2006; 
KleinJan, 2011). T helper (Th) 2 cells may develop from naïve T cells if allergen 
recognition occurs in the presence of interleukin (IL)-4 derived from other T cells, mast 
cells, basophils, eosinophils or natural killer (NK) T cells. The Th2 phenotype is 
defined by production of IL-4, IL-5 and IL-13 together with expression of the 
chemokine receptors, C-C Chemokine Receptor (CCR) 4, CCR3, CCR8 and 
Chemoattractant receptor‐homologous molecule expressed on Th2 lymphocytes 
(CRTh2) (Sallusto et al., 1997, 1998; Bonecchi et al., 1998; D‟Ambrosio et al., 1998; 
Nagata et al., 1999). There is a large body of evidence from human studies to support 
the presence of Th2 cells in allergic disease (Durham et al., 1992; Ying et al., 1993, 
1994; Kay et al., 1995). 
 
IgE production by B cells is dependent on immunoglobulin class-switch recombination, 
involving initial induction of ε-germline gene transcription and subsequent gene 
rearrangement. These events are dependent on the presence of IL-4 and IL-13, together 
with ligation of B cell surface CD40 (Punnonen et al., 1997). Secreted IgE enters the 
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circulation and is distributed systemically. In tissue, IgE binds to the high affinity 
receptor (FcεRI) expressed on mast cells resulting in their “sensitisation” (Yamaguchi et 
al., 1999).  
 
1.4.2. The allergic response 
1.4.2.1. Early phase response 
In IgE-sensitised individuals, re-exposure to allergen results in allergen-mediated IgE 
cross-linking and aggregation/activation of FcRI on mast cells and basophils. FcεRI-
mediated signalling results in the rapid secretion of inflammatory mediators through 
degranulation, with release of preformed mediators such as vasoactive amines, 
proteoglycans, proteases and cytokines (e.g. IL-4) and, additional de novo synthesis of 
lipid-derived mediators such as leukotrienes and prostaglandins (Galli et al., 2008). 
Secretion of these mediators gives rise to acute allergic symptoms due to vasodilation, 
increased vascular permeability, contraction of smooth muscle and mucus 
hypersecretion.  
 
1.4.2.2. Late phase response  
IgE-mediated signalling also results in synthesis of cytokines, chemokines and growth 
factors due to gene transcription. These are released more slowly than preformed 
mediators and recruit other immune cells such as T cells, eosinophils, neutrophils and 
monocytes either directly or indirectly. This cellular influx and activation gives rise to 
tissue inflammation and signifies the transition to the late-phase response occurring 
approximately 6-12 hours after initial allergen exposure. Analysis of nasal biopsies 
obtained after nasal allergen challenge has demonstrated that T cells and eosinophils 
dominate the cellular infiltrate (Varney et al., 1992). 
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1.5. T cells 
1.5.1. Overview 
T cells constitute approximately 70% of the total lymphocyte population. Recognition 
of antigen and subsequent activation of T cells occurs via the T cell receptor (TCR). 
Distinct T cell lineages may be defined according to TCR expression, with the majority 
of T cells expressing the αβ TCR (~95%). Such T cells are human leukocyte antigen 
(HLA)-restricted, recognising antigen in the form of peptide bound to HLA molecules, 
class I and class II. Surface CD8 or CD4 expression further delineates αβ T cells: CD8+ 
cells recognise antigen-derived peptides bound to HLA class I and exhibit a cytotoxic 
function.  In contrast, CD4
+
 helper cells recognise antigen-derived peptides bound to 
HLA class II and facilitate B cell antibody production, enhance CD8
+
 T cell cytotoxicity 
and regulate the function of other immune cells. A smaller population of T cells 
expressing the γδ TCR (<5%) are non-classical MHC-restricted and have a role in 
immune surveillance of microbial and non-microbial tissue stress.  
 
1.5.2. T cell development 
T cells are derived from haematopoietic stem cells but undergo maturation in the unique 
microenvironment of the thymus. The essential role of the thymus in T cell 
development is exemplified by complete DiGeorge anomaly patients, in whom 
congenital absence of the thymus results in a complete lack of T cells (Markert et al., 
1998; Hong, 2001). Additionally, in mice, neonatal thymic ablation leads to T cell 
deficiency that can be rescued upon transplantation of allogeneic thymus tissue (Miller, 
1962). 
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Haematopoietic stem cells expressing lymphoid-specific genes produce thymocytes 
when injected directly into the thymus (Allman et al., 2003; Schwarz et al., 2007). 
Thymic colonisation by these progenitors is dependent on cell surface expression of 
CCR7, CCR9 and P-selectin glycoligand-1 (PSGL-1) (Rossi et al., 2005; Schwarz et al., 
2007; Zlotoff et al., 2010). T cell development follows a number of key differentiation 
stages (Love and Bhandoola, 2011). These occur in specific regions of the thymus and 
are defined by the temporally co-ordinated expression of specific cell surface markers 
that precede the expression of CD4 or CD8 (Lind et al., 2001). Developing T cells do 
not initially express CD4 or CD8 and are thus termed, double negative (DN) 
thymocytes.  As early lymphoid progenitor cells, „DN1‟ thymocytes migrate from the 
corticomedullary junction to the cortex, where they initiate TCR gene rearrangement 
and become „DN2‟ cells (Livák et al., 1999). Commitment to either the αβ or γδ T cell 
lineage is finalised during the „DN3‟ stage following successful V(D)J recombination of 
the TCR β or TCR γ and δ chain genes in the subcapsular zone (Love and Bhandoola, 
2011). Transition to the „DN4‟ stage is dependent upon the expression and signalling of 
the pre-TCR, comprising the rearranged TCRβ chain and a surrogate invariant TCRα 
chain and occurs as the thymocytes re-enter the cortex region (Saint-Ruf et al., 1994; 
Falk et al., 2001). Thymocytes up-regulate expression of both CD4 and CD8 becoming 
double positive (DP) and successful rearrangement of the TCRα chain leads to the 
expression of the clonotypic αβ TCR complex (Love and Bhandoola, 2011). 
 
Following production of a functional αβ TCR complex, the interaction of thymocytes 
with self-ligands expressed by thymic epithelial cells is assessed (Sha et al., 1988; Surh 
and Sprent, 1994). Within the cortex, DP thymocytes expressing TCR that are able to 
recognise self-peptide/HLA complexes that result in low intensity TCR signalling are 
positively selected. This gives rise to a cell population that are able to interact with self 
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HLA. Those DP thymocytes that are positively selected through interaction with HLA 
class I molecules lose CD4 expression to become single positive (SP) CD8
+
 
thymocytes. Conversely those selected through interaction with HLA class II become 
SP CD4
+
 thymocytes. As SP thymocytes migrate through the medulla, those 
demonstrating high affinity TCR interaction with self-peptide/HLA complexes undergo 
negative selection and are deleted from the T cell repertoire by apoptosis. Negative 
selection is crucial in central tolerance and is in part regulated by autoimmune regulator 
(AIRE)-dependent transcription which ensures tissue-specific self antigen expression by 
thymic epithelial cells. Loss of AIRE function in humans and mice is associated with 
severe autoimmune phenotypes (Nagamine et al., 1997; Ramsey et al., 2002). In spite of 
central tolerance, self-reactive T cells may escape negative selection and are detectable 
in the periphery. Additional mechanisms have therefore evolved to help maintain 
peripheral tolerance in spite of the presence of these self-reactive T cells.  
 
Peripheral tolerance collectively describes a number of mechanisms that ensure the 
removal or functional inactivation of self-reactive T cells that failed to be eliminated in 
the thymus by mechanisms of central tolerance (Mueller, 2010). Mechanisms that act 
directly upon self-reactive T cells include 1) T cell ignorance, i.e. the antigen-specific T 
cell is never exposed to antigen e.g. due to antigen sequestration in an immune-
privileged site, 2) induction of anergy, i.e. a state of unresponsiveness to antigen due to 
T cell recognition of antigen in the absence of co-stimulatory molecule signalling or in 
the presence of co-inhibitory molecule signalling, 3) cell death through repetitive 
stimulation of the TCR and activation of apoptotic pathways in a Fas-dependent 
mechanism, and 4) active suppression of autoreactive T cells by regulatory T cells.  
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1.6. Major histocompatibility molecules and antigen processing 
Central to T cell activation is the recognition of antigenic peptides stably bound to the 
peptide-binding groove of MHC molecules or HLA molecules by the TCR. There are 
two classes of HLA molecule; class I, which is expressed on all cells of the body except 
red blood cells. The role of HLA class I is to present endogenous-derived antigenic 
peptides to CD8
+
 T cells (Jensen, 2007). In contrast, constitutive HLA class II 
expression is restricted to professional antigen presenting cells (APCs) which present 
exogenously-derived antigenic peptides to CD4
+
 T cells (Jensen, 2007). Further cell 
types e.g. epithelial and endothelial cells, may induce class II expression following 
stimulation with interferon-γ (IFN-γ), thus enabling antigen presentation during 
inflammatory responses. 
 
In humans, HLA class II molecules (HLA-DR, HLA-DP and HLA-DQ) are encoded by 
genes in the MHC locus on Chromosome 6. The class II genes are highly polymorphic 
with a number of different alleles existing at each locus. The IMGT/HLA database 
currently records 7 DRα, 1,027 DRβ, 44 DQα, 153 DQβ, 32 DPα and 149 DPβ alleles 
(Robinson et al., 2011) resulting in a huge available diversity. Murine class II molecules 
are encoded by the MHC locus or H-2 antigen on Chromosome 17, H-2A (I-A) and H-
2E(I-E).  
 
HLA class II molecules are composed of two non-covalently associated transmembrane 
glycoprotein α and β chains (Brown et al., 1993). The extracellular region of both 
chains comprises two domains, the immunoglobulin-like membrane-proximal domains 
(α2 and β2) and the membrane-distal domains (α1 and β1), which form the peptide-
binding cleft (Brown et al., 1993). The β2 domain has been demonstrated to interact 
with CD4 thereby stabilising the TCR-peptide-HLA interaction (Doyle and Strominger, 
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1987). The peptide-binding cleft is an open-ended, groove-like structure with a β-sheet 
floor and two α helix walls (Brown et al., 1993). The molecular interactions that govern 
binding of peptide to class II molecules has been investigated through evaluation of 
crystallographic structures in combination with characterisation of naturally processed 
peptides known to bind the HLA groove. Peptides bound by HLA class II molecules are 
usually between 12 and 26 amino acids in length although the core binding motif is only 
9 amino acids (Chicz et al., 1992, 1993). Within the core binding motif, amino acid side 
chains from key anchor residues interact with pockets P1, P4, P6 and P9 in the binding 
cleft through hydrogen bonding (Stern et al., 1994). The amino acid interacting with P1 
is closest to the N-terminus of the peptide and is the key anchor residue for effective 
peptide binding to HLA-DR. The polymorphic nature of HLA molecules determines 
their peptide-binding specificities. For HLA class II molecules, the β chain is highly 
polymorphic and the majority of the polymorphic residues locate within the peptide-
binding groove which serves to increase the diversity of peptide binding.  
 
Antigenic peptides presented by HLA class II molecules are of extracellular origin, 
processed via the exogenous pathway of antigen presentation, following their 
internalisation by phagocytosis or endocytosis (Jensen, 2007). These exogenous 
antigens include proteins of extracellular pathogens such as bacteria, viruses and 
parasites as well as environmental proteins such as pollens. Following their 
phagocytosis or endocytosis by the APC, antigenic proteins are degraded along the 
endocytic pathway through the lowering of the pH of endosomes and the action of 
numerous proteolytic enzymes such as cathepsins (Hsieh et al., 2002). 
 
The HLA class II α and β proteins are synthesised and assembled in the endoplasmic 
reticulum (ER) where they also associate with the chaperone protein invariant chain (Ii). 
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Ii stabilises the αβ heterodimer preventing the inappropriate binding of resident ER 
proteins, either processed or newly synthesised, to the peptide-binding groove (Roche 
and Cresswell, 1990). Upon exiting the ER, dileucine-base motifs in the Ii direct the 
αβ/Ii complex through the Golgi complex and Trans-golgi-network to the MHC class II 
containing compartments for antigen loading (Lamb et al., 1991). 
 
In the MHC class II containing compartments, processed antigenic peptides derived 
from exogenous proteins bind to HLA class II. Within the compartments, Ii undergoes 
sequential degradation by various proteases including cathepsin S and L (Bryant and 
Ploegh, 2004) although class II invariant chain peptide (CLIP) remains in the peptide-
binding groove. CLIP dissociation from the αβ heterodimer is catalysed by the HLA 
class II-like protein, HLA-DM, which stabilises the heterodimer and assists in antigenic 
peptide loading (Denzin and Cresswell, 1995). The peptide-HLA class II complex is 
then transported to the plasma membrane via a microtubule network or secreted 
exosomes for presentation to CD4
+
 T cells. Recognition of the peptide-HLA class II 
complex by cognate TCR upon CD4
+
 T cells leads to the formation of an 
immunological synapse and subsequent TCR signalling and T cell activation.   
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1.7. HLA association with allergic rhinitis and allergy 
The TCR receptor has no affinity for antigenic peptides alone and will only recognise 
and respond to antigenic peptides when they are associated with HLA molecules. 
Antigenic peptides are therefore termed, “HLA-restricted” (Zinkernagel and Doherty, 
1997). Often certain HLA alleles can be linked to diseases with specific alleles 
conveying protection or susceptibility (Jones et al., 2006).  
 
A number of studies have examined associations between HLA type and the allergic 
response to grass pollen. For example, Marsh and colleagues reported an association of 
HLA-DR3 and DR5 with the allergic response to Rye grass (Lolium perenne) (Freidhoff 
et al., 1988; Ansari et al., 1989). In contrast, Young and colleagues failed to 
demonstrate association between a positive IgE response to Phl p 5 and HLA type 
(Young et al., 1994). Finally, Boehncke and colleagues reported an association between 
HLA-DQB1*0301 and grass pollen allergy (Boehncke et al., 1998). In summary, the 
results of these studies, when viewed together, are inconclusive.  
 
An alternative approach taken to evaluating the role of HLA in grass pollen allergy has 
involved the study of T cell lines and T cell clones in vitro and the blocking effects of 
monoclonal antibodies directed towards HLA-DR, DP or DQ molecules. However, 
these studies have also yielded variable and inconsistent results. For example, Müller 
and colleagues demonstrated that proliferation of T cell clones from grass-allergic 
individuals in response to natural Phl p 5 could be blocked by addition of anti-HLA-DR 
antibodies, although a dominant HLA-DR haplotype could not determined upon further 
tissue typing of the donors (Müller et al., 1998b). In additional studies identifying Phl p 
5 epitopes, van Neerven and colleagues established that Phl p 5-specific T cells derived 
from 3 donors were variously restricted by HLA-DR, -DP and -DQ (Würtzen et al., 
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1999b). In a recent extensive study of T cell epitopes within Phl p 5, Oseroff and 
colleagues demonstrated preferential HLA-DR restriction of epitopes after blocking the 
individual class II molecules and evaluating T cell line cytokine responses upon peptide 
or whole extract stimulation (Oseroff et al., 2010). Additionally, having identified the 
restricting HLA locus the restricting HLA allele was also defined. However, data were 
highly variable amongst subjects with identified antigenic regions often displaying 
multiple HLA-restrictions (Oseroff et al., 2010). 
 
In summary, the HLA-DR locus has tended to emerge as being more prominently 
involved in presentation of grass pollen allergens than the HLA-DQ or HLA-DP loci. 
However, within the HLA-DR locus no single HLA-DR allele has emerged as 
obviously dominant in T cells responses to grass pollen.  
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1.8. T cell subsets 
Following activation naïve CD4
+
 T cells may differentiate into a number of types of Th 
cells: Th1, Th2, Th9, Th17, Th22 and inducible regulatory T (iTreg) cells. Th subsets 
may be distinguished by both their function and cytokine expression profile. 
 
1.8.1. Th1/Th2 paradigm and relevance to allergy 
In 1986 Mosmann and Coffman proposed that T cell subsets are functionally 
heterogeneous according to patterns of cytokine production (Mosmann et al., 1986). 
Th1 cells are characterised by the predominant expression of IFN-γ together with 
additional cytokines, tumour necrosis factor (TNF)-α, TNF-β and IL-2 (Mosmann et al., 
1986). The role of Th1 cells is most obvious in immunity against intracellular 
pathogens. In man, disruption of the Th1-mediated immune response is associated with 
susceptibility to mycobacterial infection (Newport et al., 1996; de Jong et al., 1998). In 
contrast, Th2 cells are characterised by the co-expression of IL-4, IL-5 and IL-13 
(Coffman and Carty, 1986; Mosmann et al., 1986) and most obviously have a role in 
clearance of helminthic infections (Urban et al., 1991) through mechanisms involving 
induction of IgE and eosinophil recruitment and activation. For example, in mouse 
models, antagonism of IL-4 and IL-5 during nematode infection was associated with 
inhibition of IgE antibody responses and eosinophilia, respectively, and with a failure to 
develop protective immunity (Urban et al., 1991). Amongst the first studies to 
demonstrate Th2 cells in humans was published by Del Prete and colleagues who 
derived Th2 T cell clones specific for the nematode Toxocara canis from healthy 
subjects (Del Prete et al., 1991). At this time, allergen-specific Th2 T cell clones were 
established for the first time from house dust mite sensitised patients with eczema 
(Wierenga et al., 1991). Subsequently, numerous studies performed in well 
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characterised patients with allergic disease demonstrated, using in situ hybridisation, the 
presence of T cells expressing messenger ribonucleic acid (mRNA) for Th2 cytokines in 
biopsies or bronchoalveolar lavage (BAL) taken from the site of disease or allergen 
challenge in allergic but not control subjects (Robinson et al., 1992; Durham et al., 
1992; Ying et al., 1993, 1994; Kay et al., 1995). The effects of Th2 cytokines on 
inflammatory cells relevant to the allergic response are summarised in Table 1.1. 
 
Th subsets may also be distinguished according to their expression of specific cell 
surface antigens, in particular chemokine receptors. The expression of C-X-C 
chemokine receptor (CXCR) 3 and CCR5 has been demonstrated to preferentially 
associate with Th1 cells (Sallusto et al., 1998; Bonecchi et al., 1998; Loetscher et al., 
1998). Whilst CCR3, CCR4, CCR8 and CRTh2 are preferentially expressed on Th2 
cells (Sallusto et al., 1997, 1998; Bonecchi et al., 1998; D‟Ambrosio et al., 1998; 
Nagata et al., 1999). 
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Table 1.1: Cytokines produced by Th2 cells. 
Cytokine Function 
IL-4 Promotes IgE synthesis through initiating B cell class switch
1
. 
Role in mast cell development
2
. 
Activation and recruitment of eosinophils and basophils
3
. 
Induces mucus hypersecretion
4
. 
Positive-feedback loop for Th2 differentiation
5
. 
Increases endothelial VCAM expression
3
. 
IL-5 Promotes differentiation, maturation and activation of 
eosinophils and basophils
6
. 
IL-6 Role in Th2 cell differentiation
7 
Cofactor for IgE synthesis
8 
IL-9 Induces development of mast cells and eosinophils
9
. 
Up-regulates high affinity IgE receptor on mast cells
10
. 
Induces airways hyperreactivity
11 
Induces mucus hypersecretion
12 
Promotes production of IgE
13 
IL-13 Role in Th2 differentiation
14 
Role in mast cell development
15 
Promotes B cell class switch to IgE synthesis
16 
Recruitment of inflammatory cells including eosinophils, 
monocytes and T cells
17 
Induces airways hyperreactivity
18 
Induces mucus hypersecretion
19 
IL-25 Role in Th2 development and subsequent IL-4, IL-5, IL-13 
production
20 
1
 (Pène et al., 1988; Finkelman et al., 1988); 
2
 (Madden et al., 1991); 
3
 (Schleimer et al., 
1992); 
4
 (Temann et al., 1997; Dabbagh et al., 1999); 
5 
(Swain et al., 1990); 
6
 
(Clutterbuck et al., 1989; Bischoff et al., 1990); 
7
 (Rincón et al., 1997); 
8
 (Vercelli et al., 
1989); 
9
 (Hültner et al., 1990; Gounni et al., 2000; Ying et al., 2002); 
10
 (Louahed et al., 
1995); 
11
 (Kung et al., 2001); 
12 
(Louahed et al., 2000); 
13
 (Petit-Frere et al., 1993); 
14
 
(McKenzie et al., 1998); 
15
 (Kaur et al., 2006); 
16
 (Punnonen et al., 1993); 
17
 (Bochner et 
al., 1995; Ying et al., 1997); 
18
 (Walter et al., 2001); 
19
 (Zhu et al., 1999); 
20
 (Fort et al., 
2001). 
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1.8.2. Th cell differentiation  
1.8.2.1. Cytokine-driven differentiation 
A major factor in determining Th cell differentiation is the cytokine milieu at the time 
of antigen encounter. For example, IL-4 and IFN- promote development of human Th2 
and Th1 T cell clones from peripheral blood mononuclear cells (PBMC), respectively 
(Maggi et al., 1992). Studies utilising IL-4 deficient transgenic mouse models have 
further demonstrated the critical role of IL-4 in the generation of an effective Th2 
immune response which is abrogated in deficient animals (Grunewald et al., 1998; 
Kurup et al., 1999; Kühn et al., 1991). IL-12 is a potent inducer of human Th1 
responses and reciprocally inhibits Th2 differentiation (Manetti et al., 1993). Numerous 
other extrinsic factors have been associated with differentiation of human Th2 over Th1 
subsets from uncommitted precursors including low antigen concentration (Secrist et 
al., 1995), APC type (Secrist et al., 1995) and co-stimulatory signals (Brinkmann et al., 
1996). 
 
1.8.2.2.  Role of Transcription factors 
The Th1 master regulator is T-bet, a member of the T-box family of transcription 
factors, and it has been shown to be up-regulated during Th1 differentiation (Szabo et 
al., 2000). Ectopic expression of T-bet activates IFN-γ gene transcription. Furthermore, 
retroviral gene transduction of T-bet into polarised Th2 cells induces a Th1 phenotype 
with concomitant repression of Th2 cytokine expression (Szabo et al., 2000). CD4
+
 T 
cells isolated from T-bet
-/-
 mice demonstrate defective Th1 cell differentiation under in 
vitro polarising conditions (Szabo et al., 2002). Signal Transducer and Activator of 
Transcription protein (Stat) 4 may also have a role in the amplification of Th1 responses 
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since IL-12-mediated signalling is impaired in deficient mice (Kaplan et al., 1996b; 
Thierfelder et al., 1996).  
 
The master regulator for Th2 differentiation is GATA-3 (Zheng and Flavell, 1997). 
GATA-3 and IL-12/Stat4 signalling are mutually antagonistic, with overexpression of 
GATA-3 skewing towards IL-4 production in vitro (Ouyang et al., 1998). In mouse 
knockout models GATA-3 expression is essential for in vitro and in vivo Th2 responses 
(Zhu et al., 2004; Pai et al., 2004). The Stat6 transcription factor is the major signal 
transducer for IL-4-receptor signalling and Th2 differentiation in vitro (Kaplan et al., 
1996a; Takeda et al., 1996). However, in vivo studies utilising Stat6-deficient mice 
suggest that Stat6 signalling may also have a role in the perpetuation and stabilisation of 
Th2 differentiation in addition to initial Th2 development (Jankovic et al., 2000; 
Finkelman et al., 2000). In addition, Stat5, a transcription factor known to be involved 
in mediating IL-2 receptor signalling, may also have a role in Th2 differentiation since 
expression of a constitutively active Stat5a mutant induced IL-4 production when naïve 
CD4
+
 T cells were primed in the absence of IL-2 (Zhu et al., 2003).  
 
1.8.3. Innate lymphoid cells 
Whilst Th2 cells are an important source of Th2 cytokines, innate non-T, non-B cell 
populations have also been identified in the mouse that produce high amounts of Th2-
type cytokines in response to IL-25 (Fort et al., 2001; Hurst et al., 2002; Fallon et al., 
2006).  Recently, four independent research groups have further characterised these 
innate lymphoid cell (ILC) populations termed natural helper cells (NHCs) (Moro et al., 
2010), nuocytes (Neill et al., 2010), innate helper type 2 (Ih2) cells (Price et al., 2010) 
and multipotent progenitor type 2 (MPP
type2
) cells (Saenz et al., 2010).  Although 
differences between these ILC populations exist, they share a common surface marker 
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phenotype being lineage marker negative and c-Kit positive. Furthermore they all 
produce Th2 cytokines, particularly IL-5 and IL-13, in response to either IL-25 or IL-33 
administration or in the context of helminth parasite infection mediating both 
eosinophilia and goblet cell hyperplasia. In an experimental model, allergen-induced 
nuocytes have been shown to infiltrate the inflamed lung and contribute to airways 
hyperreactivity in an IL-13 dependent manner (Barlow et al., 2011). In humans, NHCs 
present in fat-associated lymphoid clusters, similar to those found in mouse, have been 
identified (Moro et al., 2010), together with lung-resident ILCs populations analogous 
to murine NHCs and nuocytes (Monticelli et al., 2011). Furthermore, an enriched novel 
subset of IL-25 and IL-33 responsive, IL-13-producing ILCs expressing CRTh2 have 
been identified in nasal polyps isolated from patients with atopic disease (Mjösberg et 
al., 2011). Together, these observations suggest that a similar mechanism for the 
induction of ILCs in mice and humans and implicate a potential role for Th2 cytokine-
producing ILCs in atopic disease. 
 
1.8.4. Additional Th subsets 
Additional Th effector subsets have also been identified these comprise: Th9, Th17 and 
Th22 cells. Th9 cells, characterised by production of IL-9, differentiate either from 
naïve  CD4
+
 T cells or differentiated Th2 cells in the presence of IL-4 and transforming 
growth factor (TGF)-β (Veldhoen et al., 2008; Dardalhon et al., 2008; Wong et al., 
2010). The immunological role of Th9 cells is yet to be fully elucidated although IL-9 
expression has been linked to airway hyperresponsiveness, mucus hypersecretion and 
mast cell infiltration in murine models of asthma (Cheng et al., 2002; Chang et al., 
2010) and is elevated in the bronchial mucosa of asthmatics (Ying et al., 2002). 
However, the results of experimental studies have not always proved consistent 
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(Temann et al., 1998; McMillan et al., 2002) and the importance of Th9 cells in allergic 
disease remains controversial.  
 
Th17 cells can be induced in vitro from naïve  CD4
+
 T cells in the presence of IL-6 and 
TGF-β (Bettelli et al., 2006; Veldhoen et al., 2006; Mangan et al., 2006), whilst IL-23 
and IL-21 are required for maintaining Th17 cells following their initial differentiation 
(Aggarwal et al., 2003; Langrish et al., 2005; Park et al., 2005; Zhou et al., 2007; 
Nurieva et al., 2007; Korn et al., 2007). This subset is characterised by the production of 
IL-17A and F, IL-21 and IL-22 (Liang et al., 2006; Zhou et al., 2007; Nurieva et al., 
2007; Korn et al., 2007) and surface expression of CCR6 and CCR4 (Acosta-Rodriguez 
et al., 2007).  It has been reported that Th17 cells have a role in mediating resistance to 
infection and are responsible for the induction and propagation of some autoimmune 
processes including experimental autoimmune encephalitis (EAE)/multiple sclerosis 
(Langrish et al., 2005) and collagen-induced arthritis/rheumatoid arthritis (Nakae et al., 
2003). RORγt is the master regulator of Th17 differentiation (Ivanov et al., 2006). 
RORγt is up-regulated in T cells in response to IL-23 stimulation and Th17 cells are 
absent in RORγt-deficient mice (Ivanov et al., 2006). Furthermore, RORγt-deficient 
mice are partially resistant to EAE induction (Ivanov et al., 2006), an autoimmune 
disease in which Th17 cells have been implicated (Langrish et al., 2005; Park et al., 
2005). Increased numbers of Th17 cells have been reported in peripheral blood of both 
allergic rhinitic (Ciprandi et al., 2010) and asthmatic patients (Zhao et al., 2010) as 
compared to healthy controls. Additionally, Th17 cells have been shown to infiltrate the 
asthmatic lung (Pène et al., 2008). In experimental models of allergic asthma have 
demonstrated a role for Th17 cells in allergic inflammation, sensitisation through the 
airway has been shown to induce strong Th17 responses that promote acute airway 
hyperreactivity and airway neutrophilia (Wilson et al., 2009). Furthermore, adoptive 
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transfer of Th17 has been shown to enhance Th2-mediated eosinophilia (Wakashin et 
al., 2008).  
 
Th22 cells were initially identified as a subset of skin-homing T cells characterised by 
production of IL-22 but not IL-17 or IFN-γ and can be differentiated from naïve  CD4+ 
T cells in the presence of IL-6 and TNF-α (Duhen et al., 2009; Trifari et al., 2009; 
Eyerich et al., 2009). Th22 cells have been shown to express chemokine receptors; 
CCR6, CCR4 and CCR10 (Duhen et al., 2009; Trifari et al., 2009). The aryl 
hydrocarbon receptor (AHR) has been proposed as a key transcription factor for Th22 
differentiation since AHR ligation by inhibitors prevented IL-22 production (Trifari et 
al., 2009; Ramirez et al., 2010). Th22 cells have been proposed to enhance wound 
healing and are increased in inflammatory skin diseases including atopic dermatitis 
(Eyerich et al., 2009). The number of IL-22 mRNA
+
 PBMC has been shown to be 
elevated in asthmatics and correlated with disease severity (Farfariello et al., 2011). The 
role of IL-22 in allergic asthma has been investigated by Besnard and colleagues who 
reported an increase in serum IL-22 protein levels in asthmatics as compared to healthy 
controls (Besnard et al., 2011). Furthermore, in a model of ovalbumin (OVA)-induced 
allergic asthma they demonstrated a dual role for IL-22 in allergic inflammation. 
Absence of IL-22 at allergen sensitisation, either in knockout animals or wild type mice 
administered anti-IL-22 neutralising antibodies, diminished OVA-induced airway 
inflammation. Conversely, in established allergic inflammation, neutralisation of IL-22 
during allergen challenge enhanced allergic lung inflammation. Together, this suggests 
that IL-22 is necessary for initiation of allergic inflammation but demonstrates an 
inhibitory function during established disease. Further investigation of the Th22 subset 
is required in human allergic disease (Besnard et al., 2011).   
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1.8.5. Memory cells 
The key characteristic of adaptive immunity is the acquisition of immunological 
memory. Recognition of antigen leads to clonal expansion and differentiation of 
antigen-specific lymphocytes. The effector cell population subsequently contracts, 
giving rise to a population of long-lived memory cells. These memory cells are 
responsible for the rapid initiation of an effective immune response on secondary 
challenge by specific antigen. Memory cells are heterogeneous, comprising at least two 
distinct populations; central memory cells (TCM) and effector memory cells (TEM) 
(Sallusto et al., 1999). TCM cells constitutively express CCR7 and CD62L, which direct 
their migration to secondary lymphoid organs (Campbell et al., 1998; Förster et al., 
1999; Sallusto et al., 1999). Following TCR stimulation, TCM produce IL-2 but not 
lineage specific cytokines such as IL-4 and IFN-γ (Sallusto et al., 1999).  However, TCM 
demonstrate a reduced threshold for TCR triggering and are potent activators of 
dendritic cells (Sallusto et al., 1999). Dendritic cell activation in turn causes TCM to 
proliferate and differentiate into CCR7
-
 effector cytokine producing cells (Sallusto et 
al., 1999). Therefore, TCM represent a population of memory cells that circulate through 
the lymphatic system and undergo clonal expansion upon recognition of antigen. TEM 
cells do not express CCR7 or CD62L (Sallusto et al., 1999), but do express non-
lymphoid homing receptors such as CCR4 and CCR3 that direct migration to sites of 
inflamed tissues (Sallusto et al., 1999). Following TCR stimulation these cells rapidly 
produce effector cytokines such as IL-4, IL-5 and IFN-γ (Sallusto et al., 1999). 
Therefore TEM represent a population of circulating memory cells that upon antigen 
recognition migrate to sites of inflammation and mediate the immune response through 
immediate cytokine release.  
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1.9. Regulatory T cells 
The existence of a population of thymus-derived „suppressor cells‟ was first proposed 
by Gershon and Kondo over 40 years ago (Gershon and Kondo, 1970). Following 
thymectomy, lethal irradiation and bone marrow grafting, mice pre-treated with large 
doses of sheep red blood cells (SRBC) were unable to mount a specific-antibody 
response to subsequent antigen challenge. Furthermore, following administration of 
normal thymocytes, after the initial pre-treatment period, the antibody response could be 
restored (Gershon and Kondo, 1970). However, if mice were reconstituted with 
thymocytes prior to SRBC pre-treatment, subsequent addition of thymocytes was not 
sufficient to re-establish the antibody response upon further antigen challenge. This 
suggested the generation of a population of immunosuppressive thymocytes, capable of 
regulating antigen-specific antibody production by B cells (Gershon and Kondo, 1970). 
Additionally, it was shown that the immunosuppressive effect of thymus-derived cells 
could be transmitted through adoptive cell transfer (Gershon and Kondo, 1971). In 
1972, Gershon and colleagues demonstrated that not only were thymus-derived cells 
capable of suppressing antibody responses but also the responses of other thymocytes, 
presumably T cells (Gershon et al., 1972). The role of thymus-derived cells in the 
prevention of organ-specific autoimmune disease was established in concurrent studies  
(Nishizuka and Sakakura, 1969; Penhale et al., 1973, 1976) Sakaguchi and co-workers 
established that CD4
+
 T cells, rather than CD8
+
 T cells, are able to inhibit thymectomy-
induced autoimmunity (Sakaguchi et al., 1982b). However, it was also observed that 
once autoimmunity had developed, adoptive transfer of CD4
+
 T cells to T cell-deficient 
mice could establish autoimmune disease in these animals (Sakaguchi et al., 1982a). In 
summary, these observations suggest the presence of two opposing types of CD4
+
 T 
cells able to mediate or suppress autoimmune disease, respectively. 
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In 1995 Sakaguchi and colleagues identified CD25 (the IL-2 receptor α chain) as a 
putative marker of CD4
+
 T cells with suppressive activity. Adoptive transfer of 
CD4
+
CD25
+
-depleted T cells to athymic nude mice was shown to induce autoimmune 
disease in a number of organs that was inhibited following reconstitution of the 
CD4
+
CD25
+
 T cell population (Sakaguchi et al., 1995). A role for these CD4
+
CD25
+
 T 
cells, subsequently termed „regulatory T cells‟ (Tregs), was therefore inferred in the 
maintenance of self tolerance and control of immune responses to non-self antigens. It 
is now widely recognised that Tregs represent a diverse population, which can be 
broadly divided into two categories: naturally occurring Tregs (nTregs) or peripherally 
induced, iTregs. 
 
1.9.1. Natural regulatory T cells (nTregs) 
These cells represent a subset of CD4
+
CD25
+
 T cells, that are detectable during 
thymocyte development, representing approximately 5% of mature CD4
+
 thymocytes 
(Itoh et al., 1999; Fontenot et al., 2005): nTreg differentiation requires communication 
between the Tregs and thymic stromal cells, with interactions between both TCR and 
self-peptide/MHC and T cell accessory molecules and their ligands contributing to 
nTreg generation. Expression of forkhead/winged-helix transcription factor box P3 
(FoxP3) subsequent to cell fate determination confers a stable suppressive phenotype 
(Hori et al., 2003; Fontenot et al., 2003).   
 
1.9.2. Inducible Treg (iTreg) 
In the periphery, FoxP3
+
CD4
+
 T cells with regulatory function can be induced from 
naïve CD4
+
CD25
-
FoxP3
-
 T cells. Possible factors that may induce Tregs include the 
cytokine environment at the time of antigenic stimulation, route of antigen exposure and 
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the intensity of stimulation. In vitro stimulation of naïve cells in the presence of TGF-β 
induces FoxP3 gene expression and confers a Treg phenotype on murine CD4
+
 T cells. 
These cells become non-responsive to TCR stimulation and suppress effector CD4
+
 T 
cell cytokine production in vitro and inhibit allergic airway inflammation in vivo 
following adoptive transfer (Chen et al., 2003). Oral administration of antigen is 
associated with an increase in Treg populations in OVA-specific TCR transgenic 
models (Thorstenson and Khoruts, 2001; Zhang et al., 2001; Coombes et al., 2007) and 
experimental models of asthma (Mucida et al., 2005). Thorstenson and Khoruts further 
demonstrated that the dose of antigen influenced Treg induction, with lower doses 
favouring higher numbers of Tregs (Thorstenson and Khoruts, 2001). Finally, 
repetitive/chronic antigenic stimulation may also preferentially induce these cells 
(Anderson et al., 2006).  
 
Additional types of Tregs described include Type 1 regulatory (Tr1) cells and Th3 cells. 
The Tr1 subset of Tregs was first described following chronic stimulation of human and 
murine CD4
+
 T cells in the presence of IL-10 (Groux et al., 1997). Tr1 cells, similar to 
nTregs, can be identified within the CD4
+
CD25
high
 T cell population and proliferate 
poorly to antigen (Groux et al., 1997). However, unlike nTregs they do not 
constitutively express FoxP3 (Vieira et al., 2004). Tr1 cells are defined by production of 
high levels of IL-10 but with low concomitant IL-2 and IL-4 expression (Groux et al., 
1997). The suppressive function of Tr1 cells has been demonstrated in a number of 
studies including; prevention of colitis in murine models of inflammatory bowel disease 
(Groux et al., 1997), prevention of determinant spreading in EAE (Wildbaum et al., 
2002), domination of the immune response to allergen in non-allergic individuals 
(Akdis et al., 2004) and induction of tolerance to transplanted pancreatic islet cells for 
treatment of diabetes in mice (Battaglia et al., 2006). 
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Th3 cells are defined by production of TGF-β production and were initially identified as 
mediating oral tolerance in EAE (Miller et al., 1992; Chen et al., 1994). The exact role 
of Th3 cells remains poorly defined although it has been proposed that they participate 
in maintenance of both nTregs and iTregs in a TGF-β-dependent mechanism (Zhang et 
al., 2006; Weiner et al., 2011).  
 
1.9.3. Molecular markers for Treg identification 
1.9.3.1. Cell surface markers 
CD25 is a marker of T cell activation as well as of Treg populations and is therefore 
insufficient alone to specifically identify these cells. However, numerous other cell 
surface molecules have been proposed as being markers of Tregs populations. These 
include: cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) (Read et al., 2000; 
Takahashi et al., 2000), glucocorticoid-induced tumour necrosis factor receptor family-
related gene (GITR) (McHugh et al., 2002), lymphocyte activation gene-3 (LAG-3) 
(Huang et al., 2004), CD127 (IL-7 receptor α chain) (Seddiki et al., 2006; Liu et al., 
2006) and CD39 (Borsellino et al., 2007). However, accurate surface identification of 
Tregs continues to be hampered by the fact that each of these markers, with the 
exception of CD127, is also associated with T cell activation status.  
 
1.9.3.2. FoxP3 
The critical importance of FoxP3 for Treg differentiation, function and maintenance is 
evident from the human and murine phenotypes associated with deficiency of 
expression. In particular, mutations in the FOXP3 gene give rise to the 
immunodysregulation polyendocrinopathy enteropathy X-linked (IPEX) syndrome, 
comprising type 1 diabetes mellitus, severe enteropathy, eczema, anaemia, 
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thrombocytopenia and hypothyroidism (Bennett et al., 2001; Wildin et al., 2002). 
Scurfy mice, in which the FOXP3 gene is under expressed, also display a similar 
predisposition to severe autoimmune-like disease characterised by hyperresponsive 
CD4
+
 T cells and overproduction of cytokines (Godfrey et al., 1991; Brunkow et al., 
2001). Conversely, retroviral gene transfer and ectopic expression of FoxP3 in naïve T 
cells confers a Treg phenotype (Hori et al., 2003; Fontenot et al., 2003).  
 
1.9.4. Treg function and mechanism 
Tregs suppress proliferation, differentiation and effector function of naïve and 
differentiated CD4
+
 and CD8
+
 T cells in vivo (Tang and Bluestone, 2008). In vitro co-
culture experiments with Tregs and effector T cells have demonstrated Treg-mediated 
suppression of proliferation and cytokine production (Tang and Bluestone, 2008). 
Activated Tregs also have the capacity to act on other T cells irrespective of antigen-
specificity (Takahashi et al., 1998). Tregs mediate suppression through both contact-
dependent and -independent mechanisms including secretion of inhibitory cytokines, 
cytolysis, metabolic disruption and targeting of dendritic cells (reviewed by (Vignali et 
al., 2008)). Inhibitory cytokines produced by Tregs include TGF-β, IL-10 and IL-35. In 
murine models of inflammatory bowel disease, IL-10 production by Tregs mediates 
suppression of colitis (Asseman et al., 1999), whilst in models of asthma, roles have 
been demonstrated for TGF-β and IL-10 in regulating the degree of inflammation 
(Joetham et al., 2007). More recently, production of IL-35 has been shown by Tregs 
(Collison et al., 2007). Exogenous IL-35 has been shown to suppress T cell proliferation 
in vitro whilst ectopic expression in naïve T cells conferred regulatory activity (Collison 
et al., 2007).  
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In addition to cytokine-dependent mechanisms, Tr1 cells can directly induce necrosis of 
effector T cells through granzyme B and perforin-dependent pathways (Grossman et al., 
2004). Although the functional significance of this remains largely unexplored in vivo, 
granzyme B-deficient mice demonstrate some impairment of Treg-dependent 
suppression of tumour immunity (Cao et al., 2007). Tregs can also regulate effector T 
cells indirectly though interaction with APCs. For example, CTLA-4 expressed on the 
surface of Tregs is able to ligate CD80 (B7-1) and CD86 (B7-2) on dendritic cells and 
induce expression of indolamine 2, 3-dioxygenase (IDO). This enzyme metabolises 
tryptophan in dendritic cells into mediators that can induce apoptosis in effector T cells 
(Fallarino et al., 2003). Tregs may also down regulate the expression of costimulatory 
molecules on dendritic cells and prevent their maturation. For example LAG-3 
expressed by Tregs reduces dendritic cell surface expression of HLA class II, thereby 
reducing their ability to activate effector T cells (Cederbom et al., 2000; Misra et al., 
2004; Liang et al., 2008).  Finally, Tregs can express the „ectoenzyme‟ CD39, which 
appears able to antagonise costimulatory molecule expression on dendritic cells and 
subsequent maturation and T cell activation (Borsellino et al., 2007).  
 
1.9.5. Tregs in allergic disease- function and dysfunction 
It has been proposed that that the expression of allergic disease is reflective of a 
fundamental imbalance between allergen-specific pro-allergic Th2 cells and anti-
inflammatory Tr1 cells. Several studies exist to support this concept: for example, 
Akdis and colleagues demonstrated that allergic and non-allergic individuals generate 
allergen-specific Th1, Th2 and Tr1 cells that recognise the same immunodominant 
epitopes but that the immune response to allergen in allergic individuals is dominated 
by Th2 cells in contrast to non-allergic individuals, who show a Treg bias (Akdis et al., 
2004). Ling and co-workers further demonstrated that CD4
+
CD25
+
 T cells inhibit recall 
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responses to grass pollen allergen in non-allergic but not allergic donors (Ling et al., 
2004), and that this difference is accentuated during the pollen season. This effect is 
allergen-specific since seasonal fluctuations in the regulatory function of CD4
+
CD25
+
 T 
cells are apparent only in recall responses to grass pollen but not house dust mite even 
within the same subjects. Moreover, this suppressive effect appears to be more marked 
on production of Th2 than Th1 cytokines (Grindebacke et al., 2004).  
 
Functional impairment within the Treg compartment has also been reported in wasp 
venom allergy (Bellinghausen et al., 2005) although in that study the suppressive effect 
of Tregs from normal individuals was demonstrable only at low antigen concentrations. 
More recently, Han and colleagues investigated the frequencies of nTregs, Tr1, Th1 and 
Th2 cells in the peripheral blood of allergic rhinitic and non-allergic subjects. Although 
the frequency of Tr1 cells was lower in allergic subjects, the frequency of nTregs was 
similar in both groups. Tr1 cells were potent suppressors of recall responses to house 
dust mite in vitro (Han et al., 2010). The mechanism of Tr1 induction in non-allergic 
individuals is likely to involve repetitive exposure to high dose potential „allergens‟. 
Evidence for this comes from studies of non-allergic beekeepers who develop delayed 
cutaneous responses to stings: the size of the cutaneous response diminishes as the 
number of stings received during the season increases. Analysis of peripheral blood T 
cells revealed this „desensitisation‟ was accompanied by a switch from a dominant 
venom-specific mixed Th1/Th2 response to a Tr1-dominant response (Meiler et al., 
2008). This was defined in vitro by the cytokine expression profile of bee venom 
allergen-stimulated PBMC cultures and in vivo by investigation of TCRVβ gene 
clonality (Meiler et al., 2008). The switch to a tolerant phenotype was maintained 
throughout the beekeeping season with effector responses returning to initial levels by 
three months after cessation of allergen exposure (Meiler et al., 2008). Tregs are 
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therefore important regulators of the immune response to allergen and harnessing their 
suppressive activity holds much potential for immune modulation as a therapeutic 
target. In summary, these studies support a key role of Tregs in regulation of the 
immune response to allergens and dysfunction in allergic disease.   
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1.10. Current treatment strategies for allergic rhinitis 
1.10.1. Pharmacotherapy 
Current treatment approaches for allergic rhinitis include a number of 
pharmacotherapies that target the allergic response pathways and serve to counter the 
production or effects of inflammatory mediators. These include, antihistamines (oral 
and topical), corticosteroids (topical or systemic), glucocorticosteroids (oral or 
intramuscular), local chromones, decongestants, anticholinergics and leukotriene 
receptor antagonists (Greiner and Meltzer, 2011; Meltzer and Bukstein, 2011). Whilst 
pharmacotherapies are effective at relieving symptoms in most patients, such treatments 
are not disease-modifying and may be associated with side-effects. Moreover, levels of 
dissatisfaction with conventional with pharmacotherapy are high (Ciprandi et al., 2011). 
However, specific immunotherapy may be considered in patients with moderate/severe 
allergic rhinitis who are poorly controlled by conventional treatment (Walker et al., 
2011) 
 
1.10.2. Allergen-specific Immunotherapy 
Allergen-specific immunotherapy (SIT) was originally described by Noon in 1911, who 
reported that subcutaneous injection of grass pollen extract suppressed allergen-induced 
symptoms. The first randomised control trial of grass pollen immunotherapy was 
carried out at St Mary‟s Hospital by Frankland and Augustin (1954). A century after the 
first description, immunotherapy still represents the only treatment for allergic disease 
which induces allergen-specific clinical and immunological tolerance. In the UK, 
immunotherapy for rhinitis most commonly involves treatment with grass or tree pollen, 
although house dust mite and animal danders are also, less commonly, administered 
(Walker et al., 2011). Conventional immunotherapy involves repeated subcutaneous 
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injection of the offending allergen at fortnightly to monthly intervals, either pre-
seasonally or throughout the year, typically for 3 years (Walker et al., 2011). 
Alternatively, immunotherapy may be administered daily as sublingual dissolvable 
tablets or drops (sublingual immunotherapy; SLIT) an approach that that is associated 
with fewer systemic reactions than subcutaneous immunotherapy (SCIT) (Wilson et al., 
2003). For the treatment of grass pollen allergy, both SCIT and SLIT are associated 
with the reduction of seasonal symptoms, rescue medication requirements and improved 
quality of life. Unlike pharmacotherapies, the clinical efficacy of SIT has been shown to 
extend beyond cessation of treatment and is sustained for a number of years (Durham et 
al., 1999, 2010). Furthermore, SIT reduces the onset of new allergen sensitisations in 
children (Des Roches et al., 1997) and has been suggested to prevent the procession of 
allergic rhinitis to asthma (Novembre et al., 2004; Niggemann et al., 2006; Jacobsen et 
al., 2007). 
 
1.10.2.1.  Mechanisms of Allergen-specific Immunotherapy 
Induction of allergen-specific tolerance established following SIT is associated with 
changes to both humoral and cellular responses to allergen. The underlying mechanisms 
of SCIT and SLIT show some similarities; although for the latter the precise details 
remain less well defined.  
 
Following a transient early increase in allergen-specific IgE, SIT is associated with 
reductions in seasonal increases of IgE and long-term decreases in serum allergen-
specific IgE concentrations (Lichtenstein et al., 1973; Van Ree et al., 1997; Lima et al., 
2002; Cosmi et al., 2006). Conversely, allergen-specific IgG1 and IgG4 concentrations 
increase within the first few months of treatment (Nouri-Aria et al., 2004; Francis et al., 
2008; Rossi et al., 2007; Scadding et al., 2010; James et al., 2011). Allergen-specific 
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IgG antibodies compete with allergen-specific IgE for allergen binding, thereby 
blocking IgE activity through FcRI and FcRII receptors. Thus allergen-specific IgG 
inhibits IgE-dependent basophil activation (Francis et al., 2008) and facilitated antigen 
binding and presentation by B cells to T cells (Wachholz et al., 2003). IgG4 shows the 
greatest proportionate increase (Francis et al., 2008). Memory B cells class switch to 
IgG4 production in the presence of IL-10 (Jeannin et al., 1998) and Tr1 cells (Akdis et 
al., 1996; Müller et al., 1998a). Following SIT there is also a reduced recruitment of 
effector cells to sites of allergen exposure including T cells, eosinophils, neutrophils and 
basophils, as demonstrated by cutaneous or nasal allergen challenge models in addition 
to biopsies taken during natural seasonal exposure (Varney et al., 1993; Nish et al., 
1994; Durham et al., 1996; Wilson et al., 2001).  
  
The principal underlying mechanism driving SIT-induced tolerance is the modification 
of the phenotype of the allergen-specific T cell response, i.e. immune deviation or 
induction of Tregs. Following SIT, a shift towards a dominant Th1 cytokine expression 
pattern in peripheral blood cells has been described by some (Akoum et al., 1996; Ebner 
et al., 1997; Benjaponpitak et al., 1999; Cosmi et al., 2006) though not all studies 
(Wachholz et al., 2002; Francis et al., 2003; Bohle et al., 2007). However, evaluation of 
local cytokine expression within the nasal mucosa reveals increases in the ratio of Th1 
to Th2 cytokine mRNA expression, even when peripheral changes are not demonstrable 
(Durham et al., 1996; Wachholz et al., 2002). A highly reproducible finding is the 
induction of IL-10 producing Tr1 cells (Francis et al., 2003; Jutel et al., 2003; Gardner 
et al., 2004; Bohle et al., 2007; Möbs et al., 2010) and  CD4
+
CD25
+
FoxP3
+
 T cells 
(Radulovic et al., 2008; Scadding et al., 2010; Aslam et al., 2010).  
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1.11. Peptide immunotherapy 
The limitations of conventional immunotherapy include the long duration of treatment 
and need for numerous administrations together with the risk of systemic IgE-mediated 
side-effects (Varney et al., 1991; Bousquet et al., 1998). Systemic side-effects arise due 
to IgE recognition of whole allergen proteins and ensuing mast cell activation. If the 
goal of high dose allergen immunotherapy is to induce Tr1 cells, it is the propensity for 
IgE activation that limits the amount of allergen that can be administered to patients. A 
potential strategy for improving the efficacy and safety profile of specific 
immunotherapy is to use allergen-derived peptides that are recognised by T cells but 
which are unable to bind to IgE.   
 
Successful peptide-induced tolerance has been reported for a number of self-antigens in 
autoimmune diseases including EAE (Metzler and Wraith, 1993; Anderton and Wraith, 
1998), arthritis (Staines et al., 1996; Prakken et al., 1997), diabetes (Daniel and 
Wegmann, 1996; Jones et al., 2006) and experimental allergic uveoretinitis (Dick et al., 
1993). These studies demonstrated that administration of peptides containing 
immunodominant CD4
+
 T cell epitopes, either through intranasal or subcutaneous 
routes, can be sufficient to prevent development of autoimmune disease.  
 
1.11.1. Peptide immunotherapy in experimental models of allergic disease  
Peptide-induced tolerance has also been explored in experimental models of allergic 
disease. In 1993, Hoyne and colleagues used a murine model of T cell recognition of the 
house dust mite major allergen, Der p 1, to demonstrate that intranasal administration of 
a peptide containing an immunodominant T cell epitope of Der p 1 was sufficient to 
inhibit the immune response in naïve animals upon whole allergen challenge. In that 
model, draining lymph node T cells isolated from peptide-treated mice, failed to 
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proliferate in response to whole Der p 1 and were unable to provide cognate help to B 
cells for allergen-specific antibody production (Hoyne et al., 1993). Furthermore, in the 
same study these investigators showed that administration of the immunodominant 
peptide was able to induce tolerance in an established immune response to Der p 1 in 
addition to preventing new sensitisation. The development of peptide-induced tolerance 
was preceded by transient T cell activation (Hoyne et al., 1996) and the effect was 
maintained for at least six months after (Hoyne et al., 1997). 
 
Similar findings have been reported for other allergens. For example, subcutaneous 
injection of immunodominant peptides of the major birch pollen allergen, Bet v 1, also 
resulted in tolerance to whole allergen in mice (Bauer et al., 1997). Also, intranasal or 
subcutaneous administration of peptides containing immunodominant epitopes of Api m 
1 (bee venom) or Dol m 5 (hornet venom) allergens successfully tolerised mice (King et 
al., 1998). Tolerance induced by Api m 1 T cell epitopes could also be adoptively 
transferred with CD4
+
 T cells to naïve animals (Astori et al., 2000; von Garnier et al., 
2000). 
   
More recently, peptide-induced tolerance has been investigated by our research group in 
collaboration with others in a humanised mouse model of allergic asthma (Campbell et 
al., 2009). Transgenic mice, expressing the human HLA-DR1 class II but lacking 
endogenous murine class II molecules, were sensitised with Fel d 1 and then treated 
with a known HLA-DR1-restricted Fel d 1-derived peptide before challenge with cat 
dander. Peptide injections, given intradermally in the context of an established immune 
response, reduced the subsequent Th2 response, IgE production, eosinophilia, airway 
hyperresponsiveness and mucus hypersecretion (Campbell et al., 2009).  
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1.11.2. Clinical studies of peptide immunotherapy 
Clinical studies of allergen-derived peptide immunotherapy in humans have thus far 
been confined to bee venom and cat allergy.  
 
1.11.2.1.  Bee venom allergy 
Successful peptide immunotherapy for bee venom allergy has been described in small 
cohorts in a number of reports. Carballido and colleagues identified T cell epitopes of 
the major bee venom allergen, phospholipase A2 (PLA2), by establishing CD4
+
 T cell 
clones from both bee venom allergic and non-allergic individuals (Carballido et al., 
1993). Using synthetic overlapping 12-mer or 18-mer peptides, the CD4
+
 T cell clones 
were screened for epitope specificity by 
3
H-thymidine incorporation assays, which 
identified three immunodominant CD4
+
 T cell epitopes. Moreover successful 
conventional venom immunotherapy was shown to be associated with anergy of T cells 
specific for these same epitopes (Akdis et al., 1996). Subsequently, these peptides were 
administered subcutaneously in a small uncontrolled clinical study to five bee venom-
allergic individuals (Müller et al., 1998a). Although 2 of these 5 subjects subsequently 
experienced systemic allergic reactions on bee venom challenge, PBMC assays did 
indicate an immunological effect of the peptides since reduced proliferation and 
cytokine production were observed. Similar effects on peripheral T cell responses have 
also been reported using long synthetic peptides designed to contain multiple bee 
venom epitopes (Fellrath et al., 2003). Finally, immunodominant epitopes in bee venom 
have been identified by HLA binding studies and selected for promiscuous binding to 
multiple HLA (Texier et al., 2000). Four immunodominant epitopes were then tested in 
an open-label, clinical study including individuals with mild bee venom allergy (Tarzi et 
al., 2006). Following intradermal administration of the PLA2-derived peptides, the 
peptide treatment group demonstrated reduced late-phase skin responses to both PLA2 
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and whole bee venom extract. In addition, reduced allergen-induced PBMC 
proliferation and IFN-γ/IL-13 production was associated with concomitant induction of 
IL-10 production (Tarzi et al., 2006). 
 
Together these studies strongly suggest that administration of either short or long bee 
venom-derived peptides is capable of inducing peripheral Treg responses comparable to 
those observed during conventional venom SIT.  
 
1.11.2.2.  Cat allergy 
Having validated cat allergen-derived peptides, IPC-1 and IPC-2 in an experimental 
murine model of cat allergy (Briner et al., 1993), subsequent clinical trials were 
performed to address safety and efficacy in cat allergic patients. In a double-blind, 
placebo-controlled trial, IPC-1 and IPC-2 were given subcutaneously at different doses 
to cat allergic individuals (Norman et al., 1996). Administration of high doses of the 
peptide mix led to the significant improvement of both lung and nasal symptoms, as 
measured by clinical symptom scores recorded following exposure to live cats (Norman 
et al., 1996). Furthermore, peptide but not placebo treatment was associated with 
increases in the amount of nebulised cat allergen required to provoke a 20% reduction in 
forced expiratory volume in one second (FEV1) (Pène et al., 1998). Analyses of the 
cytokine profile of Fel d 1 peptide-specific T cell lines or cultured PBMC, showed 
decreases in allergen-induced IL-4 production following peptide treatment (Marcotte et 
al., 1998; Pène et al., 1998). 
 
Subsequently, Haselden and colleagues gave three overlapping Fel d 1-derived peptides 
to cat allergic individuals by the intradermal route (Haselden et al., 1999). Peptide 
injections led to reduced cutaneous early and late phase responses to whole cat dander 
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extract. Interestingly, isolated bronchial late responses reactions („Late Asthmatic 
Responses‟) were observed in a number of asthmatic subjects. Given that these peptides 
were unable to elicit either basophil activation or cutaneous early responses, it was 
hypothesised that isolated bronchial late responses were the result of direct T cell 
activation. In support of this, responding subjects were predominantly HLA-DR13
+
 and 
HLA-DR13-dependent T cell activation was confirmed in cellular assays. The same 
investigators then performed an experimental study to investigate if intradermal peptide 
administration to allergic individuals resulted in hyporesponsiveness on rechallenge 
with whole allergen. A single dose of a mixture of sixteen 16- and 17-mer overlapping 
peptides given to cat allergic individuals (Oldfield et al., 2001) was associated with 
inhibition of bronchial and cutaneous late responses to whole allergen together with 
suppression of Th2 cytokine production in PBMC assays (Oldfield et al., 2001). These 
effects were reproduced in a double-blind placebo-controlled trial examining multiple 
doses of 12 overlapping peptides and further shown to be associated with peripheral T 
cell IL-10 production, presumed to reflect induction of Tr1 cells (Oldfield et al., 2002). 
T cell unresponsiveness was observed even to Fel d 1 allergen peptides not 
administered, suggesting the induction of so-called „linked epitope suppression‟ and 
therefore the generation of a wide ranging antigen-specific tolerance following peptide 
immunotherapy (Campbell et al., 2009).  
 
These studies provide proof of concept for use of peptide immunotherapy in the 
treatment of cat-induced allergic disease. However, all of these studies have examined 
challenge responses under experimental conditions. The efficacy of this approach in the 
treatment of allergic disease induced by environmental cat allergen exposure needs to be 
tested in randomised double blind placebo-controlled trials. 
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1.11.3.  Mechanisms of peptide-induced tolerance 
The mechanism of peptide-induced tolerance has been studied extensively and is likely 
to involve components of clonal deletion, anergy and Treg induction.  
 
1.11.3.1. Induction of Tregs 
The central importance of Tregs in controlling adaptive immune responses is now 
widely accepted. Following conventional immunotherapy, Tregs are detectable in the 
periphery (Francis et al., 2003; Jutel et al., 2003) and at the sites of allergen exposure 
(Nouri-Aria et al., 2004; Radulovic et al., 2008). Immunohistochemical analysis of skin 
biopsies taken from cat peptide-treated individuals has not provided definitive results: 
although significant increases were observed in numbers of CD4
+
/IFN-γ+ T cells, no 
changes were seen in CD4
+
/IL-10
+
 or CD4
+
/CTLA-4
+
 cells (Alexander et al., 2005b).  
The effect of peptide immunotherapy on the function of CD4
+
CD25
+
 T cells was 
evaluated within a double-blind placebo-controlled trial (Smith et al., 2004). Since 
functional differences are seen in the suppressive capabilities of CD4
+
CD25
+
 T cells 
isolated from allergic and non-allergic individuals (Ling et al., 2004), it was 
hypothesised that peptide immunotherapy may act to restore the suppressive function of 
these cells. However, no such effect could be demonstrated (Smith et al., 2004). A 
separate study did report an increase in functional suppressive activity of CD4
+
CD25
+
 T 
cells, although the clinical study was uncontrolled and Treg comparisons were only 
made pre- and post-peptide administration within the same subjects (Verhoef et al., 
2005). 
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1.11.3.2.  IL-10 
The role of IL-10 in conventional specific immunotherapy and in non-allergic immune 
response to allergen has been explored previously in this thesis. In brief, both pollen and 
insect venom immunotherapy increases the numbers of IL-10
+
 T cells in local tissues 
(skin and nasal mucosa) and peripherally (Bellinghausen et al., 1997; Nasser et al., 
2001; Nouri-Aria et al., 2004). Furthermore, the allergen-specific T cell response in 
non-allergic individuals is dominated by an IL-10-producing regulatory phenotype 
(Akdis et al., 2004).  
 
An essential role for IL-10 has been demonstrated in peptide-induced tolerance to 
myelin basic protein in murine EAE. Intranasal administration of Ac1-9, an 
immunodominant epitope of myelin basic protein, induces tolerance and protects 
against development of EAE (Liu and Wraith, 1995). Using transgenic mice (Tg4) 
expressing a TCR specific for Ac1-9, Burkhart and co-workers demonstrated that 
effective peptide-induced tolerance was associated with increased in vitro IL-10 
production by T cells (Burkhart et al., 1999). Furthermore, peptide-induced protection 
from EAE was abrogated in vivo upon administration of an IL-10 neutralising antibody 
(Burkhart et al., 1999). In an additional study, Sundstedt and colleagues characterised 
the T cells isolated from tolerised Tg4 transgenic mice and demonstrated their ability to 
suppress antigen-specific T cell responses both by in vitro proliferation assays and in 
vivo by adoptive transfer experiments (Sundstedt et al., 2003). Moreover, induction of 
these cells was abrogated by treatment with an anti-IL-10 receptor antibody (Sundstedt 
et al., 2003). Finally, an unequivocal role for IL-10 in effective peptide-induced 
tolerance was demonstrated using IL-10 knockout mice (IL-10
-/-
), with administration of 
tolerogenic peptide to IL-10
-/-
 animals failing to protect against subsequent EAE 
induction (O‟Neill et al., 2006). 
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In our own study, a role for IL-10 in the mechanism of intradermal peptide-induced 
tolerance in a mouse model of allergic airways disease has also recently been 
demonstrated. Following peptide-induced tolerance, an increase in the amount of IL-10
 
protein in both lung tissue homogenate and bronchoalveolar lavage was observed. The 
numbers of IL-10
+
 T cells following in vitro culture of lung tissue digests were also 
increased in peptide-treated animals as compared to control animals. Finally, 
neutralisation of IL-10 at the time of peptide administration prevented onset of peptide-
induced tolerance highlighting the requirement for this cytokine in this model 
(Campbell et al., 2009). Human clinical studies of peptide immunotherapy further 
highlight the involvement of IL-10 in successful tolerance induction. For example, in 
vitro allergen stimulation of PBMC is associated with increases in IL-10 production 
after peptide immunotherapy (Oldfield et al., 2002; Fellrath et al., 2003; Verhoef et al., 
2005; Tarzi et al., 2006). 
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1.12. Epitope mapping 
The T cell-mediated immune response to antigen is HLA-restricted (Zinkernagel and 
Doherty, 1997). Antigenic proteins may contain a number of potential T cell epitopes, 
although only a selected few are likely to be immunodominant and therefore responsible 
for shaping the immune response (Berzofsky, 1988). The immunodominance of an 
epitope is shaped by a number of characteristics, namely 1) the efficiency with which 
peptides containing that epitope are processed by APCs, 2) the binding affinity of the 
processed peptide for HLA molecules expressed by the APC, and 3) the ability of the 
HLA-bound peptide to interact with and activate an epitope-specific T cell response 
(Berzofsky, 1988). Therefore, in order to define a peptide as an HLA-restricted epitope 
these three features must be evaluated through epitope mapping. Identification and 
characterisation of immunodominant epitopes that drive T cell-mediated immunity is 
therefore a necessary step in the development of peptide vaccines that directly target T 
cell responses. 
 
1.12.1. In silico prediction 
The first stage of epitope identification is usually in silico-based prediction, during 
which a smaller number of peptide sequences are highlighted from the antigenic protein 
of interest. Epitope prediction software is readily available that screens for putative 
epitopes based on historical knowledge of amino acid sequences in known HLA binding 
motifs. Prediction algorithms draw upon experimental data from peptide binding assays, 
sequencing of natural HLA ligands and structural studies of peptide-HLA complexes. 
They employ computational strategies such as quantitative matrices, virtual matrices 
and machine learning algorithms, hybrid models and consensus models (Raddrizzani 
and Hammer, 2000).  
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Matrix-based algorithms predict peptide binding to HLA class II according to the 
interactions between the individual amino acid side chains of the binding peptide and 
the peptide-binding groove of the HLA molecule. Within the binding peptide a core of 
nine amino acids represents the main binding motif, with the amino acid at position 1 
being the key anchoring side chain. The peptide-binding groove of the HLA class II 
molecule comprises a number of pockets which serve to stabilise peptide binding 
through interaction with the individual amino acid side chains of the binding peptide. 
Due to the polymorphic nature of the residues involved, the physiochemical properties 
of these pockets vary between different HLA alleles. These properties determine the 
interaction with the binding peptide. Some amino acids within a given peptide sequence 
may therefore promote binding to an HLA whilst others may be inhibitory (Hammer et 
al., 1994; Sinigaglia and Hammer, 1994). Peptide binding to HLA molecules therefore 
represents a composite outcome of all side chain effects. By assigning a position-
specific coefficient to the binding effect of each side chain within the core motif, 
quantitative matrices generate a numerical description of peptide-HLA class II binding. 
Peptides are ranked according to this theoretical relative binding score thus identifying 
putative HLA binding molecules. A quantitative matrix can be split into individual 
constituent „pocket profiles‟ based on the assumption that the effects of the individual 
amino acid side chains upon peptide binding are independent of each other (Sturniolo et 
al., 1999; Raddrizzani and Hammer, 2000). A pocket profile is generated by quantifying 
the interaction of all naturally occurring amino acid side chains with a given single 
HLA class II pocket and is determined experimentally in competitive HLA-binding 
assays (Sturniolo et al., 1999). Structural and modelling studies have shown that whilst 
the residues contributing to the pockets are polymorphic, there is similarity between 
HLA alleles (Sturniolo et al., 1999). Therefore once a pocket profile has been 
determined for one HLA allele, it can be shared with other HLA alleles, assuming the 
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residues contributing to the pocket are identical between the alleles. By assigning and 
combining pocket-specific quantitative binding values derived from one HLA allele to 
other alleles, virtual matrices can be formed and used for effective HLA binding 
prediction (Sturniolo et al., 1999; Raddrizzani and Hammer, 2000). Furthermore, virtual 
matrices allow evaluation of promiscuous peptide binding by enabling the systematic 
prediction of peptides for a broad range of HLA binding specificities (Sturniolo et al., 
1999). TEPITOPE represents the best-known example of a virtual matrix based epitope 
prediction program (Sturniolo et al., 1999). It has been successfully used to identify 
HLA-binding motifs (a pre-requisite for a T cell epitope) within a number of antigenic 
proteins in cancer (Manici et al., 1999), autoimmunity (Veeraraghavan et al., 2004), 
infection (Fonseca et al., 2005) and allergy (de Lalla et al., 1999).   
 
Another approach to in silico epitope prediction programmes is the use of artificial 
neural networks. Artificial neural networks are machine learning systems that identify 
and retain patterns present in data and subsequently recognise the patterns in a novel 
data set (Raddrizzani and Hammer, 2000). Unlike virtual matrix-based prediction 
programs, artificial neural networks make no assumptions about the lack of interaction 
between amino acid side chains in potential epitopes binding to the HLA pocket. 
NetMHCIIpan is an artificial neural network prediction program that offers quantitative 
prediction of peptide-HLA binding affinities (Nielsen et al., 2007, 2008). The prediction 
accuracy of artificial neural networks is slightly higher than that of matrix-based 
algorithms as it can take into account the binding requirements of both the peptide and 
also binding specificity between the peptide-HLA molecules. However, they are limited 
by a requirement for large amounts of data that is not currently available for most HLA 
alleles and by a need for alignment matrices which are required to train the HLA class II 
prediction systems. 
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Comparative studies have been performed in order to evaluate the effectiveness of HLA 
class II epitope prediction methods (Wang et al., 2008; Lin et al., 2008). In the study by 
Wang and colleagues, TEPITOPE emerged as the best performing HLA class II 
prediction algorithm overall (Wang et al., 2008). However, it was noted that in general 
class II prediction algorithms did not perform as effectively as those programs for class 
I predictions. In order to improve predictive performance of the class II prediction 
algorithms a Consensus approach was implemented (Wang et al., 2008, 2010). For the 
Consensus approach, potential HLA class II binding peptides are scored and ranked by 
combining epitope prediction scores from three different predictive algorithms. Each 
peptide is analysed using the individual algorithms and peptides are ranked by their 
score, with the highest ranking peptides demonstrating the best binding. Finally the 
median of all three rank values from the different algorithms is calculated to define the 
Consensus rank score (Wang et al., 2008, 2010). Lin and colleagues also compared 
prediction methods and reported that NetMHCIIpan, ProPred (based upon the virtual 
matrices of TEPITOPE) and Consensus approaches were the best prediction methods to 
identify HLA binding peptides (Lin et al., 2008).  
 
Having identified potential T cell epitopes on the basis of HLA binding, these epitopes 
require experimental testing to confirm natural processing of the predicted peptide and 
T cell recognition. For verification of T cell recognition, sources of antigen-specific T 
cells include PBMC from patients or healthy individuals that are primed either in vivo 
or in vitro. Additionally, HLA transgenic mice, engineered to express human HLA 
molecules, can be immunised with the antigen of interest and T cell responses 
evaluated. A number of methods can be employed to measure epitope-specific T cell 
responses including proliferation and enzyme-linked immunosorbent spot (ELISPOT) 
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assays, intracellular cytokine staining, and HLA tetramer staining of antigen-specific T 
cells.  
 
1.12.2. HLA Class II Tetramers 
HLA class II tetramers are reagents that enable the detection of individual antigen-
specific T cells by virtue of the antigen-specificity of the TCR-peptide/HLA interaction. 
They are based upon the concept of synthetic HLA molecules complexed to T cell 
peptide epitopes and labelled with a fluorochrome for flow cytometric analysis of 
binding. However, the monomeric TCR-peptide/HLA interaction is of too low affinity 
to achieve stable binding, being substantially weaker than comparable interactions 
between antibody and antigen (Matsui et al., 1991): the TCR dissociates rapidly from 
peptide/HLA complexes. Therefore, in order to effectively label T cells via the TCR-
peptide/HLA interaction, peptide/HLA reagents with increased avidity for the TCR 
were developed. High avidity binding was achieved by development of HLA tetramers 
comprising at least four recombinant biotinylated HLA molecules tetramerised by 
fluorochrome-conjugated streptavidin and loaded with an antigen-specific peptide. HLA 
tetramers were first employed to identify and characterise the antigen-specific CD8
+
 T 
cell responses in individuals infected with the human immunodeficiency virus (HIV) 
(Altman et al., 1996). This first study was followed by publications establishing use of 
HLA class II tetramers for investigation of Borrelia-specific CD4
+
 T cell responses in 
Lyme arthritis patients (Meyer et al., 2000). Key differences in the molecular structure 
and protein folding requirements of HLA class I and class II molecules have however, 
impeded the development of class II tetramers. Recombinant HLA class I molecules, 
comprising a single polypeptide chain fused to the β2-microglobulin chain, readily 
renature in the presence of antigenic peptide using Escherichia coli expression systems 
(Garboczi et al., 1992; Denkberg et al., 2000). However, HLA class II molecules 
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comprise two non-covalent α and β polypeptide chains, which have limited ranges of 
stability and solubility in solution. Therefore folding conditions have to be optimised for 
each individual HLA-type (Vollers and Stern, 2008). Furthermore, the refolding and 
combination of the two HLA class II polypeptide chains is restricted by the instability 
of the polypeptide chains in the absence of peptide in the peptide-binding groove. The 
production of recombinant HLA class II molecules in eukaryotic expression systems, in 
particular insect cells, is now the favoured approach and may include various 
modifications to improve HLA molecule stability and peptide loading, such as addition 
of leucine zippers or covalently bound peptide (Vollers and Stern, 2008).  
 
HLA class II tetramers have now been widely employed to identify and characterise 
antigen-specific CD4
+
 T cell responses in various diseases for example, bacterial 
infection (Meyer et al., 2000), autoimmune disease (Reijonen et al., 2002), viral 
infection (Day et al., 2003) and allergy (Macaubas et al., 2006) An additional 
application of class II tetramers is the mapping of HLA-restricted immunodominant 
epitopes through a technique known as tetramer guided epitope mapping (TGEM) 
(Novak et al., 2001; Reijonen and Kwok, 2003). In the TGEM approach to epitope 
identification, HLA tetramers are loaded with pooled mixtures of overlapping peptides, 
synthesised to encompass the entire antigenic protein of interest (Novak et al., 2001; 
Reijonen and Kwok, 2003). These pooled-peptide tetramers are then used to label 
epitope-specific CD4
+
 T cells from PBMC that have been expanded in vitro, in the 
presence of the same overlapping peptides or whole antigenic protein (Novak et al., 
2001; Reijonen and Kwok, 2003). If a positive signal is identified with the pooled 
peptide tetramer, the individual peptides from the pool are used to synthesise individual-
peptide tetramers and the staining repeated. Observation of a positive signal during 
individual-peptide tetramer labelling, indicates the presence of an HLA-restricted CD4
+
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T cell epitope within that peptide (Novak et al., 2001; Reijonen and Kwok, 2003).  
TGEM has been effectively used to identify T cell epitopes in a number of different 
antigens including herpes simplex virus (Novak et al., 2001), influenza virus (Yang et 
al., 2005, 2006b; Roti et al., 2008; Yang et al., 2009a), tetanus toxin (Yang et al., 2005; 
James et al., 2007) islet-specific glucose-6-phosphatase catalytic subunit-related protein 
(Yang et al., 2006a), severe acute respiratory syndrome („SARS‟) coronavirus (Yang et 
al., 2009b), major cat allergen Fel d 1 (Kwok et al., 2010) and the major peanut allergen 
Ara h 1 (DeLong et al., 2011). 
 
Tetramers have also been successfully used to identify and characterise allergen-specific 
CD4
+
 T cells following in vitro expansion and immediately ex vivo after T cell isolation. 
These studies, which are summarised in Table 1.2, illustrate how HLA class II tetramers 
can represent a powerful tool for identifying and characterising allergen-specific CD4
+
 
T cell responses in humans.  
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Table 1.2: Summary of published reports identifying and characterising allergen-
specific CD4
+ 
T cells using HLA class II tetramers. 
Allergen Labelling step 
Tetramer-positive 
cell frequency: 
allergic vs. non-
allergic 
individuals 
Phenotype of 
tetramer-positive 
cells from allergic 
individuals 
Reference 
Lol p 1 
(Rye 
grass) 
Post in vitro 
expansion 
Not detected in 
non-allergic 
Produce IL-4 
 
(Macaubas 
et al., 
2006) 
Fel d 1 
(Cat) 
Ex vivo 
Allergic > non-
allergic 
Skin-homing, Th2-
type, central memory 
(Bateman 
et al., 
2006) 
Fel d 1 
(Cat) 
Ex vivo 
Allergic > non-
allergic 
Th2-type, central 
memory 
(Kwok et 
al., 2010) 
Ves v 5 
(Wasp) 
Ex vivo 
Allergic > non-
allergic 
Not determined 
(Aslam et 
al., 2010) 
Der p 1 
(House 
dust mite) 
Post in vitro 
expansion 
Not determined Not determined 
(Ardern-
Jones et 
al., 2007; 
McPherson 
et al., 
2010) 
Art v 1 
(Mugwort) 
Post in vitro 
expansion/ T 
cell clones 
Not determined Not determined 
(Jahn-
Schmid et 
al., 2008) 
Bos d 2 
(Cow) 
Post in vitro 
expansion 
 
Allergic > non-
allergic (memory 
cells) 
Allergic ≈ non-
allergic (naïve 
cells) 
Not determined 
(Kinnunen 
et al., 
2010) 
Bet v 1 
(Birch) 
Post in vitro  
expansion 
Allergic > non-
allergic 
Effector memory 
Produce IL-5 
(Van 
Overtvelt 
et al., 
2008; 
Wambre et 
al., 2008) 
Bet v 1 
(Birch) 
Ex vivo 
Allergic > non-
allergic 
Not determined 
(Van 
Overtvelt 
et al., 
2008) 
Ara h 1 
(Peanut) 
Ex vivo 
Allergic > non-
allergic 
Memory, Th2-type 
(DeLong 
et al., 
2011) 
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1.12.3. HLA Class II transgenic mice 
Investigation of human CD4
+
 T cell responses in allergic patients represents the gold 
standard for identifying and characterising immunodominant epitopes. However, this 
approach has limitations: firstly, antigen-specific CD4
+
 T cells are present only at low 
frequency in the periphery and therefore direct isolation of these cells is problematic. 
Secondly, in vitro expansion to boost allergen-specific T cell frequency may result in 
bias through selective outgrowth of certain epitope-specific CD4
+
 T cell populations. 
Finally, human APCs simultaneously express several different polymorphic HLA 
molecules (e.g. HLA-DR,-DQ and DP). Therefore establishing HLA-restriction for any 
given epitope is often not technically possible in human studies. 
 
To circumvent these issues, transgenic mice have been engineered to express human 
HLA class II molecules in the absence of endogenous murine class II molecules. Thus, 
antigenic peptides are presented to the CD4
+
 T cell population in the context of a single 
known HLA class II allele, enabling a clear elucidation of HLA-restriction. These mice 
offer the additional major advantage of being genetically identical and following 
immunisation with protein draining lymph nodes provide an abundant source of 
antigen-specific T cells in single cell suspension. These cells may be expanded in vitro 
in the presence of immunising antigen to generate HLA-restricted CD4
+
 T cell lines for 
use in epitope mapping using proliferation assays or ELISPOT assays with overlapping 
peptides encompassing the entire sequence of the immunising antigen. 
 
HLA transgenic mice have previously been used to identify T cell epitopes for antigens 
relating to autoimmune diseases such as the diabetic autoantigen glutamic acid 
decarboxylase 65 (GAD-65) (Patel et al., 1997), hepatitis B virus envelope protein 
(Pajot et al., 2006), major ragweed allergens Amb a 5 and Amb t 5 (Chapoval et al., 
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1998) and major rye grass allergen Lol p 1 (Macaubas et al., 2006). Beyond epitope 
mapping studies, these mice also enable the development of disease models that reflect 
human antigen processing and presentation to the immune system.  
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1.13.  Hypotheses  
The over-riding hypothesis behind this thesis is that HLA-restricted immunodominant T 
cells epitopes within major grass pollen allergens have therapeutic potential as a peptide 
vaccine for seasonal allergic rhinitis.  
 
As a step towards addressing this, the following specific hypotheses have been tested in 
this thesis: 
1. HLA-DR1-restricted CD4+ T cell epitopes are identifiable within the major 
Timothy grass pollen allergens, Phl p 1 and Phl p 5. 
2. Immunodominant epitopes may be recognised by allergic subjects of a given 
HLA type. 
3. CD4+ T cell populations specific for these immunodominant epitopes undergo 
numerical expansion and demonstrate disease-relevant phenotypic change in 
grass pollen allergy. 
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1.14.  Aims 
The aims of this thesis were to: 
1. Identify HLA-DR1-restricted CD4+ T cell epitopes within the major grass pollen 
allergens, Phl p 1 and Phl p 5 using complementary approaches of epitope 
mapping, i.e. in silico prediction, HLA class II tetramer technology and using 
transgenics expressing human HLA-DR, knockout for mouse class II. 
2. Look at recognition of these HLA-DR1-restricted CD4+ T cell epitopes using 
HLA-DR1 tetramers in allergic and non-allergic individuals. 
3. Characterise the phenotype of the epitope-specific CD4+ T cells in allergic and 
non-allergic subjects by markers of cell surface phenotype and cytokine 
production. 
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2. Materials and Methods 
2.1. Nomenclature 
2.1.1. Human leukocyte antigen alleles 
Human leukocyte antigen (HLA) allele nomenclature is governed by the World Health 
Organisation (WHO) Nomenclature Committee for Factors of the HLA System. Each 
HLA allele name consists of a unique number which relates to the sequence of both the 
allele and its closest relative.  
 
The HLA allele studied in this thesis was HLA-DRB1*01:01 its nomenclature is 
defined in Table 2.1. 
 
In this thesis, the abbreviation HLA-DR1, is used throughout to refer to HLA-
DRB1*01:01. Reference to additional HLA alleles also uses the HLA-DRx form, where 
x represents the allele group.  
 
2.1.2. Grass pollen allergens  
Allergen nomenclature is governed by the WHO/ International Union of Immunological 
Societies (IUIS) Allergen Nomenclature Sub-committee. Each allergen is defined by a 
systematic nomenclature based on the Linnaean system. Two grass pollen allergens 
from Phleum pratense (Timothy grass) are studied in this thesis, Phl p 1 and Phl p 5b, 
their nomenclature is defined in Table 2.2. 
 
In this thesis, the abbreviations Phl p 1 and Phl p 5b are used to refer to the isoallergens 
Phl p 1.0102 and Phl p 5.0201 respectively 
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Table 2.1: HLA allele nomenclature. 
HLA-DRB1*01:01 
HLA 
HLA region and prefix for an HLA 
gene 
HLA-DRB1 HLA locus i.e. DRB1 
HLA-DRB1*01 
The group of alleles which encode 
the DR1 antigen 
HLA-DRB1*01:01 A specific HLA allele 
 
 
Table 2.2: Phleum pratense pollen allergen nomenclature. 
Phl p 1.0102 
Phl p  
First three letters of the genus and 
first letter of the species i.e. Phleum 
pratense 
Phl p 1 Allergen group i.e. Group 1 
Phl p 1.01 
Isoallergen, allergen from single 
species, sharing molecular size, 
identical biological function and ≥ 
67% amino acid identity 
Phl p 1.0102 
Variant, allergen sequence with a 
limited number of amino acid 
substitutions 
 Phl p 5.0201 
Phl p  
First three letters of the genus and 
first letter of the species i.e. Phleum 
pratense 
Phl p 5 Allergen group i.e. Group 5 
Phl p 5.02 Isoallergen* 
Phl p 5.0201 Variant 
*Group 5 allergens of Phleum pratense can be subdivided in to two main isoallergens, 
Phl p 5.01x (Phl p 5a) and Phl p 5.02x (Phl p 5b). 
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2.2. Proteins and peptides 
2.2.1. Extracts and natural protein 
Phleum pratense extract and purified natural Phl p 5b (nPhl p 5b) were provided by 
ALK Abelló (Hørsholm, Denmark).  
 
2.2.2. Recombinant proteins 
Recombinant Phl p 1 (rPhl p 1) (Figure 2.1) and recombinant Phl p 5b (rPhl p 5b) 
(Figure 2.2) were provided by Allergopharma and synthesised by methods previously 
described (Cromwell et al., 2004; Jutel et al., 2005; Suck et al., 2006). 
 
Briefly, copy deoxyribonucleic acid (cDNA) sequences encoding the grass pollen 
allergens were subcloned into Escherichia coli (E. coli)-specific expression vectors and 
transformed into E. coli.  Recombinant allergens were purified using various 
chromatographic techniques including metal affinity, size exclusion and hydrophobic 
interaction and finally gel filtration. Identity and purity of recombinant allergens was 
assessed by biochemical analyses including: SDS-PAGE electrophoresis, isoelectric 
focussing, analytical size exclusion chromatography, reverse-phase HPLC, 
microsequencing and MALDI-TOF analysis. 
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rPhl p 1 
 
MASSSSVLLVVVLFAVFLGSAYGIPKVPPGPNITATYGDKWLDAKSTWYG
50
 
KPTGAGPKDNGGACGYKDVDKPPFSGMTGCGNTPIFKSGRGCGSCFEIKC
100
 
TKPEACSGEPVVVHITDDNEEPIAPYHFDLSGHAFGAMAKKGDEQKLRSA
150
 
GELELQFRRVKCKYPEGTKVTFHVEKGSNPNYLALLVKYVNGDGDVVAVD
200
 
IKEKGKDKWIELKESWGAIWRIDTPDKLTGPFTVRYTTEGGTKTEAEDVI
250
 
PEGWKADTSYESK
263
 
 
Figure 2.1: Recombinant Phl p 1 sequence. 
The sequence of rPhl p 1 (residues 24-263) was identical to Phl p 1.0102 with the 
mutation of a single serine residue to cysteine in the sequence, shown here at position 
259 highlighted in yellow. This was performed to optimise the production of 
monomeric rPhl p 1 (Suck et al., 2006). The signal peptide (residues 1 – 23) is 
highlighted in green. 
 
 
 
 
 
rPhl p 5b 
 
AAAAVPRRGPRGGPGRSYTADAGYAPATPAAAGAAAGKATTEEQKLIEDI
50
 
NVGFKAAVAAAASVPAADKFKTFEAAFTSSSKAAAAKAPGLVPKLDAAYS
100
 
VAYKAAVGATPEAKFDSFVASLTEALRVIAGALEVHAVKPVTEEPGMAKI
150
 
PAGELQIIDKIDAAFKVAATAAATAPADDKFTVFEAAFNKAIKESTGGAY
200
 
DTYKCIPSLEAAVKQAYAATVAAAPQVKYAVFEAALTKAITAMSEVQKVS
250
 
QPATGAATVAAGAATTAAGAASGAATVAAGGYKV
284
 
 
Figure 2.2: Recombinant Phl p 5b sequence. 
The sequence of rPhl p 5b (residues 20-284) was identical to Phl p 5.0201 with the 
exception that the single cysteine in the sequence, shown here at position 205, was 
substituted with phenylalanine, highlighted in yellow. The signal peptide (residues 1-
19) is highlighted in green. It is possible that this sequence may be a partial sequence 
due to the absence of the initiating methionine residue.  
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2.2.3. Peptides 
Phl p 1- and Phl p 5b-derived peptide libraries, comprising 20-mer peptides overlapping 
by 12 amino acids, were synthesised from the 240 amino acid sequence of Phl p 1.0102 
and the 264 amino acid sequence of Phl p 5.0201 respectively (Table 2.3). 
 
Peptides for preliminary epitope mapping experiments were purchased from Sigma 
PEPScreen® Handling, Sigma Genosys, Gillingham, UK). Lyophilised peptides, 
synthesised by Fmoc chemistry, were reconstituted in dimethyl sulphoxide (DMSO, 
Sigma-Aldrich, Gillingham, UK) at 10 mM, and diluted as required in RPMI-1640 
Gibco, Paisley, UK). 
 
For subsequent epitope mapping assays, peptides were purchased from ProImmune 
thinkpeptides, PEPScreen® Custom peptide library (ProImmune Ltd, Oxford, UK). 
Lyophilised peptides, synthesised by Fmoc chemistry, were reconstituted to 2 mg/ml in 
1x phosphate buffered saline (PBS) and diluted as required. 
 
Following epitope mapping experiments, additional Phl p 1-derived peptide 20 was 
purchased from ProImmune Ltd. Further Phl p 5b-derived peptide 26 was obtained from 
AMS Biotechnology (Europe) Ltd (Abingdon, Oxford, UK) or ProImmune Ltd.  
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Table 2.3: 20-mer overlapping peptide sequences for Phl p 1.0102 and Phl p 
5.0201. 
Each peptide was designed to overlap by 12 amino acids, thus ensuring any 9 residue 
epitope will be represented with at least one flanking amino acid. Amino acid residues 
highlighted in yellow represent those that vary from the respective recombinant protein 
sequences as detailed in Figure 2.1 and Figure 2.2. 
 
Phl p 1 
peptide 
Sequence 
Phl p 5b 
peptide 
Sequence 
1 IPKVPPGPNITATYGDKWLD 1 DAGYAPATPAAAGAAAGKAT 
2 NITATYGDKWLDAKSTWYGK 2 PAAAGAAAGKATTEEQKLIE 
3 KWLDAKSTWYGKPTGAGPKD 3 GKATTEEQKLIEDINVGFKA 
4 WYGKPTGAGPKDNGGACGYK 4 KLIEDINVGFKAAVAAAASV 
5 GPKDNGGACGYKDVDKPPFS 5 GFKAAVAAAASVPAADKFKT 
6 CGYKDVDKPPFSGMTGCGNT 6 AASVPAADKFKTFEAAFTSS 
7 PPFSGMTGCGNTPIFKSGRG 7 KFKTFEAAFTSSSKAAAAKA 
8 CGNTPIFKSGRGCGSCFEIK 8 FTSSSKAAAAKAPGLVPKLD 
9 SGRGCGSCFEIKCTKPEACS 9 AAKAPGLVPKLDAAYSVAYK 
10 FEIKCTKPEACSGEPVVVHI 10 PKLDAAYSVAYKAAVGATPE 
11 EACSGEPVVVHITDDNEEPI 11 VAYKAAVGATPEAKFDSFVA 
12 VVHITDDNEEPIAPYHFDLS 12 ATPEAKFDSFVASLTEALRV 
13 EEPIAPYHFDLSGHAFGAMA 13 SFVASLTEALRVIAGALEVH 
14 FDLSGHAFGAMAKKGDEQKL 14 ALRVIAGALEVHAVKPVTEE 
15 GAMAKKGDEQKLRSAGELEL 15 LEVHAVKPVTEEPGMAKIPA 
16 EQKLRSAGELELQFRRVKCK 16 VTEEPGMAKIPAGELQIIDK 
17 ELELQFRRVKCKYPEGTKVT 17 KIPAGELQIIDKIDAAFKVA 
18 VKCKYPEGTKVTFHVEKGSN 18 IIDKIDAAFKVAATAAATAP 
19 TKVTFHVEKGSNPNYLALLV 19 FKVAATAAATAPADDKFTVF 
20 KGSNPNYLALLVKYVNGDGD 20 ATAPADDKFTVFEAAFNKAI 
21 ALLVKYVNGDGDVVAVDIKE 21 FTVFEAAFNKAIKESTGGAY 
22 GDGDVVAVDIKEKGKDKWIE 22 NKAIKESTGGAYDTYKCIPS 
23 DIKEKGKDKWIELKESWGAI 23 GGAYDTYKCIPSLEAAVKQA 
24 KWIELKESWGAIWRIDTPDK 24 CIPSLEAAVKQAYAATVAAA 
25 WGAIWRIDTPDKLTGPFTVR 25 VKQAYAATVAAAPQVKYAVF 
26 TPDKLTGPFTVRYTTEGGTK 26 VAAAPQVKYAVFEAALTKAI 
27 FTVRYTTEGGTKTEAEDVIP 27 YAVFEAALTKAITAMSEVQK 
28 GGTKTEAEDVIPEGWKADTS 28 TKAITAMSEVQKVSQPATGA 
29 DVIPEGWKADTSYESK 29 EVQKVSQPATGAATVAAGAA 
  30 ATGAATVAAGAATTAAGAAS 
  31 AGAATTAAGAASGAATVAAG 
  32 GAASGAATVAAGGYKV 
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2.3. Computational analyses 
2.3.1. Sequence alignment 
Published amino acid sequences of Phl p 1 and Phl p 5b isoallergens were obtained 
from the WHO/IUIS Allergen Nomenclature Sub-committee (www.allergen.org). 
Sequences were aligned using the CLUSTAL 2.0.12 multiple sequence alignment 
program (Larkin et al., 2007) available from the European Bioinfomatics Institute web 
server: http://www.ebi.ac.uk/tools/clustalw2. 
 
2.3.2. Bioinformatic identification of HLA-DR1-restricted CD4+ T cell epitopes  
Potential HLA-DR1-restricted epitopes for Phl p 1.0101 and Phl p 5.0201 were 
identified by bioinformatic analyses performed using HLA class II-restricted epitope 
prediction software, TEPITOPE (Sturniolo et al., 1999; Raddrizzani and Hammer, 
2000; Bian and Hammer, 2004) . 
 
Both single amino acid sequences were individually pasted into the “sequence editor” of 
TEPITOPE. The percentage threshold was set at 3% and HLA-DRB1*0101 selected as 
the restricting HLA-DR allele. The TEPITOPE analysis was run highlighting nonamer 
amino acid sequences corresponding to core HLA-DR1-binding motifs within the whole 
protein sequence.  
 
Further analyses were performed using additional prediction methods to analyse peptide 
binding to HLA class II molecules:  NetMHCIIpan available from the Center For 
Biological Sequence Analysis server: http://www.cbs.dtu.dk/services/NetMHCIIpan-
1.0/ (Nielsen et al., 2008) and the Consensus method available from the Immune 
Epitope Database (IEDB) Analysis Resource 
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(http://tools.immuneepitope.org/analyze/html/mhc_II_binding.html) (Wang et al., 2008, 
2010).   
 
The single amino acid sequences were individually entered into the protein sequence 
text area field and binding predictions restricted to the HLA-DRB1*0101 allele.  
 
These analyses generated sequences of 15 amino acids from the whole protein sequence 
predicted to demonstrate binding to HLA-DR1 ranked according to prediction scores 
obtained. For NetMHCIIpan, scores obtained were IC50 values (nM). IC50 values <50 
nM were considered high affinity, <500 nM intermediate affinity and <5000 nM low 
affinity.  For the Consensus method the median rank score was calculated from the 
SMM-align, NN-align and Combinatorial library prediction methods. The lower the 
Consensus rank score the stronger the predicted binding affinity.  
 
2.3.2.1. TEPITOPE 
TEPITOPE enables the in silico prediction of HLA-DR-restricted epitopes using virtual 
matrix-based algorithms (Sturniolo et al., 1999; Raddrizzani and Hammer, 2000; Bian 
and Hammer, 2004). Virtual matrices quantify the contribution the binding of each 
amino acid to each pocket within the HLA binding cleft. Peptide binding to HLA 
molecules is through the interaction of the peptide‟s amino acid side chains and pockets 
within the HLA binding cleft. Using competitive HLA class II binding assays, „pocket 
profiles‟, can be generated which quantify the interactions of all amino acid residues 
with a single HLA class II pocket (Sturniolo et al., 1999). Structural analyses of HLA 
class II molecules have shown that the polymorphic residues contributing to each HLA 
class II binding pocket are the same for different HLA-DR alleles.  Consequently, once 
a pocket profile has been determined for one HLA-DR allele in vitro, it can be applied 
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to additional alleles via HLA sequence comparison, providing the amino acid residues 
contributing to the binding pocket are identical (Sturniolo et al., 1999). Pocket profiles 
can therefore be recycled, rather than determined experimentally for each individual 
allele, which would require an enormous experimental effort. The TEPITOPE algorithm 
comprises twenty-five virtual matrices to predict HLA-DR epitopes.   
 
In order to analyse a given protein/peptide sequence for HLA-DR epitopes TEPITOPE 
uses three basic parameters to describe peptide binding; peptide frame, peptide side 
chain effects on binding and peptide length (Raddrizzani and Hammer, 2000). The 
peptide frame (PF), is a sequence of nine amino acids which correspond to the nonamer 
core peptide binding frame of HLA class II ligands (Raddrizzani and Hammer, 2000). 
Due to the binding requirements of position 1 of an HLA-DR binding peptide any PF 
will start with an aliphatic or aromatic amino acid due to their hydrophobic side chains. 
Peptide side chain effect (PS) values are derived using the virtual matrices. They 
comprise relative binding data calculated by normalising experimental IC50 data with 
IC50 values obtained for alanine at the same peptide position (Raddrizzani and Hammer, 
2000). The linear combination of PS values generates the peptide score (PSC) for each 
individual PF. Peptide length (PL) has been shown to affect HLA binding. However, in 
predictive models, such as TEPITOPE, if the nonamer peptide core is flanked by at least 
two amino acids on each side, PL can be ignored (Raddrizzani and Hammer, 2000).  
 
The final parameter required for TEPITOPE analysis is the user-defined „percentage 
threshold‟. This threshold is defined as the „percentage of best scoring natural peptides‟ 
and determines the stringency of the analysis (Raddrizzani and Hammer, 2000). Thus a 
high stringency, low percentage threshold such as 1%, would predict peptides in any 
protein sequence which belong to the 1% best-scoring natural peptides, with a low rate 
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of false positives but a higher rate of false negatives. This contrasts with low stringency, 
high percentage thresholds that correspond to a higher rate of false positives but a lower 
rate of false negatives.  
 
In order to derive threshold values, the PSC for all PF in a representative database of 
natural protein sequences are calculated for any given virtual matrix. The distribution of 
PSC within the sequence database is determined and PF are sorted according to their 
PSC. Finally, the PSC values corresponding to the 1%, 2%, 3% etc. best-scoring 
peptides are determined. Percentage threshold therefore, is correlated with the PSC 
value and consequently is an indicator for the possibility that the predicted peptides will 
bind to a given HLA molecule (Raddrizzani and Hammer, 2000). 
 
For TEPITOPE analysis, once all possible PF have been extracted from the user-input 
protein sequence, PS values are assigned to each residue and PSC values calculated. 
The calculated PSC values are then compared to the database values and those 
corresponding to the percentage threshold defined values highlighted (Raddrizzani and 
Hammer, 2000).   
 
2.3.2.2. NetMHCIIpan 
NetMHCIIpan is a weight matrix data-driven method derived from quantitative peptide 
HLA-DR binding data covering 14 HLA-DR alleles (Nielsen et al., 2008). The 
prediction algorithm takes in to account information regarding the peptide-binding core, 
peptide flanking residues and the HLA-DR residues estimated to be within interaction 
distance of the bound peptide in order to predict peptide/HLA binding affinities.  
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In order to assess the interactions between the HLA-DR residues and the peptide, a 
pseudo HLA sequence is encoded, consisting of the polymorphic amino acid residues 
within 4.0 Å of bound peptide (Nielsen et al., 2008). 
 
The peptide nonamer core is then identified using the SMM-align method (Nielsen et 
al., 2007). The SMM-align algorithm was designed on a quantitative training dataset 
comprising IC50  values for peptides binding to HLA alleles available from the IEDB 
databases (Nielsen et al., 2007). It makes the assumption that only the 9 amino acids 
within the HLA binding core affect binding affinity. Consequently the algorithm is 
based on a weight matrix, (9 x 20, where 9 is the length of the HLA binding motif and 
20 the number of different amino acids) and was designed to optimally reproduce the 
measured IC50 values for each peptide included in the training dataset. The weighting 
concept is required since certain amino acids in specific positions within the nonamer 
binding core will contribute more favourably to binding than others (Hammer et al., 
1994; Sinigaglia and Hammer, 1994). Therefore, SMM-align identifies HLA binding 
motifs in terms of a position specific weight matrix. The output of SMM-align analysis 
is an IC50 binding affinity value thus provides a direct readout of peptide/HLA binding 
affinity.   
 
Amino acid residues outside of the HLA binding core have been demonstrated to affect 
peptide/HLA binding (Godkin et al., 2001; Lovitch et al., 2006). Once the peptide core 
has been identified by SMM-align, N- and C-terminal peptide flanking regions are 
identified comprising up to 3 amino acids either side of the core.  The effects on binding 
of the length of the peptide flanking regions and constituent amino acids are then 
considered using a modified SMM-align algorithm to recalculate the peptide binding 
score (Nielsen et al., 2007).  
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The final peptide/HLA binding prediction/score is made based on the combinatorial 
contributions of the peptide nonamer score, peptide flanking residues and interactions of 
the HLA contact residues (Nielsen et al., 2008).  
 
2.3.2.3. Consensus method 
The Consensus method for prediction of HLA/peptide binding affinities is a 
combinatorial approach that draws upon three separate predictive algorithms to generate 
a median value (Wang et al., 2008, 2010). Combinatorial library, SMM-align and NN-
align analyses were found to be the best performing predictive algorithms currently 
available. The combinatorial library method is based upon experimental data obtained 
from the use of combinatorial peptide libraries, where peptides of the same length 
sharing one residue at the same position, are used to characterise HLA class II binding 
(Wang et al., 2010). NN-align method is an improvement of both SMM-align and 
NetMHCIIpan prediction algorithms (Nielsen and Lund, 2009). The Consensus rank 
score is generated as a median of the rank scores obtained from these methods (Wang et 
al., 2010). 
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2.4. HLA-DR1 tetramers 
2.4.1. HLA-DR1 tetramer synthesis 
Soluble HLA-DR1 tetramers (DRA1*0101/DRB1*0101) were provided by Professor 
W. Kwok (Benaroya Research Institute, Virginia Mason Research Center, Seattle, 
USA) and synthesised by methods previously described for HLA-DRB1*0401 (Novak 
et al., 1999).  
 
cDNA sequences, encoding the extracellular domains of DRA1*0101 and DRB1*0101, 
were appended to the acidic and basic segments of leucine zipper cDNA motifs, 
respectively, via a polymerase chain reaction (PCR)-mediated splicing overlap 
technique. Following addition of a site-specific biotinylation sequence, to the 3‟ end of 
the DRB1*0101 leucine zipper motif, the chimeric cDNAs were subcloned into the Cu-
inducible Drosophila expression vector, pRmHa3 and co-transfected with the 
pUChsneo plasmid (carrying a neomycin resistance marker) into Schneider S-2 cells by 
calcium phosphate transfection. Positively transfected cells were selected for with 
neomycin and expanded. Soluble class II molecule production was induced by addition 
of CuSO4. Following purification by affinity chromatography with L243 antibody, 
soluble HLA-DR molecules were biotinylated using the Bir A enzyme. Peptide loading 
was achieved by incubating empty class II molecules with peptide for 72 hours, in the 
presence of n-octyl-β-D-glucopyranoside. Finally, tetrameric HLA-DR/peptide 
complexes were formed by incubation of the class II molecules with phycoerythrin 
(PE)-conjugated streptavidin. 
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2.4.2. Tetramer guided epitope mapping (TGEM) 
Tetramer guided epitope mapping (TGEM) was performed in the laboratory of 
Professor W. Kwok (Benaroya Research Institute, Virginia Mason Research Center, 
Seattle, USA). PBMC from HLA-DR1-positive, grass-allergic patients (recruited from 
the Royal Brompton Hospital Allergy Clinic) were isolated from heparinised blood and 
frozen as described in Section 2.7. Frozen cells were transported in liquid nitrogen to 
Professor Kwok‟s laboratory and TGEM performed as previously described (Novak et 
al., 2001; James et al., 2007; Roti et al., 2008). 
 
A panel of 20-mer peptides, overlapping by 12 amino acids, spanning Phl p 1.0102 and 
Phl p 5.0201 was synthesised (Table 2.3). The peptides were divided into pools each 
containing 5 peptides. Pooled peptide tetramers were generated by incubating empty 
HLA-DR1 tetramers with the peptide mixtures in each pool.  
 
CD4
+
 T cells were isolated from thawed PBMC using a Miltenyi “no-touch” CD4+ T 
cell isolation kit. Non-CD4
+
 cells were recovered from the magnetic column and 
incubated in wells of a 48-well plate for 1 hour at a density of 3 x 10
6
 cells/well. Plates 
were then washed and adherent cells were used as APCs. 2 x 10
6
 CD4
+
 T cells were 
added per well and cells cultured in the presence of the pooled peptides for 7 days at 
which point IL-2 was added. Between days 10 and 14, cells were stained with an anti-
CD4 antibody and the pooled peptide tetramers. Positive pooled peptide tetramer 
staining was identified using flow cytometry. On detection of a positive response with 
pooled peptide tetramers, individual peptide tetramers were generated from peptides 
contained within the positive pool. Cell staining was repeated with the individual 
peptide tetramers. Positive staining with individual peptide tetramers highlighted the 
presence of a potential HLA-DR1-restricted epitope within the individual peptide. A 
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diagrammatic explanation is shown in Figure 2.3. Staining with pooled peptide 
tetramers from peptides 26-29 produces positive CD4
+
 T cell staining. On staining with 
individual peptide tetramers loaded with peptides 26 to 29, positive staining is seen with 
tetramer loaded with peptide 26.  
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Figure 2.3: Tetramer guided epitope mapping (TGEM).  
A panel of overlapping peptides encompassing the protein of interest are divided into 
pools, each comprising 5 peptides. Pooled peptide tetramers are generated by loading 
each peptide pool onto soluble HLA-DR1 molecules. These tetramers are then used to 
stain CD4
+
 T cells, previously stimulated with the relevant antigen. Peptides, from the 
pools that give positive staining, are used to generate individual peptide tetramers. 
Identification of positive individual peptide tetramer staining highlights the presence of 
an HLA-DR1-restricted epitope. 
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2.5. HLA-DR1 transgenic mice 
The HLA-DR1 (DRA*0101/DRB1*0101) transgenic mice used in this study were 
obtained from and previously described by Professor D Altmann (Altmann et al., 1995). 
HLA-DR1 transgenic mice on a FVB/N background were crossed for eight generations 
with C57BL/6 Ao mice to yield animals on a C57BL/6 background without 
endogenous mouse MHC class II. The presence of HLA-DRA1*0101/DRB1*0101 and 
absence of endogenous H2-A was verified in mice by polymerase chain reaction. All 
animals used in experiments were 8 to 12 weeks old and matched for weight and sex. 
The UK Home Office approved all animal procedures and regulations for animal 
welfare, based on the Animals (Scientific Procedures) Act 1986, were strictly observed. 
 
2.5.1. HLA-DR1 transgenic mouse genotyping 
The presence of HLA-DR1 and absence of endogenous H2-A was verified in 
transgenic mice by PCR. Mice were assigned identification based on cage number and 
ear marking at the time of tail biopsy. Genomic deoxyribonucleic acid (DNA) was 
extracted using a high salt DNA extraction method, from a small sample of tail tissue 
for genotyping purposes. 
 
2.5.1.1. Genomic DNA extraction 
Solutions: 
Digestion buffer: 
 50 mM Tris HCL (pH 8.0),  
 100 mM Ethylenediaminetetraacetic acid (EDTA),  
 100 mM NaCl 
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 1% SDS 
 
400 µl of digestion buffer and 10 µl of 20 mg/ml proteinase K (Sigma-Aldrich) were 
added to each tissue sample and incubated at 56
o
C overnight. Following digestion, 
200 µl 6 M (saturated) NaCl (Sigma-Aldrich) was added and the sample mixed well 
before centrifuging at 16000 x g for 15 minutes. The supernatant was transferred into a 
new tube and 600 µl isopropanol added in order to precipitate DNA. The sample was 
mixed by inversion and centrifuged for 10 minutes at 16000 x g in order to pellet the 
DNA. The supernatant was removed and the DNA pellet washed once with 800 µl of 
70% ethanol followed by a 5 minute centrifugation at 16000 x g. The pellet was briefly 
air-dried and redissolved by addition of 50 µl molecular biology water (DNase, RNase 
and Protease free, Sigma-Aldrich) and incubated at 56
o
C for 15 minutes. Samples were 
stored at 4
o
C for up to one week or -20
o
C for more long term storage. 
 
2.5.1.2. Polymerase Chain Reaction (PCR) 
A general PCR protocol is described below. All oligonucleotide primer sequences and 
reaction product sizes and any reaction conditions that varied from those described 
below are listed in Table 2.4. 
 
Solutions: 
Tris-acetate-EDTA (TAE) buffer: 
 40 mM Tris acetate (Sigma-Aldrich) 
 1 mM EDTA pH 8.0 (Sigma-Aldrich) 
6x Loading buffer: 
 40% sucrose (Sigma-Aldrich) 
 0.25% bromophenol blue (Sigma-Aldrich) 
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The DNA samples were diluted 1 in 50 with molecular biology water (Sigma-Aldrich) 
before performing PCRs. All PCR reactions were carried out in a reaction volume of 
25 µl containing 50-100 ng of template DNA, 16 mM (NH4)2SO4, 67 mM Tris-HCL 
(pH 8.8), 0.01% Tween® 20, 1.5 mM MgCl2, 200 µM dATP, dCTP, dGTP, dTTP 
(Bioline, London, UK), 0.5 µM of each oligonucleotide primer (Sigma Genosys) and 
0.6 units of BIOTAQ DNA polymerase (Bioline). The reaction mixture was incubated 
at 95
o
C for 5 minutes, 35 cycles of 95
o
C for 1 minute, 55
o
C for 1 minute (temperature 
determined by primer pair used, Table 2.4) and 72
o
C for 1 minute, and a final cycle at 
72
o
C for 8 minutes. Loading buffer, diluted to 1x concentration was added to each 
reaction. The PCR product obtained was analysed by running the reactions in individual 
lanes on a 1% agarose (Sigma-Aldrich) TAE gel stained with ethidium bromide (Sigma-
Aldrich) alongside a Promega 1 kb DNA ladder (Promega, Southampton UK) and 
visualised under UV light.  
  106 
 
Table 2.4: PCR primer sequences and conditions. 
 
 Primer Sequence (5‟– 3‟) 
Annealing 
temp. 
Size 
Control RBPWT1 (F) GTTCTTAACCTGTTGGTCGGAACC 55
o
C 500 bp 
 RBPWT2 (R) GCTTGAGGCTTGATGTTCTGTATTGC   
HLA-DR1 HumanDR1alphaF (F) CTCCAAGCCCTCTCCCAGAG 55
 o
C 150 bp 
 HumanDR1alphaR (R) ATGTGCCTTACAGAGGCCCC   
 HumanDR1BETAF (F) TTCAATGGGACGGAGCGGGTC 55
 o
C 200 bp 
 HumanDR1betaR (R) CTGCACTGTGAAGCTCTC   
Knockout DR1ABOF (F) TCCGCAGGGCATTTCGTGTA 60
 o
C 500 bp 
 DR1ABO-KO3 (R) GAGGATCTCGTCGTGACCAA   
(F) = forward primer 
(R) = reverse primer 
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2.5.2. HLA-DR1 transgenic mouse footpad immunisation  
Phl p 5b-derived peptide 26 (VAAAPQVKYAVFEAALTKAI), rPhl p 1, nPhl p 5, rPhl 
p 5b or groups of 5 Phl p 5b peptides were used for immunisation. 50 μg of 
peptide/protein in an emulsion with Complete Freund‟s Adjuvant (CFA, Sigma-
Aldrich) was administered subcutaneously into the left footpad. Emulsions were 
prepared by vortexing a 1:1 mixture of peptide/protein solution and CFA for 30 
minutes, followed by incubation in an iced sonic water bath for 1 hour.  
 
2.5.3. T cell proliferation assays 
2.5.3.1. Immediately ex vivo T cell proliferation assay 
10 days following immunisation with peptide or protein, mice were killed by cervical 
dislocation and the draining popliteal lymph node (DLN) harvested. The lymph node 
was passed through a nylon cell strainer (70 µm, BD Biosciences, Oxford, UK) and 
resuspended into a single cell suspension with HL-1 medium (BioWhittaker, 
Loughborough, UK) supplemented with 2 mM L-glutamate (Gibco), 25 U/ml penicillin 
G (Gibco) and 25 µg/ml streptomycin sulphate (Gibco). Cells were counted using a 
Neubauer haemocytometer with cell viability assessed by Trypan blue staining. Cells 
were cultured in triplicate in 96-well plates (Nunc, SLS, Nottingham, UK) with 6 x 10
5
 
cells per well in the presence of different concentrations of the immunising peptide or 
protein. After 48 hours, 5 μCi of [3H]-thymidine (MP Biomedicals, Cambridge, UK) 
was added to each well. Cells were cultured for an additional 16 hours before plates 
were harvested onto glass fibre filtermats (Wallac, Turku, Finland) using a MACH III 
M Harvester 96. This was followed by beta scintillation counting using 1450 Microbeta 
TRILUX (Wallac).  
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2.5.3.2. T cell line proliferation assay 
Proliferation assays were performed for each T cell line at each restimulation to check 
peptide/ protein specificity. Proliferation assays were performed as described above. In 
triplicate wells of a 96-well plate (Nunc, SLS) with 2 x 10
4
 T cells with 3 x 10
5
 
irradiated autologous splenocytes in RPMI-1640 medium per well. 
 
2.5.3.3. Epitope mapping proliferation assay 
Proliferation assays for epitope mapping were performed as described above. In 
triplicate wells of a 96-well plate (Nunc, SLS) T cells from either the rPhl p 1 or rPhl p 
5 T cell lines (2 x 10
4 
cells/well) were incubated for 48 hours with Autologous, 
irradiated splenocytes (3 x 10
5
 cells/well) in the presence or absence of 50 µg/ml of 20-
mer overlapping peptides spanning either Phl p 1.0102 or Phl p 5.0201 (PEPScreen® 
Handling, Sigma Genosys or ProImmune thinkpeptides, PEPScreen® Custom peptide 
library, ProImmune) (Table 2.3). 
 
2.5.4. Culture of T cell lines 
Following T cell isolation from the draining lymph node, T cell lines were set up with 
3 x 10
6
 cells/ml DLN cells in the presence of 25-50 µg/ml rPhl p 1, nPhl p 5, rPhl p 5b 
or Phl p 5b-derived peptide 26 in a 12-well plate (Nunc, SLS) in HL-1 medium. After 
48 hours, cells were resuspended in complete T cell culture media; RPMI 1640 medium 
containing 50 U/ml penicillin G, 50 µg/ml streptomycin sulphate, 2 mM L-glutamine 
(all Gibco), 50 µM 2-beta-mercaptoethanol (2-ME; Sigma-Aldrich) and 10% foetal calf 
serum (FCS, Globepharm, Guildford, UK), with the addition of 10 IU/ml IL-2 (R & D 
Systems, Abingdon, UK). Cells were cultured for a further 8 days. At day 10, the cells 
were resuspended in complete T cell culture media and restimulated with 25-50 μg/ml 
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of appropriate peptide in the presence of 3 x 10
6
/ml irradiated autologous splenocytes at 
a ratio of 1:25, T cells to APCs. Splenocytes were irradiated by exposure to 3000 rads 
of γ-radiation (Gammacell® 3000 Elan irradiator, Nordian International Inc.). All T cell 
lines were restimulated repeatedly every 9-11 days and maintained in 10 IU/ml IL-2.  
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2.6. Clinical Measurements 
2.6.1. Ethical statement 
This study was approved by the Royal Brompton, Harefield and National Heart and 
Lung Institute Ethics Committee (Reference: 06/Q0404/43). For all participants written 
consent was obtained prior to involvement.  
 
2.6.2. Participant characterisation 
Patient characterisation: assessment of symptoms, skin prick testing and phlebotomy 
were performed by Ms Andrea Goldstone. 
 
Allergic subjects were required to have symptoms of moderate/severe allergic rhinitis 
during the UK grass pollen season (Bousquet et al., 2008). In addition, a positive skin 
prick test result to Phleum pratense (Timothy grass) and elevated total and allergen-
specific IgE levels were required. Multiple aeroallergen sensitisations were permitted. 
 
Non-allergic subjects were required to be non-symptomatic. In addition, negative skin 
prick test results to common aeroallergens, including Phleum pratense, were required, 
together with total and allergen-specific IgE concentrations within normal levels. 
 
All subjects were HLA-DRB typed and were HLA-DRB1*0101 positive. 
 
2.6.2.1. Skin prick testing 
Skin prick tests were performed on the volar aspect of the forearm with aeroallergen 
extracts (Table 2.5, Soluprick, ALK Abellό, Horsholm, Denmark). Drops of allergen 
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were applied to the skin. Positive (histamine dihydrochloride, 10 mg/ml) and negative 
(allergen diluent) controls were also included. The skin was pierced through the site of 
the allergen drops using a sterile lancet. After 15 minutes, the wheal diameter (mean of 
two orthogonal diameters) was measured. A positive skin test was defined as a wheal of 
3 mm or greater in diameter than the negative control in the presence of a positive 
histamine control. Oral anti-histamines were withheld for 72 hours where appropriate 
prior to skin prick testing.  
 
2.6.2.2. Total and allergen-specific IgE measurements 
Total serum IgE concentrations and allergen-specific IgE concentrations in the serum 
were measured in the Biochemistry Department at the Royal Brompton Hospital by 
radioallergorsobent tests (Phadebas RAST, Pharmacia, Uppsala, Sweden). Elevated 
serum total and allergen-specific IgE concentrations were defined as those in excess of 
the upper limit of the normal range established in the hospital laboratory; Total IgE: 
150 IU/ml and allergen-specific IgE 0.35 IU/ml.  
 
2.6.2.3. HLA-DRB typing 
High resolution HLA-DRB typing was performed on genomic DNA, extracted from 
whole blood, according to standard methods at the Anthony Nolan Histocompatibility 
Laboratories or the Department of Clinical Immunology, Hammersmith Hospital, 
Imperial College Healthcare NHS Trust. 
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Table 2.5: Aeroallergens used for skin prick testing. 
 
Binomal name  
Alternaria alternate Alternaria 
Artemisia vulgaris Mugwort 
Betula verrucosa Silver birch 
Aspergillus fumigatus Aspergillus 
Canis familiaris Dog hair 
Cladosporium herbarum Cladosporium 
Dermatophagoides pteronyssinus House dust mite 
Equus caballus Horse dander 
Felis domesticus Cat hair 
Phleum pratense Timothy grass 
3 Tree mix: 
Alnus glutinosa/Alnus incana, Betula 
verrucosa, Corylus avellana 
 
Black/Grey Alder, Silver birch, Hazel 
6 grass mix:  
Avena sativa, Dactylis glomerata,  
Poa pratensis, Festuca pratensis,  
Lolium perenne, Phleum pratense 
 
Common oat, Orchard grass,  
Smooth meadow grass, Meadow fescue, 
Rye grass, Timothy grass 
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2.7. Cell isolation and processing 
2.7.1. Peripheral blood mononuclear cell (PBMC) extraction 
Venous blood was collected into heparinised syringes (heparin sulphate, 1000 U/ml). 
Blood was diluted in an equal volume of RPMI-1640 (Invitrogen, Paisley, UK). PBMC 
were isolated by density gradient centrifugation. 35 ml diluted blood was layered over 
15 ml pre-warmed Ficoll-Paque
TM
 PLUS (GE Healthcare Life Sciences, Little Chalfont, 
UK) or Histopaque 1077 (Sigma-Aldrich, Poole, UK) and centrifuged, without brake, 
for 25 minutes, 1136 x g at room temperature. The PBMC layer at the Ficoll-
Paque/Histopaque-plasma interface was extracted by gentle aspiration with a Pasteur 
pipette. PBMC were washed three times in excess RPMI-1640 by centrifugation at 528 
x g for 10 minutes at room temperature. Cell viability was assessed by trypan blue 
exclusion (Section 2.7.2.1). Cells were resuspended in complete medium: RPMI-1640 
containing 10% human AB serum (PAA Laboratories GmbH, Austria), 2 mM 
L-glutamine and 25 mM 4-(2-hydroxyethyl)-1-piperazineethanesulphonic acid (HEPES; 
Gibco) and 100 IU/ml penicillin/streptomycin (Invitrogen).  
 
2.7.2. Assessment of cell viability 
2.7.2.1. Trypan blue stain 
20 μl aliquots of cell suspension were diluted 1:1 in Trypan blue (Sigma-Aldrich). Cells 
were counted on a Neubauer haemocytometer under 40x magnification. Non-viable 
cells took up the dye and stained blue whilst viable cells were colourless. The cell 
density was determined from the number of viable cells.  
  114 
 
2.7.3. Cryopreservation and thawing of PBMC 
PBMC were stored for future use in liquid nitrogen. Cells were resuspended in human 
AB serum and 500 μl added to cryovials (Nunc, SLS). 500 μl human AB serum 
containing 20% DMSO (Sigma-Aldrich) was added dropwise. Cryovials were 
transferred quickly to Nalgene
TM
 Cryo 1
o
C container (Nalgene, SLS) and placed at 
-80
o
C for 24 hours prior to being transferred into liquid nitrogen storage. For thawing, 
cryovials were quickly resuspended in 10 ml pre-warmed complete medium. Cells were 
washed by centrifugation at 338 x g for 10 minutes at room temperature. The pellet was 
resuspended in complete medium and viability determined by Trypan blue exclusion.  
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2.8. Cell separation using magnetic activated cell sorting (MACS) 
Magnetic activated cell sorting (MACS) enables the separation of cell populations 
according to their expression of cell surface antigens. Cell separation is achieved 
through incubation with magnetic nanoparticles coated with either individual antibodies 
or antibody cocktails against particular surface antigens. The cell/nanoparticle solution 
is then passed through a column placed in a strong magnetic field. Cells attached to the 
magnetic nanoparticles i.e. those expressing the specific cell surface antigen will be 
retained within the column, whilst unlabelled cells will pass through.  
 
Cells may be separated by positive or negative selection. In positive selection, magnetic 
nanoparticles are used expressing cell surface antigens specific to the cell population of 
interest thus; the labelled cells are retained within the column until its removal from the 
magnetic field. For negative selection, the magnetic nanoparticles are coated with 
antibodies that are not present on the cell population of interest. The fraction that is 
collected as the sample passes through the column whilst it is within in the magnetic 
field therefore contains the cell population of interest.  
 
2.8.1. Isolation of CD4+ T cells 
CD4
+
 T cells were enriched from freshly isolated PBMC via negative selection using 
MACS MicroBeads (Miltenyi Biotec, Gladbach, Germany).  
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Solutions: 
Phosphate buffered saline (PBS): 
 10x PBS pH 7.4 (Gibco) diluted to 1x with distilled H2O. 
MACS buffer: 
 1x PBS pH 7.2-7.4  
 0.5% bovine serum albumin (BSA; Sigma-Aldrich) 
 2 mM EDTA (Sigma-Aldrich) 
 Degassed, 4-8oC 
 
PBMC were counted and pelleted by centrifugation at 300 x g at 4
o
C for 10 minutes and 
supernatant completely removed by pipetting. Cells were resuspended in 40 μl MACS 
buffer per 10
7
 total cells. Biotin-Antibody cocktail (Comprising biotinylated 
monoclonal antibodies against CD8, CD14, CD16, CD19, CD36, CD56, CD123, 
TCRγ/δ and Glycophorin A) (Miltenyi Biotech) was added, 10 μl per  107 total cells and 
incubated in the fridge at 4
oC for 10 minutes. 30 μl MACS buffer was added per 107 
total cells followed by 20 μl anti-biotin MicroBeads per 107 total cells. The samples 
were mixed well and incubated for 15 minutes at 4
o
C, then washed by centrifugation at 
300 x g for 10 minutes at 4
o
C in excess MACS buffer. The subsequent cell pellet was 
resuspended in 500 μl MACS buffer per 108 labelled cells. The cells were passed 
through a 30 μm pre-separation filter (Miltenyi Biotec) prior to running through a “LS” 
separation column (Miltenyi Biotec) clamped into “MidiMACS Separation Unit” 
magnetic field (Miltenyi Biotec). The column effluent and three washes (3 x 3 ml 
MACS buffer) were collected containing the unlabelled CD4
+
 T cell fraction. The 
column was removed from the magnetic field and the magnetically labelled non-CD4
+
 T 
cell fraction
 
eluted (3 x 3 ml MACS buffer). Both fractions were washed, 300 x g for 10 
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minutes at 20
o
C in excess MACS buffer, resuspended in 15 ml complete medium and 
counted using Trypan blue staining.  
 
2.8.2. CD25+ T cell depletion of enriched CD4+ T cells 
CD25
+
 T cells were depleted from the enriched CD4
+
 T cell population using positive 
selection MACS microbeads (Miltenyi Biotec). 
 
CD4
+
 T cells were counted and centrifuged at 300 x g for 10 minutes. The supernatant 
was completely aspirated and the cell pellet resuspended in 80 μl MACS buffer and 
20 μl CD25 MicroBeads II (Miltenyi Biotec) per 107 cells. Cells and MicroBeads were 
mixed well and incubated for 15 minutes at 4
o
C. Cells were washed in excess MACS 
buffer by centrifugation at 300 x g for 10 minutes. Cells were resuspended in 500 μl 
MACS buffer per 10
8
 labelled cells. The cell sample was passed through a 30 μm pre-
separation filter (Miltenyi Biotec) prior to running through a “MS” separation column 
(Miltenyi Biotec) clamped into “MiniMACS Separation Unit” magnetic field (Miltenyi 
Biotec). The unlabelled CD4
+
CD25
-
 fraction passed through the column and was 
collected along with three column washes. The column was removed from the magnetic 
field and the magnetically labelled CD4
+
CD25
+ 
eluted. The CD4
+
CD25
-
 fraction was 
washed, 300 x g for 10 minutes at 20
o
C in excess MACS buffer, resuspended in 15 ml 
complete medium and counted using Trypan blue staining. 
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2.8.3. Assessment of purity of MACS isolations 
The purity of the isolated cell fractions was determined using cell surface antigen 
staining and flow cytometry as described in Section 2.11.1. Representative plots are 
shown in Figure 2.4. 
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Figure 2.4: Representative plots demonstrating purity of cell populations following 
MACS isolations. 
Following MACS isolations the purity of the cell populations was evaluated by cell 
surface antigen staining and flow cytometry. Forward and side scatter were initially 
used in order to define the live lymphocyte gate (R1). Subsequent analyses were 
performed on cells within R1. Antibody labelling confirmed the enrichment of CD4
+
 
cells and depletion of CD25
+
 cells. Numbers are percentage of gated events within the 
quadrant. 
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2.9. Cell culture 
2.9.1. Whole PBMC culture 
Freshly isolated whole PBMC were counted using Trypan blue exclusion and 
resuspended at 2 x 10
6
  cells/ml in complete medium. On day 7, cells were passaged and 
recombinant human IL-2 (1 ng/ml, Proleukin, Novartis, Horsham, UK) added to the 
culture medium. The cultures were maintained with fresh media containing IL-2 every 
2-3 days. 
 
2.9.2. CD4+ T cells plus adherent cells 
Non-CD4
+
 cells were counted and incubated in wells of a 48-well plate (Nunc, SLS) at 
3 x 10
6
 cells/well in a volume of 300 μl, for 2 hours at 37oC, 5% CO2 in order to adhere 
to the base of the tissue culture well. Plates were washed by centrifugation with 
complete medium to remove non-adherent cells, 423 x g for 10 minutes at room 
temperature. CD4
+
 T cells were added to each well, 2 x 10
6
 cells/ml, in complete 
medium. On day 7, cells were passaged and recombinant human IL-2 (1 ng/ml, 
Proleukin, Novartis) added to the culture medium. The cultures were maintained with 
fresh media containing IL-2 every 2-3 days. 
 
2.9.3. CD4+CD25- T cells plus adherent cells 
Tissue culture plates were coated with non-CD4
+
 adherent cells as previously described. 
 
Isolated CD4
+
CD25
-
 T cells were added to each well, 2 x 10
6
 cells/ml, in complete 
medium. On day 7, cells were passaged and recombinant human IL-2 (1 ng/ml, 
Proleukin, Novartis) added to the culture medium. The cultures were maintained with 
fresh media containing IL-2 every 2-3 days. 
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2.9.4. Cell culture conditions 
2.9.4.1. For HLA-DR1 tetramer staining following in vitro expansion. 
PBMC were cultured in 24 well plates with 2 x 10
6
 cells/well in 2 ml complete medium 
with the following antigens: 
1. 10 µg/ml rPhl p 5b 
2. 20 µg/ml Phl p 5b-derived peptide 26  
3. 20 µg/ml Phl p 1-derived peptide 20 
 
In order to evaluate the effect of serum free medium PBMC were additionally cultured 
in 24 well plates, 2 x 10
6
 cells/well in 2 ml AIM-V (Invitrogen) in the presence of 
20 µg/ml Phl p 5b-derived peptide 26. 
 
CD4
+
CD25
+
 T cells or CD4
+
CD25
-
 T cells were cultured in 24 well plates with 2 x 10
6
 
cells/well in 2 ml complete medium with 20 µg/ml Phl p 5b-derived peptide 26. 
 
2.9.4.2. For measurement of cytokine production by enzyme-linked immunosorbent 
assays (ELISA). 
PBMC were cultured in 24 well plates at 2 x 10
6
 cells/well in 2 ml complete medium 
with the following antigens: 
1. 10 µg/ml Phleum pratense, whole grass pollen extract 
2. 1 µg/ml Purified protein derivative (PPD) of Mycobacterium tuberculosis 
(Evans Medical Ltd, Leatherhead, UK)  
3. 10 µg/ml rPhl p 5b 
4. 10 µg/ml rPhl p 1 
5.  2 µg/ml Phl p 5b-derived peptide 26 
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6. 20 µg/ml Phl p 5b-derived peptide 26  
7. 2 µg/ml Phl p 1-derived peptide 20 
8. 20 µg/ml Phl p 1-derived peptide 20 
9. Complete medium only (control)  
 
Supernatants were collected at day 7 and stored at -20
o
C until required.  
 
2.9.4.3. For evaluation of the frequency of cytokine-producing cells by dual Fluorospot 
assay. 
PBMC were cultured in 96 well plates at 1 x 10
6
 cells/well in 100 µl complete medium 
with the following antigens: 
1. 10 µg/ml phytohaemagglutinin (PHA, Sigma-Aldrich) 
2. 1 µg/ml PPD (Statens Serum Institut, Copenhagen, Denmark) 
3. 10 µg/ml Phleum pratense, whole grass pollen extract 
4. 0.2 µg/ml Phl p 5b-derived peptide 26 
5. 1 µg/ml Phl p 5b-derived peptide 26 
6. 5 µg/ml Phl p 5b-derived peptide 26 
7. 20 µg/ml Phl p 5b-derived peptide 26 
8. 0.2 µg/ml Phl p 1-derived peptide 20 
9. 1 µg/ml Phl p 1-derived peptide 20 
10. 5 µg/ml Phl p 1-derived peptide 20 
11. 20 µg/ml Phl p 1-derived peptide 20 
12. Complete medium only (Control) 
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2.9.4.4. For measurement of proliferation by carboxyfluorescein succinimidyl ester 
(CFSE)-labelling and intracellular cytokine staining. 
CFSE-labelled PBMC were cultured in 48 well plates at 1 x 10
6
 cells/well in 1 ml 
complete medium with the following antigens: 
1. 1 µg/ml PPD (Evans Medical Ltd) 
2. 20 µg/ml Phl p 5b-derived peptide 4 
3. 20 µg/ml Phl p 5b-derived peptide 5 
4. 20 µg/ml Phl p 5b-derived peptide 18 
5. 20 µg/ml Phl p 5b-derived peptide 23 
6. 20 µg/ml Phl p 5b-derived peptide 24 
7. 20 µg/ml Phl p 5b-derived peptide 26 
8. 20 µg/ml Phl p 1-derived peptide 6 
9. 20 µg/ml Phl p 1-derived peptide 7 
10. 20 µg/ml Phl p 1-derived peptide 17 
11. 20 µg/ml Phl p 1-derived peptide 20 
12. 20 µg/ml Phl p 1-derived peptide 24 
13. Complete medium only (Control) 
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2.10. Cytokine detection techniques 
2.10.1. Enzyme-linked immunosorbent assay (ELISA) 
The concentrations of cytokine in cell culture supernatants were determined by ELISA 
measuring against linear standard curves. Cytokine present within cell culture 
supernatant is captured by plate-bound capture antibodies. Bound cytokine is detected 
by labelling with biotin-conjugated detection antibodies and subsequent enzyme-
mediated substrate development.  
 
2.10.1.1.  Human IL-5 ELISA 
IL-5 concentration in supernatants was analysed using a human IL-5 DuoSet ELISA 
development kit from R & D Systems Europe Ltd (Abingdon, UK).  
 
Solutions: 
PBS: 
 10x PBS pH 7.4 (Gibco) diluted to 1x with distilled H2O. 
Wash buffer: 
 0.05% Tween® 20 (Sigma-Aldrich) in PBS, pH 7.2 – 7.4. 
Block buffer/ Reagent diluent: 
 1% BSA (Millipore, Watford, UK) in PBS, pH 7.2 – 7.4, 0.2 µm filtered. 
0.05 M Phosphate citrate buffer, pH 5.0: 
 2.84 g Na2HPO4 (Sigma-Aldrich) 
 1.92 g Anhydrous citric acid (Sigma-Aldrich) 
 200 ml distilled H2O 
Tetramethylbenzidine (TMB) solution: 
 100 mg TMB (Sigma-Aldrich) 
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 10 ml DMSO (Sigma-Aldrich) 
Substrate solution: 
 10 ml 0.05M Phosphate citrate buffer, pH 5.0 
 100 µl TMB solution 
 3 µl 30% H2O2 (Sigma-Aldrich) added just prior to use. 
Stop solution: 
 2 M H2SO4 (Sigma-Aldrich) 
 
Reagents: 
Capture antibody: 
 Reconstituted concentration:  
o 360 µg/ml of rat anti-mouse IL-5 when reconstituted with 1 ml of PBS 
 Working concentration 
o 2 µg/ml  
Detection antibody: 
 Reconstituted concentration:  
o 22.5 µg/ml of biotinylated rat anti-human IL-5 when reconstituted with 
1 ml of reagent diluent. 
 Working concentration 
o 125 ng/ml 
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Standard: 
 95 ng/ml of recombinant human IL-5 when reconstituted with 0.5 ml of reagent 
diluent. 
 Concentration range used for standard curve: 
o 2000 pg/ml to 3.9 pg/ml 
 
Protocol: 
The primary capture antibody was diluted to a working concentration in PBS without 
carrier protein and 70 µl added to wells of a 96-well ELISA plate (Maxisorp, Nunc, 
SLS). Plates were sealed and incubated overnight at room temperature. The next day, 
plates were washed three times with wash buffer (400 µl/well per wash). Remaining 
wash buffer was removed by inverting plates and blotting against paper towel. Plates 
were blocked by addition of 100 µl/well block buffer for 1 hour at room temperature. 
Plates were aspirated and washed three times with wash buffer. 50 µl/well of 
supernatant sample or standard were added to each well in duplicate. Samples were 
diluted in reagent diluent whilst a ten-point standard curve was prepared by 2-fold serial 
dilution of recombinant human cytokine with reagent diluent at a concentration range of 
2000 pg/ml to 3.9 pg/ml. Following incubation for 1 hour at room temperature on a 
plate shaker (Titramax 1000; Heidolph Instruments, Lab Plant, Huddersfield, UK), 
plates were washed three times with wash buffer. Detection antibody was diluted with 
reagent diluent to a working concentration and added to all wells 70 µl/well and plates 
incubated for 1 hour, room temperature on shaker. Plates were washed three times and 
70 µl Streptavidin-horseradish peroxidise (HRP) (R&D Systems) diluted 1:200 in 
reagent diluent added to each well. Plates were incubated for 20 minutes, at room 
temperature, in the dark, on the shaker then washed three times with wash buffer. 
Substrate solution was prepared and 70 µl added to each well for a maximum 20 
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minutes or until the development of a blue colour at room temperature, in the dark on 
the shaker. 35 µl stop solution was added to each well. Absorbances were read at 450 
nm using an automated ELISA plate reader (Emax, Molecular Probes, Oregon). 
Cytokine concentrations in samples were determined using Softmax Pro software 
(Version 4.3.1, Molecular Devices, Wokingham, UK) and calculated by interpolation 
from a four parameter logistic curve-fit standard curve averaging the duplicate reading 
for each standard and sample, subtracting the average zero standard optical density and 
multiplying by the dilution factor where necessary.  
 
2.10.1.2. Human IFN-γ ELISA 
IFN-γ concentration in supernatants was analysed using a human IFN-γ DuoSet ELISA 
development kit from R & D Systems Europe Ltd.  
 
Solutions: 
As for IL-5 ELISA with the exception of: 
Tris buffered saline (TBS): 
 20 mM Trizma base (Sigma-Aldrich) 
 150 mM NaCl (Sigma-Aldrich) 
 pH 7.2-7.4, 0.2 µm filtered. 
 
Block buffer/ Reagent diluent: 
 0.1% BSA, 0.05% Tween® 20 (Sigma-Aldrich) in TBS 
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Reagents: 
Capture antibody: 
 Reconstituted concentration:  
o 720 µg/ml of mouse anti-human IFN-γ when reconstituted with 1 ml of 
PBS. 
 Working concentration 
o 4 µg/ml  
Detection antibody: 
 Reconstituted concentration:  
o 9 µg/ml of biotinylated goat anti-human IFN-γ when reconstituted with 
1 ml of reagent diluent. 
 Working concentration 
o 50 ng/ml  
Standard: 
 120 ng/ml of recombinant human IFN-γ when reconstituted with 0.5 ml of 
reagent diluent. 
 Concentration range used for standard curve: 
o 2000 pg/ml to 3.9 pg/ml 
 
Protocol: 
As for IL-5 ELISA with the exception of detection antibody was prepared with reagent 
diluent with 2% heat inactivated normal goat serum (prepared 1-2 hours prior to use, 
Dako, Glostrup, Denmark). 
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2.10.2. Dual Fluorospots 
The frequencies of cytokine producing cells following short term PBMC culture were 
determined by dual Fluorospot assays. Cells are stimulated for a specific period in 
culture plates that have been pre-coated with capture antibodies specific to cytokines of 
interest. Following the defined culture period cells are removed and capture-antibody-
bound secreted cytokine detected by detection antibodies and fluorescent conjugates. 
 
2.10.2.1. Human dual IL-10/IL-4 Fluorospot 
The frequencies of IL-10 and IL-4 producing cells following short term PBMC culture 
were determined using a Diaclone Human Dual IL-10/IL-4 Fluorospot Set (Gen-Probe 
Diaclone SAS, Besancon, France) 
 
Solutions: 
1x PBS: 
 10x PBS pH 7.4 (Gibco, Invitrogen, Paisley, UK) diluted to 1x with distilled 
H2O. 
1% BSA:  
 0.2 g BSA in 20 ml 1x PBS 
0.1% Tween® 20: 
 70 µl Tween® 20 in 70 ml of 1x PBS 
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Reagents: 
Capture antibodies: 
 For 1 plate dilute 100 µl of IL-10 capture antibody and 100 µl of IL-4 capture 
antibody in 10 ml of PBS 
Detection antibodies: 
 Reconstituted with 0.55 ml distilled H2O 
 For 1 plate dilute 100 µl of reconstituted IL-10 detection antibody and 100 µl of 
reconstituted IL-4 detection antibody into 10 ml of 1% BSA/PBS 
Anti-fluorescein isothyocyanate (FITC)-green/fluorescence conjugate: 
 Dilute 36 µl reagent in 10 ml PBS 1% BSA with streptavidin-PE conjugate. 
Streptavidin-PE conjugate: 
 Dilute 15 µl reagent in 10 ml PBS 1% BSA with anti-FITC green/fluorescence 
conjugate.  
5% Fluorescence buffer: 
 For one plate dissolve 500 µl fluorescence buffer in 10 ml PBS. 
 
Protocol: 
Wells of a 96-well polyvinylidene difluoride (PVDF)-flat bottomed plate (Millipore 
MultiScreen plates) were rehydrated by addition of 25 µl 70% ethanol for 30 seconds at 
room temperature. Wells were emptied and plates washed three times with 100 µl/well 
PBS. Plates were coated overnight at 4
o
C with 100 µl/well anti-cytokine capture 
antibody solution. The next day, wells were emptied and washed once with 100 µl PBS. 
The plates were blocked with 100 µl/well 10% FCS/RPMI, for 2 hours at room 
temperature and washed once with PBS. 50 µl/well of stimulator at appropriate 
concentration was added to each well followed by 50 µl/well of cell suspension 
containing 1 x 10
6
 PBMC. Plates were covered and incubated undisturbed at 37
o
C in a 
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CO2 incubator for 42 hours. Plates were emptied by inversion and blotting on absorbent 
paper. 100 µl of 0.1% Tween® 20/PBS was added to each well and incubated for 10 
minutes at 4
o
C. Plates were washed three times with 0.1% Tween® 20/PBS. 100 µl 
detection antibody solution was added to each well, plates covered and incubated for 1 
hour and 30 minutes at room temperature. Wells were emptied and washed three times 
with 0.1% Tween® 20/PBS. 100 µl of anti-FITC-green fluorescence conjugate/ 
Streptavidin-PE solution was added to each well, plates sealed and incubated for 1 hour 
at room temperature. Wells were emptied and washed three times with 0.1% Tween® 
20/PBS. 100 µl 5% fluorescence buffer was added to each well, the plate sealed and 
incubated for 15 minutes at room temperature, in the dark. Wells were emptied wells by 
inversion against absorbent paper. The bottom of the plate was removed and the back of 
the PVDF-membrane washed under running distilled water ensuring water did not enter 
the wells. Residual buffer was removed by repeated tapping on absorbent paper. The 
plates were dried at room temperature away from light for approximately 2 hours. Spots 
were read on an AID iSpot Fluorospot reader system (Autoimmun Diagnostika (AID) 
GmbH, Strassberg, Germany) under a UV light source. Data were analysed using AID 
Elispot reader software (Version 5, AID).  
 
2.10.2.2. Human dual IFN-γ/IL-5 Fluorospot 
The frequencies of IFN-γ and IL-5 producing cells following short term PBMC culture 
were determined using a Diaclone Human Dual IFN-γ /IL-5 Fluorospot Set (Gen-Probe 
Diaclone SAS, Besancon, France) 
 
Solutions: 
As for dual IL-10/IL-4 Fluorospot  
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Reagents: 
Capture antibodies: 
 For 1 plate dilute 100 µl of IFN-γ capture antibody and 100 µl of IL-5 capture 
antibody in 10 ml of PBS 
Detection antibodies: 
 For 1 plate dilute 100 µl of reconstituted IFN-γ detection antibody and 100 µl of 
reconstituted IL-5 detection antibody into 10 ml of 1% BSA/PBS. 
Anti FITC-green/fluorescence conjugate: 
 Dilute 38 µl reagent in 10 ml PBS 1% BSA with streptavidin-PE conjugate. 
Streptavidin-PE conjugate: 
 Dilute 15 µl reagent in 10 ml PBS 1% BSA with anti-FITC green/fluorescence 
conjugate.  
 
Protocol: 
This was as previously described for dual IL-10/IL-4 Fluorospot but without incubation 
with 5% fluorescence buffer step. After addition of 100 µl of anti-FITC-green 
fluorescence conjugate/ Streptavidin-phycoerythrin solution was added to each well, 
plates sealed and incubated for 1 hour at room temperature. Wells were emptied and 
washed three times with 0.1% Tween® 20/PBS. The bottom of the plate was removed 
and both sides of the PVDF-membrane washed under running distilled water. Residual 
buffer was removed by repeated tapping on absorbent paper. The plates were dried and 
read as previously described.  
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2.11. Flow cytometry 
Flow cytometry, fluorescence activated cell sorting (FACS), enables the analysis of 
single cells based upon their size and granularity. In addition, labelling cells with 
antibodies conjugated to fluorophores permits analysis of the expression of cell surface 
antigens and intracellular molecules. 
 
For all experiments, cells were gated on live lymphocytes according to forward and side 
scatter. Data were acquired using a FACSCalibur™ flow cytometer (BD Biosciences) 
and subsequently analysed using BD CellQuest™ Pro v. 5.2.1 software (BD 
Biosciences) unless otherwise stated. 
 
Flow cytometry gating strategies, unless otherwise stated are shown in Section 2.12. 
 
Solutions: 
FACS buffer: 
 10% FCS (Globepharm) in PBS 
 
2.11.1. Cell surface antigen staining 
Cells were washed twice in FACS buffer by centrifugation at 528 x g for 5 minutes at 
4
o
C. Cells were resuspended in 50 µl FACS buffer and stained with fluorochrome-
conjugated monoclonal antibodies specific to cell surface antigens (Section 2.13.) for 30 
minutes on ice. Following a final wash step, cells were resuspended in 100 µl FACS 
buffer and data acquired. 
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2.11.1.1.  Purity analysis 
Cell surface antigen staining was performed using anti-CD4 and anti-CD25 antibodies 
(Section 2.13.1, BD Biosciences) following magnetic bead isolation of CD4
+
 T cells 
and CD25
+
 depletion in order to assess the efficiency of cell isolations. The gating 
strategy is shown in Figure 2.4. 
 
2.11.1.2. Phenotyping analysis 
Cell surface antigen staining was performed using fluorochrome-conjugated antibodies 
specific to a variety of cell surface antigens in order to evaluate the surface phenotype 
of tetramer-labelled CD4
+
 T cells. Following immediate ex vivo tetramer labelling (as 
described in Section 2.12.2.) cells were aliquoted into wells of a v-bottomed 96-well 
plate (Nunc). Cells were resuspended in 50 µl FACS buffer containing cell surface 
antigen specific antibodies (Section 2.13.1), labelled and analysed as described in 
Section 2.11.1. The gating strategy is shown in Figure 2.7. 
 
2.11.2. HLA-DR1 Tetramer staining 
2.11.2.1.  In vitro expanded human and mouse CD4+ T cell line tetramer staining 
Cells were harvested, washed with FACS buffer for 5 minutes at 528 x g. Cells were 
resuspended in 25 µl  complete medium and used at a concentration of 1 x 10
5
 cells/ 
well of a 96-well plate (Nunc). Cells were stained with 10 µg/ml PE-conjugated 
tetramers loaded with either candidate peptides or control peptide, for 1 hour at 37
o
C in 
5% CO2. Cells were then washed twice with FACS buffer, 3 minutes at 235 x g, and 
surface stained with cell surface antigens for 30 minutes at 4
o
C in the dark. Following a 
final wash, 3 minutes at 235 x g data were acquired. The gating strategy is shown in 
Figure 2.5. 
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2.11.2.2.  Immediate ex vivo tetramer staining of PBMC 
Freshly isolated PBMC from peripheral blood were counted by Trypan blue exclusion, 
20 x 10
6
 cells removed and pelleted by centrifugation, 528 x g, 10 minutes. Supernatant 
was completely aspirated and cells resuspended in 200 µl complete medium, 3 µg 
HLA-DR1 tetramer loaded with candidate peptide or irrelevant control peptide was 
added and cells incubated in the dark at room temperatures for 2 hours. For the final 20 
minutes, anti-CD4-PE-Cy5 antibody (BD Pharmingen) was added. Cells were washed 
twice with FACS buffer, 528 x g, 10 minutes. Cells were resuspended in 1 ml FACS 
buffer, 100 µl was reserved for ex vivo frequency analysis. The gating strategy is shown 
in Figure 2.6. The remaining 900 µl tetramer-labelled PBMC was pelleted by 
centrifugation, resuspended in FACS buffer and aliquoted for cell surface marker 
staining as described in Section 2.11.1.2.    
 
2.11.3. CFSE labelling 
Freshly isolated PBMC were resuspended, 10 x 10
6
 cells/ml, in PBS. CFSE (1 mM, 1 
µl/ml, eBiosciences) was added and cells incubated in the dark, for 2.5 minutes at 37
o
C, 
5% CO2. Staining was quenched by the addition of an equal volume of FCS 
(Globepharm) and cells were subsequently washed in PBS by centrifugation for 10 
minutes at 528 x g. Cells were resuspended in complete medium to a density of 1 x 10
6
 
cells/ml. Cultures were set up in 48-well tissue culture plates (Nunc). Cultures were 
stimulated with a variety of antigens described in Section 2.9.4 and maintained for 14 
days with the addition of IL-2 from day 7. At day 14, wells were resuspended and 
200 µl of cells taken for cell surface antigen staining (CD4-PE-Cy5) as described in 
Section 2.11.1. In order to exclude dead cells from subsequent analyses, cells were 
incubated with 7-Amino-Actinomycin D (7-AAD; BD Biosciences) for 10 minutes 
prior to a final wash by centrifugation, 5 minutes, 528 x g. Data were acquired and 
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additionally analysed using ModFit LT software (Version 3.2, Verity Software House, 
Topsham, ME, US). The gating strategy is shown in Figure 2.8. 
 
2.11.4. Intracellular cytokine staining 
2.11.4.1. Cell stimulation and surface marker staining 
For single cell analysis of intracellular cytokine expression in CD4
+
 T cells, PBMC 
were resuspended in complete medium containing 10 ng/ml phorbol myristate acetate 
(PMA, Sigma-Aldrich),1 µg/ml ionomycin (Sigma-Aldrich) and 1 µg/ml Brefeldin A 
(BFA, GolgiPlug, BD Biosciences) and incubated for 4 hours at 37
o
C in 5% CO2. For 
the final 2 hours, 1 µg/ml monensin (GolgiStop, BD Biosciences) was added. Cells 
were then washed by centrifugation in PBS at 528 x g for 10 minutes. Cells were 
resuspended and surface stained in a total volume of 50 µl FACS buffer with a 1 in 5 
dilution of anti-CD4-PE-Cy5 (BD Pharmingen) for 20 minutes at room temperature. 
Cells were washed twice with FACS buffer, 528 x g for 10 minutes and pelleted by 
centrifugation. Cells were resuspended in 100 µl Fixation/Permeabilisation solution 
(BD Pharmingen) overnight at 4
o
C in the dark. 
 
2.11.4.2. Intracellular staining 
The next day cells were washed twice in 1x BD Perm/Wash™ buffer (BD Biosciences), 
528 x g for 10 minutes, 4
oC. Cells were resuspended in 50 µl of BD Perm/Wash™ 
buffer containing fluorochrome-conjugated anti-cytokine antibody or isotype control 
(Section 2.13.2). Cells were incubated at 4
o
C for 30 minutes in the dark. Following a 
final wash in 1x BD Perm/Wash™ buffer, 3 minutes at 235 x g at 4oC, cells were 
resuspended in 100 µl FACS buffer and data acquired. The gating strategy is shown in 
Figure 2.9. 
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2.12. Flow cytometry gating strategies 
2.12.1. HLA-DR1 tetramer staining following in vitro expansion 
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Figure 2.5: HLA-DR1 tetramer staining gating strategy for in vitro expanded 
PBMC and HLA-DR1 transgenic T cell lines.  
A) Cells were initially gated according to forward and side scatter to define the live 
lymphocyte population (R1). A second region (R2) was defined by the expression of 
both CD3 and CD4 on cells within R1 to generate Gate 2. The percentage of tetramer 
positive cells was then determined within Gate 2. B) The live lymphocyte population 
was defined by forward and side scatter to generate Gate 1. The number of tetramer-
positive CD4
+
 T cells was then determined within Gate 1. Numbers are percentage of 
gated events within the upper right quadrant.  
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2.12.2. Immediate ex vivo HLA-DR1 tetramer staining 
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Figure 2.6: Gating strategy for immediate ex vivo HLA-DR1 tetramer staining to 
determine cell frequency. 
Following immediate ex vivo tetramer staining cells gates were initially gated according 
to forward and side scatter in order to define the live lymphocyte population (R1). To 
determine the frequency of tetramer-positive cells, the number of tetramer-positive 
CD4
high 
cells (R2) per the total CD4
high
 population (R3) was calculated.  
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Figure 2.7: Gating strategy for immediate ex vivo HLA-DR1 tetramer staining to 
determine cell surface phenotype. 
Following immediate ex vivo tetramer staining cells gates were initially gated according 
to forward and side scatter in order to define the live lymphocyte population (R1). To 
determine the percentage of tetramer-positive CD4
high
 T cells expressing a specific cell 
surface antigen was defined by Gate 2 (R1 + R3). This was compared to the percentage 
of total CD4
high
 cells expressing the cell surface antigen as defined by Gate 3 (R1 + R4). 
Numbers are percentage of gated events within the quadrant. 
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2.12.3. CFSE-labelled cell analysis 
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Figure 2.8: Gating strategy for CFSE analysis.  
Gate 1 defined the live lymphocyte population according to forward and side scatter 
(R1). In order to further exclude dead cells 7-AAD staining was used. Dead cells will be 
permeated by the dye and exhibit fluorescence detectable within FL-3. Gate 2 was 
defined as 7-AAD negative cells within Gate 1 (R1 + R2). CFSE dilution was analysed 
for CD4
+
 cells defined by Gate 3 (R1 + R2 + R3). 
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2.12.4. Intracellular cytokine staining 
 
Intracellular cytokine staining
R1
R2
No gate Gate 1 = R1
CFSE
C
D
4
-P
E
-C
y
5
Gate 2 = R1 + R2
CFSE
C
y
to
k
in
e-
P
E
Forward scatter
S
id
e 
sc
a
tt
er
 
Figure 2.9: Gating strategy for detection of intracellular cytokine production of 
CFSE-labelled cells. 
Cells were initially gated according to forward and side scatter to define the live 
lymphocyte population (Gate 1/R1). To generate the second gate, cells expressing CD4 
were selected (R2). The expression of intracellular cytokine was determined for CD4
+
 
cells shown by CFSE dilution to have proliferated.     
  142 
 
2.13. Monoclonal Antibodies and Fluorescent Dyes 
2.13.1. Human Cell Surface Antigen Antibodies 
Fluorescein isothiocyanate (FITC)-conjugated (FL-1): 
Specificity Clone Isotype Working concentration Company 
CD45RA L48 Mouse IgG1, κ 0.2 μg/106 cells BD Pharmingen 
CD3 HIT3a Mouse IgG2a, κ 20 μl/test* BD Pharmingen 
CXCR1 5A12 Mouse IgG2b, κ 2 μg/106 cells BD Pharmingen 
CCR7 3D12 Rat IgG2a, κ 0.25 μg/106 cells eBiosciences 
CD62L DREG-56 Mouse IgG1, κ 1.0 μg /106 cells eBiosciences 
CD25 M-A251 Mouse IgG1, κ 20 μl/ test* BD Biosciences 
*
One test: 1 x 10
6
 cells/ 100 μl staining volume 
Carboxyfluorescein-conjugated antibodies (FL-1): 
Specificity Clone Isotype Working concentration Company 
CCR5 45523 Mouse IgG2b 0.2 μg /105 cells  R&D Systems 
CD38 240742 Mouse IgG2a 0.2 μg /105 cells R&D Systems 
CXCR3 49801 Mouse IgG1 0.2 μg /105 cells R&D Systems 
CCR4 205410 Mouse IgG2b 0.2 μg /105 cells R&D Systems 
CCR3 61828.111 Rat IgG2a 0.2 μg /105 cells R&D Systems 
 
Phycoerthryin (PE)-conjugated antibodies (FL-2): 
Specificity Clone Isotype Working concentration Company 
CD4 SK3 Mouse IgG1, κ 20 μl/ test* BD Pharmingen 
*
One test: 1 x 10
6
 cells/ 100 μl staining volume 
 
PE-Cy5-conjugated antibodies (FL-3): 
Specificity Clone Isotype Working concentration Company 
CD4 RPA-T4 Mouse IgG1, κ 20 μl/ test* BD Pharmingen 
*
One test: 1 x 10
6
 cells/ 100 μl staining volume 
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2.13.2. Human Cytokine Antibodies 
PE-conjugated antibodies (FL-2): 
Specificity Clone Isotype Working concentration Company 
IL-4 3010.211 Mouse IgG1, κ 20 μl/ test* BD Biosciences 
IL-10 JES3-19F1 Rat IgG2a 0.5 μg/106 cells BD Biosciences 
IFN-γ 25723.11 Mouse IgG2b, κ 20 μl/ test* BD Biosciences 
*
One test: 1 x 10
6
 cells/ 100 μl staining volume 
2.13.3. Mouse Cell Surface Antigen Antibodies 
FITC-conjugated antibodies (FL-1): 
Specificity Clone Isotype Working concentration Company 
CD4 GK1.5 Rat IgG2b 0.25 μg/106 cells eBiosciences 
 
PE-conjugated antibodies (FL-2): 
Specificity Clone Isotype Working concentration Company 
CD4 GK1.5 Rat IgG2b 0.125 μg/106 cells eBiosciences 
 
2.13.4. Fluorescent Dyes 
7-AAD (FL-3): 
 Working concentration Company 
7-AAD 0.25 μg/106 cells BD Pharmingen 
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2.14. Statistics 
All statistical analyses were performed using GraphPad Prism software (Version 5.01 
GraphPad Software Inc., La Jolla, CA). A p value of less than 0.05 was considered to 
indicate statistical significance. 
 
A number of statistical tests were used. Parametric data were compared using an 
unpaired Student‟s t-test for between group comparisons. Non-parametric data were 
compared using the Mann-Whitney U test for between group comparisons or the 
Wilcoxon matched-pairs signed-rank test for within group comparisons.  
 
For analysis of experiments that required repeated comparisons with baseline values, 
epitope mapping with HLA-DR1 transgenic mouse CD4
+
 T cell lines and proliferation 
of CFSE-labelled PBMC, the non-parametric two-way analysis of variance by ranks, 
Friedman test was used to determine statistically significant changes. P-values were 
then calculated using Dunn‟s multiple comparisons tests.   
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Chapter Three: Mapping of HLA-DR1-restricted CD4+ T 
cell epitopes of Phl p 1 and Phl p 5b 
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3. Mapping of HLA-DR1-restricted CD4
+
 T cell epitopes of 
Phl p 1 and Phl p 5b 
3.1. Introduction 
Whilst effective, specific immunotherapy requires prolonged treatment and in the case 
of subcutaneous vaccination, can be associated with systemic IgE-mediated side-effects 
(Varney et al., 1991; Mellerup et al., 2000). A potential strategy for improved efficacy, 
potency and safety is the use of T cell-targeted allergen-derived peptides (Larché, 
2007). Peptide-induced tolerance against whole allergen has been demonstrated in 
allergic disease models for a number of allergens; house dust mite (Hoyne et al., 1993), 
cat (Briner et al., 1993; Campbell et al., 2009), birch pollen (Bauer et al., 1997) and bee 
venom (Astori et al., 2000). In addition, allergen-derived peptide immunotherapy has 
been investigated in clinical studies for cat and bee venom allergy (Müller et al., 1998a; 
Oldfield et al., 2002; Alexander et al., 2005a). Currently there is insufficient published 
information to design grass allergen-derived peptide vaccines for testing in transgenic 
mouse or human models. T cell epitope identification is an essential step towards 
selecting immunodominant epitopes that will induce tolerance to whole grass pollen.  
 
Grass pollen allergy is associated with IgE sensitisation to numerous grass species 
(Moingeon et al., 2008). Due to IgE cross-reactivity between grass species, it is 
unfeasible to determine the sensitising species in grass-allergic patients (Johansen et al., 
2009). Both subcutaneous and sublingual SIT, comprising only Phleum pratense 
(Timothy grass) pollen extract, induce long term tolerance as evidenced by continued 
remission for several years after stopping SIT (Durham et al., 1999; Niggemann et al., 
2006; Jacobsen et al., 2007). Moreover, after SIT with Phleum pratense the immune 
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response is suppressed towards grass pollens of other Pooideae species (Hejl et al., 
2009; Martínez-Cócera et al., 2010). In contrast, it is unknown whether similar clinical 
efficacy is produced by immunisation with grass pollen extracts derived from other 
single species such as Lolium perenne (Rye grass). This study therefore focused on 
epitope mapping of Phleum pratense pollen allergens. 
 
Allergenic proteins such as grass pollens can be categorised into several groups 
(Andersson and Lidholm, 2003). The major Phleum pratense Group 1 and Group 5 
grass pollen allergens, Phl p 1 and Phl p 5, have been shown to dominate the immune 
response, based on the frequency of IgE recognition, in grass pollen-sensitised 
individuals (Vrtala et al., 1993b; Laffer et al., 1994b). However, the relative 
contributions of these allergens in eliciting T cell responses to grass pollen are 
unknown. Consequently, it is not known whether immunodominant peptides from only 
a Group 1 or Group 5 allergen would be sufficient to induce tolerance if used in a 
therapeutic vaccine. This study therefore investigated both Phl p 1 and Phl p 5 allergens. 
Within the grass pollen allergen groups there are a number of homologous and 
immunologically-similar isoallergens (Andersson and Lidholm, 2003). In this study, Phl 
p 1 was represented by Phl p 1.0102 and Phl p 5 by Phl p 5.0201. A recent study, 
performed whilst this thesis was in progress, quantified Phl p 1 and Phl p 5 isoallergens 
in whole Phleum pratense extract using mass spectrometry (Seppälä et al., 2011). Phl p 
1.0101 was shown to be five times more abundant than Phl p 1.0102, whilst Phl p 
5.0201 was nine times more abundant than Phl p 5.0101.  
 
T cell epitopes for Phl p 1 and Phl p 5 have previously been described (Schenk et al., 
1995; Müller et al., 1998b; Würtzen et al., 1999a, 1999b). In these studies, T cell lines 
and T cell clones were established from the peripheral blood of grass-allergic patients 
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but HLA restriction was not fully elucidated. Recently, Oseroff et al., (2010) evaluated 
T cell epitope recognition of Phleum pratense allergens by allergic and non-allergic 
subjects. A number of promiscuous epitopes were identified and characterised by HLA 
binding assays with T cell responses evaluated by cytokine production. 
 
Allergen-derived peptides are recognised by CD4
+
 T cells in the context of HLA class II 
proteins and therefore described as HLA-restricted (Rudolph et al., 2006). HLA alleles 
can be linked to diseases, with certain alleles conveying protection or susceptibility 
(Jones et al., 2006). A number of studies have investigated HLA association with the 
immune response to grass pollen in allergic individuals, however, they have reported 
varying results (Freidhoff et al., 1988; Ansari et al., 1989; Young et al., 1994; Schenk et 
al., 1995; Boehncke et al., 1998; Müller et al., 1998b; Würtzen et al., 1999a, 1999b; 
Oseroff et al., 2010). Together the data suggest that HLA-DR locus may be 
preferentially associated with grass pollen allergy however, association of any one 
individual HLA-DR allele has not been described. In this study, HLA-DR1 was selected 
as the allele to be investigated since it is a prevalent HLA-DR allele within the 
European population (Meyer et al., 2007; Gonzalez-Galarza et al., 2010). Furthermore, 
access to HLA-DR1 transgenic mice and HLA-DR1 tetramer technology was readily 
available.  
 
There are a number of approaches established for T cell epitope mapping. In silico 
programs have been developed that draw on data from peptide-binding studies to 
generate algorithms, which are used to highlight peptide sequences with the potential to 
bind HLA molecules (Nielsen et al., 2010). HLA class II prediction software 
TEPITOPE has previously been used to predict HLA-DR epitopes in autoimmunity, 
cancer and allergy (Bian and Hammer, 2004). Furthermore, comparisons between 
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experimentally determined HLA/peptide binding affinities and in silico generated 
predictions, have demonstrated that TEPITOPE and two programs, implemented on the 
original TEPITOPE matrices, were consistently the best performers for HLA-DR1-
restricted epitope prediction (Lin et al., 2008; Wang et al., 2008, 2010). 
 
HLA binding alone does not guarantee immunogenicity; therefore predicted epitopes 
require in vitro and in vivo validation. In vitro assays assessing the allergen-specific 
CD4
+
 T cell response following stimulation with allergen-derived peptides have been 
developed. Outcome measures evaluated include 
3
H-thymidine incorporation, cytokine 
production and CFSE dilution (Malherbe, 2009). Progress in HLA class II tetramer 
technology has also enabled development of tetramer guided epitope mapping (TGEM). 
In TGEM, allergen-specific CD4
+
 T cells are expanded with pooled peptides 
encompassing the allergen and visualised using HLA class II tetramers loaded with the 
same allergen-derived peptides (Reijonen and Kwok, 2003). Allergen-specific CD4
+
 T 
cells are often present in peripheral blood of patients at low frequencies therefore; in 
vitro expansion is required prior to epitope identification. In addition, HLA restriction 
determination can be hindered by the presence of multiple HLA molecules in people. 
The use of HLA transgenic mice, engineered to express individual human HLA 
molecules, in the absence of endogenous murine class II molecules, permits epitope 
identification in the context of a single HLA molecule together with a ready source of 
allergen-specific CD4
+
 T cells (Malherbe, 2009). 
 
The aim of this chapter was to identify HLA-DR1-restricted CD4
+
 T cell epitopes 
within the major grass pollen allergens, Phl p 1 and Phl p 5b, by epitope mapping using 
complementary approaches: in silico epitope prediction, HLA-DR1 TGEM and HLA-
DR1 transgenic mouse studies. 
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3.2. Results 
3.2.1. Computational analysis of Phl p 5b isoallergen sequences 
A high sequence identity is seen following multiple sequence alignment of Phl p 5b 
isoallergens. 
A number of isoallergens have been identified for the major grass pollen allergen Phl p 
5b. In order to evaluate the homology of the different isoallergens, their single letter 
amino acid sequences were obtained from the IUIS Allergen Nomenclature Sub-
Committee website (http://www.allergen.org/). The sequences were aligned using 
CLUSTAL 2.0.12 multiple sequence alignment program (Larkin et al., 2007) (Figure 
3.1). The sequence alignment scores (percentage sequence identity) were calculated by 
comparing the number of identical amino acid residues to the total number of amino 
acids in the protein between Phl p 5.0201 and the other isoallergens. A high sequence 
identity was observed, with the lowest percentage identity of 92% seen between Phl p 
5.0206 and Phl p 5.0207 (Table 3.1). 
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Figure 3.1: Sequence alignment of Phl p5.020x isoallergens. 
Phl p 5.020x sequences were aligned using the CLUSTAL 2.0.12 multiple sequence 
alignment program available via the European Bioinformatics Institute server: 
(http://www.ebi.ac.uk/Tools/services/web/toolform.ebi?tool=clustalw2). Numbers 
represent the residue numbers. "*" highlights the residues that are identical in all 
sequences. ":" highlights conserved substitutions. "." highlights semi-conserved 
substitutions. Colours: RED = small (small + hydrophobic (including aromatic- Y)), 
BLUE = acidic, MAGENTA= basic and GREEN= hydroxyl + amine + basic- Q. The 
isoallergen investigated in this study is shown in bold. Phlp: Phleum pratense. 
 
Phl p 5.020x  
 
Phlp5.0201      -----------AAAAVPRRGPRGGPGRSYTADAGYAPATPAAAGAAAGKATTEEQKLIED 49 
Phlp5.0202      --------------AVPRRGPRGGPGRSYAADAGYAPATPAAAGAEAGKATTEEQKLIED 46 
Phlp5.0203      SVKRSNGSAEVHRGAVPRRGPRGGPGRSYAADAGYAPATPAAAGAEAGKATTEEQKLIED 60 
Phlp5.0204      ------------------------------ADAGYAPATPAAAGAAAGKATTEEQKLIED 30 
Phlp5.0205      ------------------------------ADAGYAPATPAAAGAEAGKATTEEQKLIED 30 
Phlp5.0206      -----MAVQKYTVALFLAVALVAGPAASYAADAGYAPATPAAAGAEAGKATTEEQKLIED 55 
Phlp5.0207      -----MAVQKYTVALFLAVALVAGPAASYAADAGYAPATPAAAGAEAGKATTEEQKLIED 55 
                                              *************** ************** 
 
Phlp5.0201      INVGFKAAVAAAASVPAADKFKTFEAAFTSSSKAAAAKAPGLVPKLDAAYSVAYKAAVGA 109 
Phlp5.0202      INVGFKAAVAAAASVPAGDKFKTFEAAFTSSSKAATAKAPGLVPKLDAAYSVAYKAAVGA 106 
Phlp5.0203      INVGFKAAVAAAASVPAADKFKTFEAAFTSSSKAATAKAPGLVPKLDAAYSVAYKAAVGA 120 
Phlp5.0204      INVGFKAAVAAAASVPAADKFKTFEAAFTSSSKAATAKAPGLVPKLDAAYSVAYKAAVGA 90 
Phlp5.0205      INVGFNAAVAAAASVPAADKFKTFEAAFTSSSKAATAKAPGLVPKLDAAYSVAYKAAVGA 90 
Phlp5.0206      INVGFKAAVAAAASVPAADKFKTFEAAFTSSSKAATAKAPGLVPKLDAAYSVAYKAAVGA 115 
Phlp5.0207      INVGFKAAVAAAASVPAADKFKTFEAAFTSSSKAATAKAPGLVPKLDAAYSVSYKAAVGA 115 
                *****:***********.*****************:****************:******* 
 
Phlp5.0201      TPEAKFDSFVASLTEALRVIAGALEVHAVKPVTEEPGMAKIPAGELQIIDKIDAAFKVAA 169 
Phlp5.0202      TPEAKFDSFVASLTEALRVIAGALEVHAVKPVTEEPGMAKIPAGELQIIDKIDAAFKVAA 166 
Phlp5.0203      TPEAKFDSFVASLTEALRVIAGALEVHAVKPVTEEPGMAKIPAGELQIIDKIDAAFKVAA 180 
Phlp5.0204      TPEAKFDSFVASLTEALRVIAGALEVHAVKPVTEEPGMAKIPAGELQIIDKIDAAFKVAA 150 
Phlp5.0205      TPEAKFDSLVASLTEALRVIAGALEVHAVKPVTEEPGMAKIPAGELQIIDKIDAAFKVAA 150 
Phlp5.0206      TPEAKFDSFVASLTEALRVIAGALEVHAVKPVTEDPAWPKIPAGELQIIDKIDAAFKVAA 175 
Phlp5.0207      TPEAKFDSFVASLTEALRVIAGALEVHAVKPVTEEPGMAKIPAGELQIIDKIDAAFKVAA 175 
                ********:*************************:*. .********************* 
 
Phlp5.0201      TAAATAPADDKFTVFEAAFNKAIKESTGGAYDTYKCIPSLEAAVKQAYAATVAAAPQVKY 229 
Phlp5.0202      TAAATAPADDKFTVFEAAFNKAIKESTGGAYDTYKCIPSLEAAVKQAYAATVAAAPQVKY 226 
Phlp5.0203      TAAATAPADDKFTVFEAAFNKAIKESTGGAYDTYKCIPSLEAAVKQAYAATVAAAPQVKY 240 
Phlp5.0204      TAAATAPADDKFTVFEAAFNKAIKESTGGAYDTYKCIPSLEAAVKQAYAATVAAAPQVKY 210 
Phlp5.0205      TAAATAPADDKFTVFEAAFNKAIKESTGGAYDTYKCIPSLEAAVKQPYAATVAAAPQVKY 210 
Phlp5.0206      TAAATAPADDKFTVFEAAFNKAIKESTGGAYDTYKCIPSLEAAVKQAYAATVAAAPQVKY 235 
Phlp5.0207      TAAATAPAD---TVFEAAFNKAIKESTGGAYDTYKCIPSLEAAVKQAYAATVAAAPQVKY 232 
                *********   **********************************.************* 
 
Phlp5.0201      AVFEAALTKAITAMSEVQKVSQPATGAATVAAGAATTAAGAASGAATVAAGGYKV 284 
Phlp5.0202      AVFEAALTKAITAMSEVQKVSQPATGAATVAAGAATTATGAASGAATVAAGGYKV 281 
Phlp5.0203      AVFEAALTKAITAMSEVQKVSQPATGAATVAAGAATTAAGAASGAATVAAGGYKV 295 
Phlp5.0204      AVFEAALTKAITAMSEVQKVSQPATGAATVAAGAATTAAGAASGAATVAAGGYKV 265 
Phlp5.0205      AVFEAALTKAITAMSEVQKVSQPATGAATVAAGAATTAAGAASGAATVAAGGYKV 265 
Phlp5.0206      AVFEAALTKAITAMSEVQKVSQPATGAATVAAGAATTATGAASGAATVAAGGYKV 290 
Phlp5.0207      AVFEAALTKAITAMSEVQKVSQPATGAATVAAGAATTAAGAASGAATVAAGGYKV 287 
                **************************************:**************** 
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Table 3.1: Alignment scores for Phl p 5.020x isoallergens as compared to Phl p 
5.0201. 
Following sequence alignment, pairwise alignment scores were calculated between Phl 
p 5.0201 and the remaining Phl p 5.020x isoallergens in turn. The number of identical 
amino acid residues between Phl p 5.0201 and the second sequence was compared to 
the total number of amino acids generating an alignment score indicating the percentage 
of sequence identity.  
 
Isoallergen 
Percentage identity 
(%) 
Phl p 5.0201 100 
Phl p 5.0202 98 
Phl p 5.0203 97 
Phl p 5.0204 99 
Phl p 5.0205 98 
Phl p 5.0206 92 
Phl p 5.0207 92 
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HLA-DR epitope prediction software highlights seven HLA-DR1 epitopes within Phl p 
5.0201. 
The first approach undertaken for HLA-DR1 epitope prediction was in silico analysis of 
the Phl p 5.0201 sequence using predictive algorithms to define HLA-DR1-restricted 
CD4
+
 T cell epitopes. TEPITOPE, NetMHCIIpan and Consensus methods were used to 
identify putative HLA class II binding motifs.  
 
TEPITOPE analysis highlighted 9-mer core HLA class II binding motifs. NetMHCIIpan 
analysis highlighted 15-mer peptide sequences predicted to demonstrate HLA-DR1 
binding. The NetMHCIIpan score is a measure of IC50, where a lower score indicates a 
higher affinity binding. The IEDB Consensus score represents a median score of three 
epitope prediction algorithms; combinatorial library, SMM-align and NN-align. The 
lower the Consensus rank score the higher the predicted binding affinity.  
 
For epitope prediction in this study, the HLA-DRB1*0101 allele was selected as the 
specific allele for binding predictions as this corresponds to HLA-DR1. For TEPITOPE 
analysis the user defined prediction threshold was set at 3% to positively select for 
epitopes displaying a theoretical binding to HLA-DR1 equivalent to or better than the 
corresponding score for the top 3% of peptides, experimentally determined to bind 
HLA-DR1. A 3% threshold was selected as this has previously been shown to be 
sensitive enough to detect up to 80% of HLA-DR-restricted peptides (Sturniolo et al., 
1999).  
 
Following TEPITOPE analysis, Phl p 5.0201 was predicted to contain seven potential 
HLA-DR1 binding motifs distributed across the whole protein sequence (Figure 3.2). 
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The motifs identified represent the nine amino acid core region predicted to bind to the 
HLA class II molecule and which are also recognised by T cells (Jones et al., 2006). 
 
NetMHCIIpan and Consensus methods of HLA class II/peptide binding affinity 
prediction highlighted a number of putative HLA-binding sequences within Phl 
p 5.0201 (Table 3.2). Concurrence was observed between the analyses with all, except 
one, core binding motifs identified by TEPITOPE predicted to demonstrate high affinity 
binding, with IC50 values <50 nM, by NetMHCIIpan analysis and low rank scores 
following IEDB Consensus analysis (Table 3.2). 
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Figure 3.2: Single letter amino acid sequence of Phl p 5.0201 with TEPITOPE 
predicted HLA-DR1 epitopes highlighted. 
The single letter amino acid sequence of Phl p 5.0201 was obtained from the website of 
the International Union of Immunological Societies Allergen Nomenclature Sub-
Committee (http://www.allergen.org/Allergen.aspx). The sequence was copied into the 
sequence editor of TEPITOPE HLA class II epitope prediction software. HLA-DR1 was 
selected as the HLA allele of interest and the threshold of stringency for the prediction 
was set at 3%. TEPITOPE predicted epitopes of 9 amino acids in length which are 
shown underlined in blue text with the amino acid in position 1 highlighted in red. 
Phl p 5.0201 
 
AAAAVPRRGPRGGPGRSYTADAGYAPATPAAAGAAAGKATTEEQKLIEDI50 
 
NVGFKAAVAAAASVPAADKFKTFEAAFTSSSKAAAAKAPGLVPKLDAAYS100 
 
VAYKAAVGATPEAKFDSFVASLTEALRVIAGALEVHAVKPVTEEPGMAKI150 
 
PAGELQIIDKIDAAFKVAATAAATAPADDKFTVFEAAFNKAIKESTGGAY200 
 
DTYKCIPSLEAAVKQAYAATVAAAPQVKYAVFEAALTKAITAMSEVQKVS250 
 
QPATGAATVAAGAATTAAGAASGAATVAAGGYKV284 
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Table 3.2: In silico analyses of Phl p 5.0201 with NetMHCIIpan and Consensus 
methods.  
The single letter amino acid sequence of Phl p 5.0201 was obtained from the website of 
the International Union of Immunological Societies Allergen Nomenclature Sub-
Committee (http://www.allergen.org/Allergen.aspx). The sequence was copied into 
NetMHCIIpan or Consensus servers in order to evaluate peptide binding to HLA class 
II molecules. HLA-DR1 was selected as the restricting HLA allele. NetMHCIIpan 
analysis generated sequences of 15-mer peptides with variable binding affinity 
(measured as IC50 values (nM)). Peptide sequences predicted to demonstrate strong 
binding to HLA-DR1 are presented. The predicted 9-mer core HLA binding motif of 
these peptides is also highlighted and where this correlates with a TEPITOPE-identified 
binding core noted. Consensus analysis also generated 15-mer peptide sequences and 
the Consensus Rank score for these sequences is shown.  
 
Position Sequence
 
 NetMHCIIpan   Consensus  
  Core Affinity (nM)
a 
% Rank
b 
Rank
c 
20-34 DAGYAPATPAAAGAA YAPATPAAA 7.39 3.00 9.25 
46-60 IEDINVGFKAAVAAA INVGFKAAV 29.49 16.0 17.57 
50-64 NVGFKAAVAAAASVP FKAAVAAAA* 3.16 0.30 0.13 
54-68 KAAVAAAASVPAADK VAAAASVPA 7.08 3.00 7.47 
66-80 ADKFKTFEAAFTSSS FKTFEAAFT* 8.93 4.00 4.64 
69-83 FKTFEAAFTSSSKAA FEAAFTSSS 12.95 5.00 7.48 
73-87 EAAFTSSSKAAAAKA FTSSSKAAA 18.13 8.00 20.03 
89-103 GLVPKLDAAYSVAYK PKLDAAYSV 31.83 16.0 28.88 
91-105 VPKLDAAYSVAYKAA LDAAYSVAY 49.92 32.0 24.49 
95-109 DAAYSVAYKAAVGAT YSVAYKAAV 44.88 16.0 15.38 
99-113 SVAYKAAVGATPEAK YKAAVGATP 4.01 0.60 19.23 
111-125 EAKFDSFVASLTEAL FDSFVASLT 8.78 3.00 8.17 
114-128 FDSFVASLTEALRVI FVASLTEAL 5.24 1.25 6.17 
122-136 TEALRVIAGALEVHA LRVIAGALE 15.63 7.00 7.48 
161-175 DAAFKVAATAAATAP FKVAATAAA* 6.96 3.00 2.27 
178-192 DKFTVFEAAFNKAIK FTVFEAAFN 13.63 6.00 6.24 
180-194 FTVFEAAFNKAIKES FEAAFNKAI 12.34 5.00 10.53 
199-213 YDTYKCIPSLEAAVK YKCIPSLEA* 10.20 4.00 7.88 
209-223 EAAVKQAYAATVAAA VKQAYAATV* 7.25 3.00 3.54 
213-227 KQAYAATVAAAPQVK YAATVAAAP 11.16 5.00 5.5 
225-239 QVKYAVFEAALTKAI YAVFEAALT* 6.66 2.00 0.79 
228-242 YAVFEAALTKAITAM FEAALTKAI 7.26 2.00 5.59 
*
NetMHCIIpan-predicted 9-mer HLA-DR1 core binding motif is also predicted by 
TEPITOPE at 3% prediction threshold. 
a
 IC50 value (nM); < 50 nM high affinity, < 500 nM intermediate affinity and < 5000 nM 
low affinity. 
b
 NetMHCIIpan % Rank score; lower % Rank predicts stronger HLA-DR1 binder. 
c
 Consensus Rank score; lower score predicts stronger affinity for HLA-DR1. 
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3.2.2. HLA-DR1 tetramer driven identification of HLA-DR1-restricted epitopes of 
Phl p 5b 
Tetramer guided epitope mapping (TGEM). 
In order to experimentally identify HLA-DR1-restricted CD4
+
 T cell epitopes in 
humans the tetramer guided epitope mapping (TGEM) approach was initially employed. 
PBMC were isolated from HLA-DR1 grass-allergic, seasonal rhinitic individuals by 
density gradient centrifugation and cryopreserved. The frozen PBMC were transported 
in liquid nitrogen to Professor W. Kwok, Benaroya Research Institute at Virginia 
Mason Medical Center, Seattle, USA. T cell cultures were established from thawed 
PBMC and stimulated with pools of overlapping 20-mer synthetic peptides that covered 
the entirety of Phl p 5b. Fourteen days post-stimulation CD4
+
 T cells were stained with 
PE-conjugated HLA-DR1 tetramers loaded with pooled Phl p 5b-derived peptides in 
order to detect peptide responsive CD4
+
 T cell populations. In the representative 
example shown in Figure 3.3 distinct populations of tetramer positive cells were 
identified in the samples stimulated with pools 5 and 6 corresponding to peptides 21-25 
and peptides 26-29, respectively. To further identify the epitope(s) recognised by these 
CD4
+
 T cells, PBMC stimulated with pool 5 and pool 6 peptides were labelled with 
HLA-DR1 tetramers loaded with the individual constituent peptides from these pools. 
Subsequently, peptide 21 (FTVFEAAFNKAIKESTGGAY), peptide 24 
(CIPSLEAAVKQAYAATVAAA) and peptide 26 (VAAAPQVKYAVFEAALTKAI) 
were identified to contain potential HLA-DR1-restricted T cell epitopes (Figure 3.3).  
 
TGEM was performed on a further two PBMC samples isolated from allergic 
individuals and additionally, peptides 4 (KLIEDINVGFKAAVAAAASV) and 5 
(GFKAAVAAAASVPAADKFKT) of Phl p 5b were found to contain HLA-DR1-
restricted T cell epitopes (Figure 3.4). 
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Tetramer Guided Epitope Mapping: HLA-DR1/Phl p 5b
 
Figure 3.3: HLA-DR1 Tetramer guided epitope mapping of Phl p 5b. 
A panel of overlapping 20-mer peptides spanning Phl p 5b was synthesised. Peptides 
were divided into pools and loaded onto PE-conjugated HLA-DR1 tetramers. Frozen 
PBMC were transported in liquid nitrogen to Professor W. Kwok. Isolated CD4
+
 T cells 
were cultured with adherent cells, in the presence of the pooled peptides for 7 days 
before adding IL-2. Between days 12 and 14 the cells were stained with anti-CD4 and 
the pooled peptide tetramers. Positive tetramer staining was identified using flow 
cytometry here seen for pools 5 and 6 (A). Individual peptide tetramers were generated 
by loading the soluble HLA-DR1 molecules with the individual peptides contained 
within the positively staining pooled peptides and staining repeated. In this 
representative example, positive labelling is seen with tetramers loaded with peptides 
21, 24 and 26 of Phl p 5b (B).  
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Figure 3.4: Identification of HLA-DR1-restricted Phl p 5b epitopes in human 
samples using tetramer guided epitope mapping. 
PBMC isolated during the grass pollen season from HLA-DR1-positive, grass-allergic, 
seasonal allergic rhinitic individuals were labelled with HLA-DR1 tetramers loaded 
with Phl p 5b peptides and tetramer guided epitope mapping performed as previously 
described.  
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3.2.3. HLA-DR1 transgenic mouse studies for identification of HLA-DR1-restricted 
epitopes in Phl p 5b 
Generation of HLA-DR1-restricted T cell lines against whole Phl p 5b protein and 
subsequent epitope mapping assays to identify HLA-DR1-restricted epitopes.  
HLA-DR1 transgenic mice were immunised with Phl p 5b to identify HLA-DR1-
restricted CD4
+
 T cell epitopes and establish that the epitopes identified by 
computational analysis and tetramer staining were HLA-DR1-restricted and naturally 
processed during an in vivo immune response.  
 
Transgenic mice engineered to express human MHC class II molecule HLA-DR1 
(HLA-DRA/DRB1*0101) and lacking endogenous mouse MHC class II (H2-Aβo) 
(Altmann et al., 1995) were used as a model to study CD4
+
 T cell responses in the 
context of HLA-DR1 only. Mice were immunised with either nPhl p 5b or rPhl p 5b. 
Ten days later, individual or pooled T cell lines were established and propagated as 
described in Chapter 2, Materials and Methods. 
 
In order to identify epitopes in Phl p 5b, 
3
H-thymidine incorporation of a pooled T cell 
line, generated from the immunisation of three mice, towards 20-mer overlapping 
peptides (Table 3.3) spanning the entirety of Phl p 5b was measured. The assay was 
performed twice on the same Phl p 5b T cell line at the fifth and seventh restimulation 
cycles. Peptide 18 (IIDKIDAAFKVAATAAATAP), peptide 23 
(GGAYDTYKCIPSLEAAVKQA) and peptide 26 consistently induced proliferation at 
both cycles, as did stimulation with Phl p 5b protein (Figure 3.5). In addition, 
proliferation in response to peptide 30 (ATGAATVAAGAATTAAGAAS) was only 
observed at the fifth restimulation cycle whilst proliferation in response to peptide 31 
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(AGAATTAAGAASGAATVAAG) was only observed at the seventh restimulation 
cycle (Figure 3.5).  
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Table 3.3: Amino acid sequence of Phl p 5b-derived 20-mer overlapping peptides 
used for epitope mapping studies. 
Each peptide was designed to overlap by 12 amino acids, thus ensuring any 9 residue 
epitope will be represented with at least one flanking amino acid. 
 
Phl p 5b peptide Sequence 
1 DAGYAPATPAAAGAAAGKAT 
2 PAAAGAAAGKATTEEQKLIE 
3 GKATTEEQKLIEDINVGFKA 
4 KLIEDINVGFKAAVAAAASV 
5 GFKAAVAAAASVPAADKFKT 
6 AASVPAADKFKTFEAAFTSS 
7 KFKTFEAAFTSSSKAAAAKA 
8 FTSSSKAAAAKAPGLVPKLD 
9 AAKAPGLVPKLDAAYSVAYK 
10 PKLDAAYSVAYKAAVGATPE 
11 VAYKAAVGATPEAKFDSFVA 
12 ATPEAKFDSFVASLTEALRV 
13 SFVASLTEALRVIAGALEVH 
14 ALRVIAGALEVHAVKPVTEE 
15 LEVHAVKPVTEEPGMAKIPA 
16 VTEEPGMAKIPAGELQIIDK 
17 KIPAGELQIIDKIDAAFKVA 
18 IIDKIDAAFKVAATAAATAP 
19 FKVAATAAATAPADDKFTVF 
20 ATAPADDKFTVFEAAFNKAI 
21 FTVFEAAFNKAIKESTGGAY 
22 NKAIKESTGGAYDTYKCIPS 
23 GGAYDTYKCIPSLEAAVKQA 
24 CIPSLEAAVKQAYAATVAAA 
25 VKQAYAATVAAAPQVKYAVF 
26 VAAAPQVKYAVFEAALTKAI 
27 YAVFEAALTKAITAMSEVQK 
28 TKAITAMSEVQKVSQPATGA 
29 EVQKVSQPATGAATVAAGAA 
30 ATGAATVAAGAATTAAGAAS 
31 AGAATTAAGAASGAATVAAG 
32 GAASGAATVAAGGYKV 
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Figure 3.5: Epitope mapping study of pooled murine HLA-DR1-restricted T cell 
lines generated against Phl p 5b using 20-mer overlapping peptides. 
A pooled T cell line was generated from three HLA-DR1 transgenics. Mice were 
footpad immunised with nPhl p 5b emulsified with Complete Freund‟s adjuvant (CFA). 
The draining popliteal lymph node was removed at day 10, T cells were pooled and a T 
cell line generated. Cells were cultured on a 10 day cycle restimulated every 10 days 
with irradiated autologous APCs and Phl p 5b. To investigate the recall response of the 
Phl p 5b T cell line, T cells (2 x 10
4
 cells/well) were incubated for 48 h with autologous 
irradiated APCs (3 x 10
5
 cells/well) in the presence or absence of 20-mer overlapping 
peptides spanning Phl p 5b at 50 µg/ml. At 48 h cultures were terminated with a 16 h 
3
H-thymidine pulse followed by liquid scintillation counting. Values shown are mean 
Δcpm of triplicate wells (±SEM) at the fifth (A) and seventh (B) restimulation cycles. 
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In order to confirm epitopes identified in the initial peptide screening experiment with 
the pooled T cell lines, mapping experiments were repeated with a number of T cell 
lines generated from individually immunised mice. The peptides identified in the 
preceding experiments (Figure 3.5) also generated a positive response in these 
experiments (Peptides 18, 23 and 26). However, additional significant positive 
responses were also seen with peptide 13 (SFVASLTEALRVIAGALEVH), peptide 17 
(KIPAGELQIIDKIDAAFKVA), peptide 20 (ATAPADDKFTVFEAAFNKAI), peptide 
21 (FTVFEAAFNKAIKESTGGAY), peptide 22 (NKAIKESTGGAYDTYKCIPS), 
peptide 25 (VKQAYAATVAAAPQVKYAVF), peptide 27 
(YAVFEAALTKAITAMSEVQK), peptide 28 (TKAITAMSEVQKVSQPATGA), 
peptide 29 (EVQKVSQPATGAATVAAGAA) and peptide 32 
(GAASGAATVAAGGYKV) (Figure 3.6). 
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Figure 3.6: Epitope mapping study of murine HLA-DR1-restricted T cell lines generated against rPhl p 5b, first cohort. 
Five T cell lines were generated from five individual HLA-DR1 transgenic mice immunised with rPhl p 5b. T cells (2 x 10
4
 cells/well) were incubated 
for 48 h with autologous irradiated APCs (3 x 10
5
 cells/well) in the presence or absence of 20-mer overlapping peptides spanning Phl p 5b at 50 µg/ml. 
At 48 h cultures were terminated with a 16 h 
3
H-thymidine pulse followed by liquid scintillation counting. Values shown are mean cpm of triplicate 
wells from the individual lines at the third restimulation cycle. Bars represent mean cpm values for all 5 T cell lines, error bars are ±2SD. A positive 
response to peptide stimulation is defined as greater than +2SD of the medium only control which is indicated by the dotted red line. P values were 
calculated by performing a Friedman test followed by Dunn‟s Multiple Comparisons test comparing cpm of medium only control to cpm of peptide-
stimulated wells. (* = p < 0.05, ** = p < 0.01, *** = p < 0.001). 
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Since the peptide screen with five individual T cell lines gave a larger number of 
positive peptides this was repeated with a second cohort of mice. Five Phl p 5b-specific 
T cell lines were generated from the immunisation of five individual mice and their 
proliferation in response to Phl p 5b-derived peptides was assessed at the fifth 
restimulation cycle (compared to the third restimulation cycle in the previous cohort) 
due to cell numbers. In this peptide screening experiment, a significant positive 
response was observed to peptides 13, 17, 18, 20, 22, 23, 25, 26, 29 and 30 (Figure 3.7).  
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Figure 3.7: Epitope mapping study of murine HLA-DR1-restricted T cell lines generated against rPhl p 5b, second cohort. 
Five T cell lines were generated from five individual HLA-DR1 transgenic mice immunised with rPhl p 5b. T cells (2 x 10
4
 cells/well) were incubated 
for 48 h with autologous irradiated APCs (3 x 10
5
 cells/well) in the presence or absence of 20-mer overlapping peptides spanning Phl p 5b at 50 µg/ml. 
At 48 h cultures were terminated with a 16 h 
3
H-thymidine pulse followed by liquid scintillation counting. Values shown are mean cpm of triplicate 
wells from the individual lines at the fifth restimulation cycle Bars represent mean cpm values for all 5 T cell lines, error bars are ±2SD. A positive 
response to peptide stimulation is defined as greater than +2SD of the medium only control which is indicated by the dotted red line. P values were 
calculated by performing a Friedman test followed by Dunn‟s Multiple Comparisons test comparing cpm of medium only control to cpm of peptide-
stimulated wells. (* = p < 0.05, ** = p < 0.01, *** = p < 0.001). 
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Generation of HLA-DR1-restricted T cell lines against pooled Phl p 5b peptides and 
subsequent recall assays highlight a number of HLA-DR1 epitopes.  
In addition to identification of peptides containing HLA-DR1-restricted epitopes 
following immunisation of transgenic mice with whole protein, a pooled peptide 
immunisation approach was also used. Phl p 5b peptides were grouped into pools of five 
peptides and groups of three mice per pool subcutaneously immunised in the footpad. 
The immediate ex vivo response to immunised peptides by draining lymph node T cells 
was assessed. A number of peptides were highlighted by this assay including peptides 4, 
5, 6, 7, 9, 10, 13, 17, 18, 23, 26, 27 and 29 (Figure 3.8). For the pooled peptides 1-5, 11-
15 and 21-25, immunisation failed in 2 of 3 mice since a positive recall response to the 
control antigen, PPD, was not observed.  
 
In addition to the immediate ex vivo assessment of the 
3
H-thymidine incorporation ten 
days post-immunisation, pooled T cell lines were also generated by combining cells 
from the individual mice, immunised with the same pooled peptides, and the recall 
response of these lines assessed. Peptides previously identified by the ex vivo analysis 
again showed increased 
3
H-thymidine incorporation by CD4
+
 T cells (peptides 4, 5, 6, 
7, 9, 10, 13, 17, 18, 23, 26 and 27) and additionally peptides 1, 11, 12, 14, 21, 22, 24 
and 25 (Figure 3.9). 
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Figure 3.8: Pooled Phl p 5b peptide immunisation immediate ex vivo draining 
lymph node assay. 
HLA-DR1 transgenic mice were footpad immunised with groups of overlapping 20-mer 
Phl p 5b peptides (10 μg/ml per peptide) emulsified with CFA. At day 10 the draining 
popliteal lymph node was removed. T cells from individual mice were stimulated with 
50 µg/ml of individual peptide or pooled peptides. At 48 h cultures were terminated 
with a 16 h 
3
H-thymidine pulse followed by liquid scintillation counting. Values shown 
are mean Δcpm of triplicate wells (±SEM).  
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Figure 3.9: Pooled Phl p 5b peptide T cell line first restimulation cycle. 
T cell lines were generated by pooling T cells from the groups of 3 mice footpad 
immunised with groups of 5 overlapping 20-mer Phl p 5b peptides emulsified with 
CFA. T cell lines were then cultured for 10 days in the presence of pooled peptides. At 
day 10, T cells (2 x 10
4
 cells/well) were incubated for 48 h with autologous irradiated 
APCs (3 x 10
5
 cells/well) in the presence of both the individual peptides and pooled 
peptides 50 µg/ml. At 48 h cultures were terminated with a 16 h 
3
H-thymidine pulse 
followed by liquid scintillation counting. Values shown are mean Δcpm of triplicate 
wells (±SEM) at the first restimulation cycle. 
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Epitope mapping experiments performed with Phl p 5b T cell lines, generated in the 
HLA-DR1 transgenic mouse model, highlighted a number of HLA-DR1-restricted 
epitopes containing Phl p 5b-derived peptides and are summarised in Table 3.4. Data 
from all complementary epitope mapping approaches used in this thesis are summarised 
in Table 3.5: in silico TEPITOPE analysis, HLA-DR1 tetramer guided epitope mapping 
and HLA-DR1 transgenic mouse studies. Peptide 18 and peptide 26 are the only 
peptides of the Phl p 5b-derived overlapping peptides investigated that were indicated 
by all experimental approaches to contain HLA-DR1-restricted epitopes. 
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Table 3.4: Summary of Phl p 5b epitopes identified by HLA-DR1 transgenic mouse 
studies.  
Peptides that data suggest contain HLA-DR1-restricted epitopes are indicated by “+”. 
Peptides identified by all experimental groups are highlighted by boxed regions. 
 
 
 
A 
 
 
B 
 
 
C 
 
 
D 
 
E 
 
Number of mice 
immunised 
3 5 5 3/group 3/group 
Number of lines 
generated 
1 
(pooled) 
5 
(individual) 
5 
(individual) 
3 
(individual) 
1/group 
(pooled) 
Phl p 5 b 
Immunogen 
Protein Protein Protein 
Grouped 
peptides 
Grouped 
peptides 
Phl p 5b peptide      
1     + 
2      
3      
4    + + 
5    + + 
6    + + 
7    + + 
8      
9    + + 
10    + + 
11     + 
12     + 
13  + + + + 
14     + 
15      
16      
17  + + + + 
18 + + + + + 
19      
20  + +   
21  +   + 
22  + +  + 
23 + + + + + 
24     + 
25  + +  + 
26 + + + + + 
27  +  + + 
28  +    
29  + + +  
30 + + +   
31 + +    
32  +    
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Table 3.5: Summary of Phl p 5b peptides containing HLA-DR1-restricted epitopes 
following in silico analysis, tetramer analysis of HLA-DR1-positive grass-allergic 
individuals and HLA-DR1 transgenic mouse studies.  
Peptides that data suggest contain HLA-DR1-restricted epitopes are indicated by “+”. 
Peptides identified by all experimental approaches are highlighted by boxed regions. 
 
 
 
TEPITOPE 
(3% threshold) 
 
 
Tetramer guided  
epitope mapping 
 
HLA-DR1  
Transgenic mouse 
immunisations 
   Protein Peptide 
Phl p 5b peptide     
1     
2     
3     
4 + +  + 
5 + +  + 
6 +   + 
7 +   + 
8     
9    + 
10    + 
11     
12     
13    + 
14     
15     
16     
17 +   + 
18 + + + + 
19 +    
20     
21  +   
22     
23 +  + + 
24 + +   
25 +    
26 + + + + 
27 +   + 
28     
29     
30   +  
31     
32     
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Generation of HLA-DR1-restricted T cell line against Phl p 5b-derived peptide 26 gives 
rise to murine CD4
+
 T cells that can be detected using the same peptide 26 HLA-DR1 
tetramer used in TGEM. 
To further verify peptide 26 as containing an HLA-DR1-restricted T cell epitope, a T 
cell line specific for peptide 26 was generated in the HLA-DR1 transgenic mouse 
following footpad immunisation with peptide in CFA. The T cell line proliferated in 
response to peptide 26 (Figure 3.10a). Furthermore, when labelled with an HLA-DR1 
tetramer loaded with peptide 26, a clear tetramer-positive CD4
+
 T cell population was 
identified (Figure 3.10b). 
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Figure 3.10: Generation of transgenic HLA-DR1-restricted T cell line against Phl p 
5b-derived peptide 26. 
A T cell line was generated in the HLA-DR1 transgenic mouse against Phl p 5b peptide 
26 (peptide 26). Three HLA-DR1 transgenic mice were footpad immunised with 
peptide 26 and CFA. After 10 days mice were culled and the draining popliteal lymph 
node removed. The T cell line was generated by pooling T cells from the immunised 
mice. T cells were cultured for 10 days in the presence of peptide 26 and restimulated 
every 10 days with irradiated autologous APCs and peptide. A) 
3
H-thymidine 
incorporation of the T cell line in response to peptide 26. B) Peptide 26-specific CD4
+
 T 
cells can be detected following tetramer staining with HLA-DR1 tetramer loaded with 
peptide 26 (Provided by Professor W. Kwok). The T cell line was labelled for 1 h at 
37
o
C with PE-conjugated tetramer loaded with irrelevant control peptide or peptide 26. 
This was followed by surface staining with anti-CD4. Samples were analysed using 
flow cytometry. Cells were gated on live lymphocytes according to forward and side 
scatter and on the CD4
+
 population in order to detect the peptide 26-specific T cell 
population. Numbers are percentage of gated events in the upper right quadrant. 
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3.2.4. Validation of Phl p 5b-derived epitope responses in primary cultures of PBMC 
from allergic subjects 
Proliferation of CFSE-labelled grass-allergic PBMC following in vitro stimulation with 
Phl p 5b-derived peptide 26.      
To evaluate epitope recognition in a number of HLA-DR1-positive grass-allergic 
individuals, PBMC isolated from five donors were labelled with CFSE and cultured 
with selected Phl p 5b-derived peptides, previously identified by computational 
analysis, TGEM or HLA-DR1 transgenic mouse studies. Significant proliferative 
responses were only observed following stimulation with peptide 26 and the PPD 
positive control (Figure 3.11a).  
 
In summary, of the thirty two overlapping peptides derived from Phl p 5b, peptides 18 
and 26 were found to contain HLA-DR1-restricted epitopes using all identification 
approaches i.e. in silico, HLA-DR1 tetramer analysis and HLA-DR1 transgenic mouse 
studies. However, only stimulation with peptide 26 was shown to elicit a significant 
proliferation in a number of HLA-DR1-positive grass-allergic individuals.  
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Figure 3.11: Phl p 5b epitope identification in HLA-DR1 allergic individuals. 
A) PBMC isolated from HLA-DR1, grass-allergic individuals were labelled with CFSE 
(1 µM) and cultured in medium only or PPD (1 µg/ml) control or in the presence of Phl 
p 5b peptides 4, 5, 18, 23, 24 or 26 (20 µg/ml) for 14 days with recombinant human IL-
2 (1 ng/ml, from day 7 onwards). At day 14 cells were harvested and co-stained with 
anti-CD4-PE-Cy5 and 7-AAD to exclude dead cells. Cells were gated on the live 
lymphocyte gate according to forward and side scatter, 7-AAD negative and CD4 
positive. Precursor frequency was calculated using ModFit LT software. P values were 
calculated using Friedman test followed by Dunn‟s Multiple Comparison test (** = p < 
0.01). B) ModFit LT data plots for all allergic individuals PBMC following stimulation 
with peptide 26.  
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3.2.5. Analysis of the homology of the Phl p 5b-derived peptide 26 epitope within the 
Poaceae grass family 
The predicted HLA-DR1 binding motif identified within Phl p 5b-derived peptide 26 is 
also present in other commonly occurring grass species.  
The levels of homology of the region corresponding to Phl p 5b-derived peptide 26 
were evaluated amongst common grass species of the Poales order. The predicted HLA-
DR1-restricted CD4
+
 T cell epitope for peptide 26 (YAVFEAALT) was also present in 
the other grass species investigated; Dactylis glomerata (Orchard grass; Dac g 5 
isoallergens 1 and 2), Holcus lanatus (Common velvet grass; Hol l 5.0201) and Lolium 
perenne (Rye grass; Lol p VA and Lol p 5C) (Table 3.6). Allergens of Holcus lanatus 
(Hol l 5b and Hol l 5.0101) and Poa pratensis (Kentucky blue grass; Poa p 5.0201) also 
contained orthologues with amino acid substitutions at positions 1 and 5. These 
orthologues were still predicted to bind HLA-DR1 by TEPITOPE analysis (3% 
prediction threshold). Other grass isoallergens with less sequence identity (Phl p 5.0101, 
Hol l 5.0101 and Lol p 5.0101) were not predicted to bind HLA-DR1.    
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Table 3.6: Sequence alignment of the in silico identified epitope, within Phl p 5b-
derived peptide 26, from Phleum pratense, and other commonly occurring grass 
species within the UK. 
The TEPITOPE-predicted HLA-DR1-restricted epitope within Phl p 5b-derived peptide 
26 was identified in other grass species. Sequences were aligned using the CLUSTAL 
2.0.12 multiple sequence alignment program available via the European Bioinformatics 
Institute server: 
(http://www.ebi.ac.uk/Tools/services/web/toolform.ebi?tool=clustalw2). The Phl p 
isoallergen investigated in this study is shown in bold. The table highlights the 
percentage identity of the epitope sequences following calculation of pairwise sequence 
alignment scores when compared to Phl p 5.0201. The presence or absence of a 
TEPITOPE-predicted HLA-DR1-restricted epitope at a 3% percentage threshold 
analysis is also indicated. Phl p: Phleum pratense; Hol l: Holcus lanatus; Lol p: Lolium 
perenne; Dac g: Dactylis glomerata; Poa p: Poa pratensis. 
 
Allergen Sequence 
Percentage Identity 
to Phl p 5.0201 (%) 
Predicted HLA-DR1 
epitope* 
Phl p 5.0201 YAVFEAALT 100 Y 
Dac g 5 isoallergen 2 YAVFEAALT 100 Y 
Dac g 5 isoallergen 1 YAVFEAALT 100 Y 
Dac g 5 YAVFEAALT 100 Y 
Lol p VA YAVFEAALT 100 Y 
Lol p 5C YAVFEAALT 100 Y 
Hol l 5.0201 YAVFEAALT 100 Y 
Hol l 5b FAVFKAALT 77 Y 
Poa p 5.0201 FAVFKAALT 77 Y 
Phl p 5.0101 YTVFETALK 66 N 
Hol l 5.0101 YTVFETALK 66 N 
Lol p 5.0101 YTVSETALK 55 N 
*
In silico analysis with TEPITOPE with 3% prediction threshold. 
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3.2.6. Computational analysis of Phl p 1 isoallergen sequences 
A high sequence identity is seen following multiple sequence alignment of the Phl p 1 
isoallergens. 
In order to evaluate the homology of previously identified Phl p 1 isoallergens, the only 
two single letter amino acid sequences available were obtained from the IUIS Allergen 
Nomenclature Sub-Committee website (http://www.allergen.org/). The sequences were 
aligned using the CLUSTAL 2.0.12 multiple sequence alignment program (Larkin et al., 
2007) (Figure 3.12). A high degree of identity between the two isoallergens at 93% was 
observed (Table 3.7).  
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Figure 3.12: Sequence alignment of Phl p 1 isoallergens. 
Phl p 1 isoallergen sequences were aligned using the CLUSTAL 2.0.12 multiple 
sequence alignment program available via the European Bioinformatics Institute server: 
(http://www.ebi.ac.uk/Tools/services/web/toolform.ebi?tool=clustalw2). Numbers 
represent the residue numbers. "*" highlights the residues that are identical in both 
sequences. ":" highlights conserved substitutions. "." highlights semi-conserved 
substitutions. Colours: RED = small (small + hydrophobic (including aromatic- Y)), 
BLUE = acidic, MAGENTA= basic and GREEN= hydroxyl + amine + basic- Q. The 
isoallergen investigated in this study is shown in bold. Phlp: Phleum pratense. 
Phl p 1 
 
Phlp1.0101      MASSSSVLLVVALFAVFLGSAHGIPKVPPGPNITATYGDKWLDAKSTWYGKPTAAGPKDN 60 
Phlp1.0102      MASSSSVLLVVVLFAVFLGSAYGIPKVPPGPNITATYGDKWLDAKSTWYGKPTGAGPKDN 60 
                ***********.*********:*******************************.****** 
 
Phlp1.0101      GGACGYKDVDKPPFSGMTGCGNTPIFKSGRGCGSCFEIKCTKPEACSGEPVVVHITDDNE 120 
Phlp1.0102      GGACGYKDVDKPPFSGMTGCGNTPIFKSGRGCGSCFEIKCTKPEACSGEPVVVHITDDNE 120 
                ************************************************************ 
 
Phlp1.0101      EPIAAYHFDLSGIAFGSMAKKGDEQKLRSAGEVEIQFRRVKCKYPEGTKVTFHVEKGSNP 180 
Phlp1.0102      EPIAPYHFDLSGHAFGAMAKKGDEQKLRSAGELELQFRRVKCKYPEGTKVTFHVEKGSNP 180 
                ****.******* ***:***************:*:************************* 
 
Phlp1.0101      NYLALLVKFVAGDGDVVAVDIKEKGKDKWIALKESWGAIWRIDTPEVLKGPFTVRYTTEG 240 
Phlp1.0102      NYLALLVKYVNGDGDVVAVDIKEKGKDKWIELKESWGAIWRIDTPDKLTGPFTVRYTTEG 240 
                ********:* ******************* **************: *.*********** 
 
Phlp1.0101      GTKGEAKDVIPEGWKADTAYESK 263 
Phlp1.0102      GTKTEAEDVIPEGWKADTSYESK 263 
                *** **:***********:**** 
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Table 3.7: Alignment scores for Phl p 1.0102 and Phl p 1.0101. 
Following sequence alignment, pairwise alignment scores were calculated between the 
Group 1 isoallergens. The number of identical amino acid residues between Phl p 
1.0102 and Phl p 1.0101 was compared to the total number of amino acids generating an 
alignment score indicating percentage of sequence identity.  
 
 
Isoallergen 
Percentage identity 
(%) 
Phl p 1.0101 93 
Phl p 1.0102 100 
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HLA-DR epitope prediction software highlights six HLA-DR1 epitopes within Phl p 
1.0102. 
TEPITOPE analysis was performed on the Phl p 1.0102 sequence, selecting for HLA-
DR1 and a 3% prediction threshold. Following TEPITOPE analysis, Phl p 1.0102 was 
predicted to contain six potential HLA-DR1 binding motifs (Figure 3.13). In contrast to 
Phl p 5.0201, only one of the six TEPITOPE-predicted HLA-DR1 binding motifs was 
predicted to demonstrate high affinity binding with an IC50 value <50 nM by 
NetMHCIIpan analysis and low rank scores from IEDB Consensus analysis (Table 3.8). 
 
The epitopes highlighted by TEPITOPE analysis of Phl p 1.0102 were clustered at the 
beginning of the protein sequence. Four regions identified within the signal sequence of 
the protein sequence (amino acids 1-23) were not included in further analyses as this is 
cleaved from the mature secreted protein (Laffer et al., 1994a; Grobe et al., 1999).  
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Figure 3.13: Single letter amino acid sequence of Phl p 1.0102 with TEPITOPE 
predicted HLA-DR1 epitopes highlighted. 
The single letter amino acid sequence of Phl p 1.0102 was obtained from the website of 
the International Union of Immunological Societies Allergen Nomenclature Sub-
Committee (http://www.allergen.org/Allergen.aspx). The sequence was copied into the 
sequence editor of TEPITOPE HLA class II epitope prediction software. HLA-DR1 was 
selected as the HLA allele of interest and the threshold of stringency for the prediction 
was set at 3%. TEPITOPE predicted epitopes of 9 amino acids in length, are shown 
underlined in blue text with the amino acid in position 1 highlighted in red.  
 
Phl p 1.0102 
 
MASSSSVLLVVVLFAVFLGSAYGIPKVPPGPNITATYGDKWLDAKSTWYG50 
 
KPTGAGPKDNGGACGYKDVDKPPFSGMTGCGNTPIFKSGRGCGSCFEIKC100 
 
TKPEACSGEPVVVHITDDNEEPIAPYHFDLSGHAFGAMAKKGDEQKLRSA150 
 
GELELQFRRVKCKYPEGTKVTFHVEKGSNPNYLALLVKYVNGDGDVVAVD200 
 
IKEKGKDKWIELKESWGAIWRIDTPDKLTGPFTVRYTTEGGTKTEAEDVI250 
 
PEGWKADTSYESK263 
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Table 3.8: In silico analyses of Phl p 1.0102 with NetMHCIIpan and Consensus 
methods. 
The single letter amino acid sequence of Phl p 1.0102 was obtained from the website of 
the International Union of Immunological Societies Allergen Nomenclature Sub-
Committee (http://www.allergen.org/Allergen.aspx). The sequence was copied into 
NetMHCIIpan or Consensus servers in order to evaluate peptide binding to HLA class 
II molecules. HLA-DR1 was selected as the restricting HLA allele. NetMHCIIpan 
analysis generated sequences of 15-mer peptides with variable binding affinity 
(measured as IC50 values (nM)). Peptide sequences predicted to demonstrate strong 
binding to HLA-DR1 are presented. The predicted 9-mer core HLA binding motif of 
these peptides is also highlighted and where this correlates with a TEPITOPE-identified 
binding core noted. Consensus analysis also generated 15-mer peptide sequences and 
the Consensus Rank score for these sequences is shown.  
 
Position Sequence
 
 NetMHCIIpan   Consensus 
  Core Affinity (nM)
a
 % Rank
b 
Rank
c
 
11-25 VLFAVFLGSAYGIPK VFLGSAYGI 40.75 16.00 6.34 
177-191 SNPNYLALLVKYVNG YLALLVKYV* 12.73 5.00 1.58 
*
NetMHCIIpan-predicted 9-mer HLA-DR1 core binding motif is also predicted by 
TEPITOPE at 3% prediction threshold. 
a
 IC50 value (nM); < 50 nM high affinity, < 500 nM intermediate affinity and < 5000 nM 
low affinity. 
b
 NetMHCIIpan % Rank score; lower % Rank predicts stronger HLA-DR1 binder. 
c
 Consensus Rank score; lower score predicts stronger affinity for HLA-DR1. 
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3.2.7. HLA-DR1 tetramer driven identification of HLA-DR1-restricted epitopes in 
Phl p 1 
Tetramer guided epitope mapping. 
TGEM was performed in Professor Kwok‟s laboratory using PE-conjugated HLA-
DR1/Phl p 1-derived pooled peptide tetramers in order to detect peptide responsive 
CD4
+
 T cell populations (as previously described for Phl p 5b). Pooled peptide 
tetramers loaded with peptides 16 – 20 showed a distinct tetramer positive population 
(Figure 3.14). Subsequent labelling with the individual peptide tetramers demonstrated 
this was due to CD4
+
 T cells expanded by peptide 20 
(KGSNPNYLALLVKYVNGDGD) (Figure 3.14).  
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Figure 3.14: Identification of an HLA-DR1-restricted Phl p 1 epitope in an allergic 
individual. 
PBMC isolated during the grass pollen season from HLA-DR1-positive, grass-allergic, 
seasonal allergic rhinitic individuals were labelled with HLA-DR1 tetramers loaded 
with Phl p 1-derived peptides and TGEM performed as previously described. Flow 
cytometric analysis of pooled peptide tetramer staining highlights pool 4 for further 
investigation (A). A distinct CD4
+
 tetramer-positive population is seen following 
labelling with individual peptide tetramer loaded peptide 20 (B). 
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3.2.8. HLA-DR1 transgenic mouse studies for identification of HLA-DR1-restricted 
epitopes in Phl p 1 
Generation of HLA-DR1-restricted T cell lines against whole Phl p 1 protein and 
subsequent epitope mapping studies highlight a number of HLA-DR1 epitopes.  
HLA-DR1 transgenic mice were immunised with rPhl p 1 to identify HLA-DR1-
restricted CD4
+
 T cell epitopes and confirm that the epitopes identified by 
computational analysis and tetramer staining are HLA-DR1-restricted and naturally 
processed during an in vivo immune response. Ten days later, individual or pooled T 
cell lines were established and maintained as described in Chapter 2, Materials and 
Methods. To identify epitopes within Phl p 1, the proliferative response of a pooled T 
cell line to 20-mer overlapping peptides (Table 3.9) spanning the entirety of Phl p 1 was 
assessed after the first restimulation cycle. Peptides highlighted by this assay include 
peptide 6 (CGYKDVDKPPFSGMTGCGNT), peptide 7 
(PPFSGMTGCGNTPIFKSGRG), peptide 9 (SGRGCGSCFEIKCTKPEACS), peptide 
10 (FEIKCTKPEACSGEPVVVHI), peptide 20 (KGSNPNYLALLVKYVNGDGD) 
and peptide 24 (KWIELKESWGAIWRIDTPDK) (Figure 3.15). 
 
In order to confirm epitopes identified in the initial peptide screening experiment with 
the pooled T cell line, epitope mapping experiments were repeated with individual T 
cell lines generated from individually immunised mice.  The peptides identified in the 
preceding experiment (Figure 3.15) also generated a positive response in these 
experiments (Peptides 6, 7, 9, 10 and 20) (Figure 3.16).  
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Table 3.9: Amino acid sequence of Phl p 1-derived 20-mer overlapping peptides 
used for epitope mapping studies. 
Each peptide was designed to overlap by 12 amino acids, thus ensuring any 9 residue 
epitope will be represented with at least one flanking amino acid. 
 
Phl p 1 peptide Sequence 
1 IPKVPPGPNITATYGDKWLD 
2 NITATYGDKWLDAKSTWYGK 
3 KWLDAKSTWYGKPTGAGPKD 
4 WYGKPTGAGPKDNGGACGYK 
5 GPKDNGGACGYKDVDKPPFS 
6 CGYKDVDKPPFSGMTGCGNT 
7 PPFSGMTGCGNTPIFKSGRG 
8 CGNTPIFKSGRGCGSCFEIK 
9 SGRGCGSCFEIKCTKPEACS 
10 FEIKCTKPEACSGEPVVVHI 
11 EACSGEPVVVHITDDNEEPI 
12 VVHITDDNEEPIAPYHFDLS 
13 EEPIAPYHFDLSGHAFGAMA 
14 FDLSGHAFGAMAKKGDEQKL 
15 GAMAKKGDEQKLRSAGELEL 
16 EQKLRSAGELELQFRRVKCK 
17 ELELQFRRVKCKYPEGTKVT 
18 VKCKYPEGTKVTFHVEKGSN 
19 TKVTFHVEKGSNPNYLALLV 
20 KGSNPNYLALLVKYVNGDGD 
21 ALLVKYVNGDGDVVAVDIKE 
22 GDGDVVAVDIKEKGKDKWIE 
23 DIKEKGKDKWIELKESWGAI 
24 KWIELKESWGAIWRIDTPDK 
25 WGAIWRIDTPDKLTGPFTVR 
26 TPDKLTGPFTVRYTTEGGTK 
27 FTVRYTTEGGTKTEAEDVIP 
28 GGTKTEAEDVIPEGWKADTS 
29 DVIPEGWKADTSYESK 
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Figure 3.15: Epitope mapping study of pooled murine HLA-DR1-restricted T cell 
line generated against rPhl p 1. 
A pooled T cell line was generated from three HLA-DR1 mice. Mice were footpad 
immunised with rPhl p 1 emulsified with CFA. The draining popliteal lymph node was 
removed at day 10, T cells were pooled and a T cell line generated. Cells were cultured 
on a 10 day cycle restimulated every 10 days with irradiated autologous APCs and rPhl 
p 1. To investigate the recall response of the Phl p 1 T cell line, T cells (2 x 10
4
 
cells/well) were incubated for 48 h with autologous irradiated APCs (3 x 10
5
 cells/well) 
in the presence or absence of 20-mer overlapping peptides spanning Phl p 1 at 50 µg/ml. 
At 48 h cultures were terminated with a 16 h 
3
H-thymidine pulse followed by liquid 
scintillation counting. Values shown are mean Δcpm of triplicate wells (±SEM) at first 
restimulation cycle. 
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Figure 3.16: Epitope mapping study of murine HLA-DR1-restricted T cell lines 
generated against rPhl p 1. 
Two T cell lines (A) and (B) were generated from two HLA-DR1 mice immunised with 
rPhl p 1. To investigate peptide specificity T cells (2 x 10
4
 cells/well) were incubated 
for 48 h with autologous irradiated APCs (3 x 10
5
 cells/well) in the presence or absence 
of 20-mer overlapping peptides spanning Phl p 1 at 50 µg/ml. At 48 h cultures were 
terminated with a 16 h 
3
H-thymidine pulse followed by liquid scintillation counting. 
Values shown are mean Δcpm of triplicate wells (±SEM) at the second restimulation. 
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The combined data from TEPITOPE analysis, TGEM and HLA-DR1 transgenic mouse 
studies are summarised in Table 3.10. Phl p 1-derived peptide 20 was the only peptide 
of the overlapping peptides investigated that was indicated by all experimental 
approaches used for epitope identification. 
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Table 3.10: Summary of Phl p 1 peptides containing HLA-DR1-restricted epitopes 
following in silico analysis, tetramer analysis of HLA-DR1-positive grass-allergic 
individuals and HLA-DR1 transgenic mouse studies. 
Peptides that data suggest contain HLA-DR1-restricted epitopes are indicated by “+”. 
Peptides identified by all experimental approaches are highlighted by boxed regions. 
 
 TEPITOPE 
(3% threshold) 
Tetramer guided  
epitope mapping 
HLA-DR1  
Transgenic mouse 
Phl p 1 peptide    
1    
2    
3    
4    
5    
6   + 
7   + 
8    
9   + 
10   + 
11    
12    
13    
14    
15    
16    
17 +   
18    
19    
20 + + + 
21    
22    
23    
24   + 
25    
26    
27    
28    
29    
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3.2.9. Analysis of the homology of the Phl p 1-derived peptide 20 epitope within the 
Poaceae grass family 
The predicted HLA-DR1 binding motif identified within Phl p 1-derived peptide 20 is 
also identified in other commonly occurring grass species.  
The levels of homology of the region corresponding to Phl p 1-derived peptide 20 were 
evaluated amongst common grass species of the Poales order. The predicted HLA-
DR1-restricted CD4
+ 
T cell epitope for peptide 20 (YLALLVKYV), was identified in 
Holcus lanatus (Common velvet grass; Hol 1.0101) and Poa pratensis (Kentucky blue 
grass; Poa p 1.0101) (Table 3.11). Other grass species investigated also contained 
orthologues with amino acid substitutions at position 4 (Lolium perenne; Lol p 1.0101 
and Lol p 1.0102), position 8 (Phleum pratense; Phl p 1.0101) and position 9 (Cynodon 
dactylon (Bermuda grass; Cyn d 1.0101, Cyn d 1.0102 and Cyn d 1.0201) and Holcus 
lanatus; Hol 1 1.0102). Despite these substitutions, these regions were still predicted to 
bind HLA-DR1.
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Table 3.11: Sequence alignment of the in silico identified epitope, within Phl p 1-
derived peptide 20, from Phleum pratense and other commonly occurring grass 
species within the UK. 
The TEPITOPE-predicted HLA-DR1-restricted epitope within Phl p 1-derived peptide 
20 was identified in other grass species. Sequences were aligned using the CLUSTAL 
2.0.12 multiple sequence alignment program available via the European Bioinformatics 
Institute server: 
(http://www.ebi.ac.uk/Tools/services/web/toolform.ebi?tool=clustalw2). The Phl p 
isoallergen investigated in this study is shown in bold. The table highlights the 
percentage identity of the epitope sequences following calculation of pairwise sequence 
alignment scores when compared to Phl p 1.0102. The presence or absence of a 
TEPITOPE-predicted HLA-DR1-restricted epitope at a 3% percentage threshold 
analysis is also indicated. Phl p: Phleum pratense; Hol l: Holcus lanatus; Lol p: Lolium 
perenne; Cyn d: Cynodon dactylon; Poa p: Poa pratensis. 
 
Allergen Sequence 
Percentage Identity 
to Phl p 1.0102 (%) 
Predicted HLA-DR1 
epitope* 
Phl p 1.0102 YLALLVKYV 100 Y 
Hol l 1.0101 YLALLVKYV 100 Y 
Poa p 1.0101 YLALLVKYV 100 Y 
Lol p 1.0101 YLAILVKYV 88 Y 
Lol p 1.0102 YLAILVKYV 88 Y 
Phl p 1.0101 YLALLVKFV 88 Y 
Cyn d 1.0101 YLALLVKYA 88 Y 
Cyn d 1.0102 YLALLVKYA 88 Y 
Cyn d 1.0201 YLALLVKYA 88 Y 
Hol l 1.0102 YLALLVKYI 88 Y 
*
In silico analysis with TEPITOPE with 3% prediction threshold. 
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3.3. Discussion 
Identification of immunodominant epitopes within candidate allergens is essential for 
the development of effective allergen-derived peptide vaccinations. The objective of the 
work described in this Chapter was to identify HLA-DR1-restricted CD4
+
 T cell 
epitopes within the major grass pollen allergens, Phl p 1 and Phl p 5b.  
 
3.3.1. Computational analysis of Phl p 1 and Phl p 5b isoallergen sequences 
Sequence alignment. 
The first approach adopted was to investigate sequence similarities between isoallergens 
within Group 1 and Group 5 allergens of Phleum pratense. Following multiple sequence 
alignment and pairwise alignment score analysis, a high percentage of sequence identity 
was observed between the isoallergens in both groups. This is in accordance with the 
findings of previous studies evaluating isoform-specific Phl p 5 T cell clones (Müller et 
al., 1998b; Würtzen et al., 1999a, 1999b). Due to the nature of environmental exposure, 
grass-allergic individuals are polysensitised to a number of different grass species and 
isoallergens (Moingeon et al., 2008). Indeed, it is not possible to identify individual 
sensitising grass pollen allergens due to extensive IgE cross-reactivity (Johansen et al., 
2009). Since a peptide-based vaccination strategy could comprise only a limited number 
of immunodominant peptides, a high percentage of sequence identity or homology 
between grass pollen isoallergens increases the likelihood that selected peptides will 
contain epitopes widely recognised by T cells within the grass-allergic population.  
 
The isoallergen sequences investigated here were obtained from public databases. It is 
possible that some isoallergens arise as artefacts of molecular biology techniques such 
as PCR used to identify and analyse grass pollen protein sequences (van Ree, 2002; 
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Ferreira et al., 2004). Furthermore, there may be additional isoallergens that have not 
yet been described. Recently, Chabre and colleagues (2010) used mass spectrometry to 
investigate the molecular variability of Group 1 and Group 5 grass pollen allergens 
amongst Pooideae species. Their study identified between five and ten Group 1 
isoallergens, and between thirty and fifty Group 5 isoallergens, based upon both amino 
acid sequences and glycosylation states. This variation further highlights the importance 
of selecting epitopes that are conserved within species between isoallergens, and also 
between different species to ensure a broad repertoire of T cell epitopes of grass-allergic 
individuals are represented in a vaccine.  
 
In silico HLA-DR epitope prediction. 
CD4
+
 T cell recognition of allergen requires processing into peptides and presentation to 
the TCR in the context of HLA class II molecules (Rudolph et al., 2006). Therefore, 
identification of peptide sequences that bind to HLA molecules has the potential to 
highlight possible CD4
+
 T cell epitopes. In this thesis, in silico analysis was used to 
identify candidate HLA-DR1-restricted epitopes within the grass pollen sequences. The 
prediction algorithms selected have recently been highlighted by performance 
evaluation analyses to accurately identify HLA class II binding epitopes verified by 
experimental HLA/peptide binding assays (Lin et al., 2008; Wang et al., 2008). 
TEPITOPE is a matrix-based algorithm which identifies and predicts whether peptide 
sequences will bind to HLA-DR molecules (Sturniolo et al., 1999) and has been used to 
successfully predict HLA-DR epitopes in autoimmunity, cancer and allergy (Bian and 
Hammer, 2004). TEPITOPE analysis of Phl p 5b revealed seven HLA-DR1-restricted 
epitopes, whilst analysis of Phl p 1 highlighted two HLA-DR1-restricted epitopes. Of 
these, the epitopes contained within Phl p 5b-derived peptide 26 and Phl p 1-derived 
peptide 20, ranked highly following additional in silico analyses with NetMHCIIpan 
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and IEDB Consensus prediction algorithms, demonstrating a high predicted binding 
affinity to HLA-DR1.  
 
The epitopes identified by in silico analyses in this study overlapped with peptide 
sequences previously highlighted by epitope mapping studies performed with T cell 
lines and clones (Schenk et al., 1995; Müller et al., 1998b; Würtzen et al., 1999a). 
However, in these historical studies, the precise HLA-restriction of epitopes was not 
fully elucidated. Recent epitope mapping studies, performed by Oseroff et al., (2010) 
whilst this thesis was in progress, have identified overlapping peptides from both Phl p 
1 and Phl p 5, containing the same in silico-predicted epitopes highlighted in this study. 
In contrast to this thesis, a panel of overlapping peptides was used to stimulate PBMC 
isolated from allergic individuals and epitope-containing peptides identified based upon 
cytokine responses. Whilst the HLA-restriction of the T cell responses was determined, 
participants were recruited irrespective of their HLA genotype and a wide range of 
HLA-restrictions were observed. Furthermore, several peptides were shown to be 
restricted by multiple loci. Whilst the work presented in this thesis was limited to HLA-
DR1, different HLA molecules (e.g. HLA-DR1, -DR4, -DR7 and -DR15), may bind the 
same „promiscuous‟ epitope (Chicz et al., 1993; Southwood et al., 1998). Therefore, 
HLA-DR1-restricted immunodominant peptides identified by this study may have the 
potential to bind other HLA-DR molecules. Indeed, on analysis of HLA class II binding 
assay data now publically available on the Immune Epitope Database (IEDB; 
www.iedb.org; Sidney et al., unpublished), the two major HLA-DR1-restricted epitopes 
identified in this study (Phl p 5b-dervived peptide 26 and Phl p 1-derived peptide 20), 
bound multiple other HLA alleles indicating promiscuity (Table 3.12 and Table 3.13).  
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In summary, there are extensive species and isoallergen homologies, cross-reactivity 
and HLA-DR binding promiscuity in epitope binding. Therefore the epitopes identified 
in this thesis may have therapeutic potential beyond tolerance induction to Phleum 
pratense in HLA-DR1-positive grass-allergic individuals.  
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Table 3.12: Additional HLA-DRB allele binding of a peptide containing the 
equivalent Phl p 5b-derived peptide 26 HLA-DR1-restricted binding motif. 
 
HLA binding data obtained from the Immune Epitope Database (IEDB; www.iedb.org) 
were analysed to determine potential HLA-binding promiscuity of the HLA-DR1-
restricted binding motif of Phl p 5b-derived peptide 26. Data were generated by 
determining the capacity of the Phl p 5b-derived peptide to bind to various HLA class II 
molecules through quantitative competition assays, based on the competitive inhibition 
of binding of a radiolabelled standard peptide to purified HLA molecules (Sidney et al., 
unpublished).  
 
Phl p 5b-derived peptide 26  
Predicted HLA-DR1 binding motif: YAVFEAALT 
 
HLA-Allele Qualitative measure 
Quantitative measure 
(IC50 nM) 
DR1 Positive, high 4.08 
DR3 Positive, low 1610 
DR4
*
 Positive, intermediate 385 
DR4
~
 Positive, high 25.4 
DR7 Positive, intermediate 857 
DR8 Positive, high 91 
DR9 Positive, high 25.5 
DR11 Positive, intermediate 207 
DR12 Positive, low 3100 
DR13 Positive, low 8060 
DR15 Positive, low 6170 
*
0401 allele, 
~
0405 allele. 
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Table 3.13: Additional HLA-DRB allele binding of a peptide containing the 
equivalent Phl p 1-derived peptide 20 HLA-DR1-restricted binding motif. 
HLA binding data obtained from the Immune Epitope Database (IEDB; www.iedb.org) 
were analysed to determine potential HLA-binding promiscuity of the HLA-DR1-
restricted binding motif of Phl p 1-derived peptide 20. Data were generated by 
determining the capacity of the Phl p 1-derived peptide to bind to various HLA class II 
molecules through quantitative competition assays, based on the competitive inhibition 
of binding of a radiolabelled standard peptide to purified HLA molecules (Sidney et al., 
unpublished). 
 
Phl p 1-derived peptide 20 
Predicted HLA-DR1 binding motif: YLALLVKYV 
 
HLA-DRB Allele Qualitative measure 
Quantitative measure 
(IC50 nM) 
DR1 Positive, high 64.9 
DR4
*
 Positive, low 5180 
DR4
~
 Positive, intermediate 170 
DR7 Positive, intermediate 738 
DR8 Positive, low 1190 
DR9 Positive, high 12.2 
DR11 Positive, intermediate 103 
DR12 Positive, intermediate 109 
DR13 Positive, low 2750 
DR15 Positive, high 95.9 
*
0401 allele, 
~
0405 allele. 
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3.3.2. HLA-DR1 tetramer driven identification of HLA-DR1-restricted epitopes 
Tetramer guided epitope mapping. 
Whilst binding to HLA molecules is a prerequisite for epitope presentation to specific T 
cells, predictions of HLA-binding per se offer no guarantee that 1) the binding peptide 
will be generated following the intracellular processing that occurs prior to HLA-
loading and subsequent cell surface presentation, or 2) that a T cell with corresponding 
specificity is present in the immune repertoire. Consequently, confirmation that an 
epitope is functionally relevant requires T cell validation studies both in vitro and in 
vivo.  
 
HLA tetramers are a powerful tool in the identification and visualisation of antigen-
specific T cells. TGEM has been used to identify epitopes of viruses e.g. influenza 
(Yang et al., 2009b), bacterial toxins e.g. tetanus (James et al., 2007) and autoantigens 
e.g. islet-specific glucose-6-phosphatase catalytic subunit-related protein (Yang et al., 
2006a). The data presented here (generated in Professor Kwok‟s laboratory) are the first 
to employ HLA-DR tetramers to investigate Phleum pratense epitopes using TGEM. 
The majority of peptides, highlighted by TGEM to contain HLA-DR1 epitopes, were 
also predicted by TEPITOPE to bind to HLA-DR1 at a minimum 3% prediction 
threshold. This establishes that at least some epitopes predicted by TEPITOPE for Phl p 
1 and Phl p 5 are functional, since peptides containing the same sequences bind to 
HLA-DR1 tetramers in vitro and stimulate CD4
+
 T cells from HLA-DR1-positive 
allergic individuals. However, one peptide identified by TGEM, peptide 21 from Phl p 
5b, was not predicted to bind to HLA-DR1 by TEPITOPE at the 3% prediction 
threshold but only at the 5% threshold. This also demonstrates that theoretical 
prediction of HLA binding alone can miss functional HLA-DR1-restricted epitopes and 
highlights the necessity for complementary in vitro and in vivo analyses. 
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Whilst TGEM is a valuable tool for epitope identification it is associated with a number 
of limitations, notably labour-intensity and expense. Synthesis of stable HLA class II 
tetramers is complex and requires extensive optimisation for individual HLA alleles 
(Vollers and Stern, 2008). Furthermore, recruitment of appropriate tissue-typed 
participants is hampered by the high polymorphism of the HLA class II gene loci. For 
example, since only a percentage of the population express the HLA allele of interest, 
screening of a much larger number of allergic individuals was required in order to 
identify sufficient HLA-DR1 participants for the work presented in this thesis. 
Additionally, TGEM is an in vitro peptide-based assay. Consequently, the peptides 
utilised might vary from those generated following the natural processing of allergen 
protein resulting in the identification of false-positive „cryptic epitopes‟ (discussed 
further in Section 3.3.3).  To be relied upon TGEM-identified epitopes therefore require 
validation in T cell assays following processing of the whole allergen, in vitro or in 
vivo. 
 
There are other shortcomings of the TGEM approach: for example the in vitro 
expansion of allergen-specific CD4
+
 T cells, required as part of this technique could 
bias the T cell population towards those high-avidity CD4
+
 T cells preferentially 
activated in culture. Additionally, the method of HLA class II tetramer preparation is 
also biased towards the selection of peptides that have high affinity towards empty HLA 
class II monomers (Yang et al., 2009a). High affinity peptides might out-compete lower 
affinity peptides at the HLA monomer peptide-loading step. As a result, low affinity but 
nonetheless genuine epitopes theoretically have the potential to be missed in such 
studies. 
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To summarise, recent advances in HLA class II tetramer technology have enabled the 
advent of TGEM for HLA-restricted CD4
+
 T cell epitope identification. This in vitro 
approach, whilst corroborating some epitopes highlighted by in silico analyses, 
demonstrates that epitope prediction on the basis of the probability of HLA binding 
alone restricts the number of identifiable epitopes. However, due to intrinsic bias within 
the TGEM methodology, additional experimentation is required for epitope 
confirmation in vivo.  
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3.3.3. HLA-DR1 transgenic mouse studies for epitope identification 
A major challenge in the identification and characterisation of human CD4
+
 T cell 
responses to allergen is the low frequency of allergen-specific CD4
+
 T cells. In contrast, 
use of mice transgenic for human HLA-DR molecules enables access to an abundant 
source of antigen-specific cells from the draining lymph nodes of allergen immunised 
animals. Furthermore, use of murine models allows the assessment of whether 
immunodominant peptides previously identified by in silico prediction and in human in 
vitro analyses are naturally processed during an in vivo immune response.  
 
Following immunisation of a group of HLA-DR1 transgenic mice and subsequent 
generation of individual T cell lines, peptide mapping highlighted a number of epitopes. 
Such a large number of responding peptides was unexpected, since the CD4
+
 T cell 
immune response is normally focused on a limited number of immunodominant 
epitopes, as demonstrated by previous epitope mapping studies (Schenk et al., 1995; 
Müller et al., 1998b; Würtzen et al., 1999a; Oseroff et al., 2010). One possible 
explanation for the high number of positive peptides observed is the overlapping nature 
of the peptides used for epitope mapping. The peptides were designed to overlap by 
twelve amino acids to ensure no potential epitopes were missed. The rationale for this is 
that the optimal motif for HLA binding is generally believed to comprise nine core 
amino acids with flanking amino acids outside the binding groove (Chicz et al., 1992; 
Brown et al., 1993; Stern et al., 1994). Therefore, using peptides overlapping by twelve 
amino acids ensures that no such region will be missed in screening. However, this also 
means that epitopes may be duplicated in the overlapping regions. This scenario is 
likely to have occurred with a number of epitopes in Phl p 5b since peptides 4 and 5, 6 
and 7, 18 and 19, 24 and 25, and 26 and 27 each share the same TEPITOPE-predicted 
 207 
 
epitope between overlapping sequences. Accordingly, the true number of epitopes 
within the allergen is likely to be somewhat less than that represented. 
 
In silico HLA class II epitope prediction using TEPITOPE requires selection of an 
appropriate prediction threshold for analysis. The percentage threshold controls the 
stringency of the analysis (Detailed in Chapter Two, Materials and Methods): the lower 
the percentage threshold, the more stringent the analysis and the fewer epitopes that will 
be identified (Bian et al., 2003; Bian and Hammer, 2004). Previously Sturniolo et al., 
have demonstrated that a 3% prediction threshold detects up to 80% of HLA-DR-
restricted peptides (Sturniolo et al., 1999) and therefore 3% was selected for the work 
represented in this thesis. The data presented here illustrate that HLA-DR1-restricted 
epitopes can be detected by alternative methods e.g. TGEM, that fall below the 3% 
threshold. Therefore, whilst the 3% prediction threshold offers a high level of 
stringency, these data indicate that important epitopes may be missed; highlighting the 
importance of pursuing complementary epitope prediction approaches.  
 
Peptides 4 and 5 of Phl p 5b are predicted to contain the same HLA-DR1-restricted 
epitope by TEPITOPE and were also identified by TGEM and in the HLA-DR1 
transgenic mouse model following pooled-peptide immunisation. However, when mice 
were immunised with whole Phl p 5b protein, no response to peptides 4 and 5 was 
observed. This discrepancy suggests that peptides 4 and 5 may contain a „cryptic 
epitope‟ i.e. an epitope that is not processed from the native protein in sufficient 
quantities to elicit a T cell response, but which can be recognised if the normal antigen 
processing pathways are circumvented by using synthetic peptides. Cryptic epitopes 
may arise for a number of reasons (Sercarz et al., 1993). Firstly, ineffective processing 
may occur due to inaccessibility of the epitope during processing, for example due to 
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incomplete denaturation of the antigen or enzymatic degradation. Secondly, dominant 
flanking epitopes may out-compete the true epitope for binding to the same HLA 
molecule. Finally, flanking amino acids may sterically hinder epitope binding to the 
HLA molecule or inhibit interaction of the peptide-HLA complex with the TCR. The 
biological importance of „cryptic epitopes‟ and whether their inclusion in peptide-based 
vaccination confers additional therapeutic benefit, requires further evaluation. 
 
In conclusion, these data highlight the value of identifying epitopes by complementary 
in silico, in vitro and in vivo approaches. In particular, the in vivo experiments 
conducted with humanised HLA-DR1 transgenic mice provide proof of principle that 
epitopes may be recognised following processing of whole antigen. Furthermore, this 
model provides a platform for testing the tolerogenic potential of these epitopes in vivo.  
  
 209 
 
3.3.4. Validation of epitope responses in primary cultures of PBMC from allergic 
subjects 
The purpose of the work in Section 3.2.4 was to validate and characterise T cell 
responses to putative epitopes identified in previous sections.  Analysis of CFSE 
dilution has previously been used to investigate antigen-specific CD4
+
 T cell 
proliferation in response to specific antigens and determine precursor frequency of 
antigen-specific cells (Rimaniol et al., 2003; Beeler et al., 2006; Wambre et al., 2008; 
Turcanu et al., 2010; Foster et al., 2011). Data presented in this thesis illustrate that Phl 
p 5-derived peptide 26-specific CD4
+
 T cells were indeed present in a number of 
allergic individuals. This observation suggests that the epitope contained within peptide 
26 is widely recognised by HLA-DR1-positive grass-allergic individuals sensitised to 
whole Phleum pratense.  
 
The CFSE studies performed in this thesis estimated precursor frequencies at a 
considerably higher level than previous studies (Rimaniol et al., 2003; Beeler et al., 
2006; Wambre et al., 2008; Turcanu et al., 2010; Foster et al., 2011). However, 
detection of peptide 26 expanded cells necessitated expansion in IL-2. The death of non-
specific T cells during this extended culture period inevitably resulted in an apparent 
increase in the relative number of proliferating CFSE
low
 T cells. Hence the frequencies 
indicated cannot be considered as an accurate measure of the precursor starting 
frequency. However, obtaining an accurate assessment of precursor frequency was not 
the aim of these experiments. Instead the aim was to examine whether peptide-specific 
cells were widely present in allergic individuals, and for this reason accuracy was 
sacrificed for sensitivity.  
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In conclusion, CD4
+
 T cell proliferation was observed in PBMC isolated from a number 
of HLA-DR1 grass-allergic individuals in response to Phl p 5b-derived peptide 26. This 
indicates that the epitope contained within this peptide is broadly recognised by the T 
cell repertoire of the grass-allergic population, further reinforcing the potential value for 
inclusion in a peptide-based vaccination.  
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3.3.5. Analysis of the homology of Phl p 5b-derived peptide 26 and Phl p 1-derived 
peptide 20 epitopes within the Poaceae grass family 
Peptide 26 of Phl p 5b and peptide 20 of Phl p 1 have been shown by in silico analysis, 
TGEM and HLA-DR1 transgenic mouse studies to contain HLA-DR1-restricted CD4
+
 
T cell epitopes. Moreover, peptide 26 was associated with strong proliferative responses 
in 5 of 5 allergic subjects tested in the CFSE assay. The final analysis of this Chapter 
compared the predicted HLA-DR1-binding motifs of peptide 26 and peptide 20 to the 
corresponding sequences from a number of commonly occurring grass species within 
the UK. Previous studies of the response of T cell lines and T cell clones, isolated from 
grass-allergic individuals and raised against Phl p 5 and Phl p 1, to other grass species 
have shown that the T cell response is heterogeneous with multiple common and 
species-specific epitopes recognised by cells isolated from different donors (Schenk et 
al., 1995; Würtzen et al., 1999b; Van Neerven et al., 2000). 
 
The data presented here indicate that peptide 20 from Phl p 1 is likely to be recognised 
by allergic individuals sensitised to different Phl p 1 isoforms and also to Group 1 
isoallergens from different grass species, due to the high levels of sequence 
conservation. Sequences corresponding to peptide 26 in other grass species, however, 
are less conserved. Therefore, confirmation of T cell recognition of these orthologues 
would be advisable before final inclusion in a vaccine. The relative contribution of the 
epitopes within peptide 20 and peptide 26, to the allergic immune response to Phleum 
pratense is unknown.  In order to establish this, further experiments are required, either 
in human or HLA transgenic mouse models, to examine the extent to which 
administration of peptide 26 or peptide 20 blocks the immune response to whole 
Phleum pratense grass pollen extract.  
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In summary, a degree of interspecies conservation is apparent within the regions 
corresponding to the HLA-DR1-restricted epitopes identified in Phl p 1 and Phl p 5b. 
These findings suggest that the identified epitopes may have therapeutic potential 
against a number of grass species to which patients are likely to be exposed in the UK.  
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3.4. Summary 
The aim of this Chapter was to identify HLA-DR1-restricted CD4
+
 T cell epitopes of 
the major grass pollen allergens, Phl p 1 and Phl p 5b. HLA-DR1-restricted epitopes 
were identified using three complementary approaches: in silico HLA-DR1-restricted 
epitope prediction, tetramer guided epitope mapping and an HLA-DR1 transgenic 
mouse model. Furthermore, recognition of these epitopes was confirmed in a group of 
HLA-DR1-positive grass-allergic individuals. Analysis of archived HLA binding data 
suggests that these HLA-DR1-restricted epitopes may demonstrate promiscuous binding 
to additional HLA molecules. The putative HLA-DR1-binding motifs of Phleum 
pratense were seen to be conserved among certain grass species. Consequently, the data 
presented here suggest that the HLA-DR1-restricted CD4
+
 T cell epitopes identified 
may be broadly recognised by T cells within the grass-allergic population and that their 
tolerogenic potential may be extended beyond Phleum pratense  and to additional grass 
species.  
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Chapter Four: Identification and characterisation of Phl p 
1 and Phl p 5b epitope-specific CD4+ T cells in allergic 
and non-allergic individuals 
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4. Identification and characterisation of Phl p 1 and Phl p 5b 
epitope-specific CD4
+
 T cells in allergic and non-allergic 
individuals 
4.1. Introduction 
The role of allergen-specific CD4
+
 T cells is fundamental to both the pathogenesis and 
regulation of allergic disease and inflammation. Their precise role is determined by their 
antigen-specificity, cell surface marker expression and cytokine secretion profiles. 
Allergic disease is characterised as a Th2 cell-driven disease due to the increased 
presence of Th2 cells and subsequent Th2 mediators in allergic patients whilst 
regulatory T cells may serve to dampen the allergic-response in non-allergic individuals 
(Reviewed by (Woodfolk, 2007)). An understanding of the differences in the response 
to allergen by CD4
+
 T cells in allergic and non-allergic individuals, specifically the 
mechanisms leading to tolerance in non-allergic individuals, will provide crucial 
information for the prevention of the allergic response in allergic individuals.  
 
The properties of antigen-specific CD4
+
 T cells have not been fully defined in humans 
primarily due to their low frequency within the peripheral T cell repertoire (Altman et 
al., 1996). To date, the majority of allergen-specific CD4
+
 T cell responses have been 
characterised by comparisons of proliferation and cytokine production in response to 
allergen stimulation of PBMC cultures or T cell lines. These techniques are relatively 
insensitive and require extensive in vitro expansion to expand the allergen-specific 
CD4
+
 T cell population. They also do not discriminate between the responses of 
allergen-specific CD4
+
 T cells and non-specific CD4
+
 T cells stimulated by bystander 
activation.  
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Identification of immunodominant epitopes restricted to certain HLA-DR allotypes 
within common and clinically relevant allergens, has enabled the development of HLA 
class II-peptide tetramers as reagents to study allergen-specific CD4
+
 T cell responses. 
Tetramers comprise four biotinylated HLA class II molecules loaded with allergen-
derived peptide, multimerized by fluorochrome-conjugated streptavidin enabling 
visualisation of epitope-specific CD4
+
 T cells (Novak et al., 2001). A number of 
allergens have been studied using tetramers including Ara h 1 (DeLong et al., 2011), Art 
v 1 (Jahn-Schmid et al., 2008), Bet v 1 (Wambre et al., 2008; Van Overtvelt et al., 2008; 
Wambre et al., 2011), Bos d 2 (Kinnunen et al., 2007, 2010), Der p 1 (Wambre et al., 
2011), Fel d 1 (Bateman et al., 2006; Kwok et al., 2010), Lol p 1 (Macaubas et al., 
2006) and Ves v 5 (Aslam et al., 2010). However, in the majority of these studies 
tetramer-based analysis was performed following an in vitro expansion phase in order to 
increase the allergen-specific CD4
+
 T cell population due to their low frequency in the 
periphery. Recently, ex vivo analyses have been performed with tetramers for Fel d 1-
specific CD4
+
 T cells (Bateman et al., 2006; Kwok et al., 2010) and Ara h 1-specific 
CD4
+
 T cells (DeLong et al., 2011). Ex vivo analysis is preferential to those employing 
in vitro expansion as culturing may result in the alteration of phenotypes and function of 
the cell population of interest.  
 
The aims of the work presented in this chapter were to: 
1) Study the recognition of HLA-DR1-restricted epitopes of Phl p 1 and Phl p 
5b identified in Chapter 3 using HLA-DR1 tetramers. 
2) Characterise the phenotype of the epitope-specific cells in allergic and non-
allergic subjects by: 
a. Cell surface phenotype (ex vivo) 
b. Cytokine production (in vitro). 
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4.2. Results 
4.2.1. Identification of tetramer-positive populations 
Clinical data. 
The clinical characteristics of study participants, 11 HLA-DR1, grass-allergic, seasonal 
allergic rhinitic donors and 10 HLA-DR1 non-allergic control donors are shown in 
Table 4.1. All participants were assessed for HLA-DR1 genotype and sensitivity to 
Phleum pratense as measured by skin prick testing and measurements of specific IgE as 
described in Chapter 2, Materials and Methods. Allergic subjects had positive skin prick 
tests to Phleum pratense (3 mm or greater in diameter as compared to negative control 
at 15 minutes following skin prick testing, in the presence of negative diluents and 
positive histamine controls). Multiple sensitivities to other common aeroallergens were 
permitted. Non-allergic controls were required to be non-symptomatic and have 
negative skin prick tests to extracts of a range of common aeroallergens including 
Phleum pratense and specific IgE levels to Phleum pratense of < 0.35 IU/ml. 
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Table 4.1: Summary of clinical characteristics of allergic and non-allergic study 
participants. 
 
Volunteer M/F 
Age 
(Yrs) 
HLA-
DRB1 
alleles 
SPT to 
Phleum 
pratense 
(mm
*
) 
SPT to other 
allergens 
IgE to 
Phleum 
pratense 
(IU/ml) 
Total 
IgE 
(IU/
ml) 
Allergic 7:4       
        
URM 018 M 29 1:15 6.0 nil 1.49 3.0 
URM 022 F 26 1:10 10.0 D 100.0 760.0 
URM 028 M 34 1:4 6 D, M 9.66 26.0 
URM 031 M 49 1:4 9 C,D,H 5.70 229.0 
URM 039
†
 F 42 1:14 13.0 nil 9.21 15.0 
URM 044 M 45 1:4 9 A,C,D 2.98 23.0 
URM 067 M 41 1:13 6 B,C,D,M 11.8 36.0 
URM 068 F 36 1:3 11.0 B, HDM 9.13 107.0 
URM 069 M 58 1:15 13.9 B, C, D, HDM 7.98 89.0 
URM 074 F 45 1:3 10 B, D 23.4 73.0 
URM 087 M 38 1:1502 7 B, M 15.4 123.0 
        
Non-
allergic 
6:4 
      
        
URM 095 M 38 1:3 0 nil <0.35 53.0 
URM 213 M 41 1:7 0 nil <0.35 5.0 
URM 222 F 48 1:14 0 nil <0.35 25.0 
URM 302 M 25 1:7 0 nil <0.35 7.0 
URM 304 M 37 1:3 0 nil <0.35 35.0 
URM 306 M 47 1:7 0 nil <0.35 26.0 
URM 308 M 27 1:15 0 nil <0.35 15.0 
URM 318 F 24 1:4 0 nil <0.35 4.0 
URM 321 F 29 1:3 0 nil <0.35 18.0 
URM 322 F 29 1:12 0 nil <0.35
~
 3.0 
 
*
Size of wheal defined as (Dl/dp)/2, where Dl is the longest diameter and dp is the 
diameter mid-orthogonal to Dl. 
†
currently undergoing immunotherapy. 
~
IgE to mixed 
grasses including Phleum pratense.  
A: Alternaria alternata; B: Betula verrucosa; C: Cat hair; D: Dog hair; H: Horse 
dander; HDM: House dust mite, Dermatophagoides pteronyssinus; M: Mugwort; SPT: 
skin prick test. 
Mean age (± SEM): Allergic 40(3) yrs; Non-allergic 34.5(3) yrs; p > 0.05. 
Mean Total IgE (± SEM): Allergic 134.9(65.5) IU/ml; Non-allergic 19.1(5.1) IU/ml; p 
> 0.05. Statistical analyses performed by unpaired Student‟s t-test.  
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Optimal detection of tetramer-positive populations occurred following 14 days of in 
vitro expansion of PBMC cultures with allergen. 
In peripheral blood, the frequency of circulating allergen-specific CD4
+
 T cells has 
generally been perceived to be too low to allow their adequate detection without any in 
vitro expansion with allergen. As a result, it was necessary to evaluate different 
stimulation and culturing protocols in order to ensure efficient expansion of those T 
cells. For all the following optimisation experiments, PBMC samples were processed 
from allergic individuals outside the grass pollen season during Winter 2008/09. 
 
For determination of an optimum length of in vitro expansion, PBMC were isolated 
from allergic donors and cultured at a density of 2 x 10
6
 cells/ml with 20 µg/ml Phl p 5b 
peptide 26 (p26) for 14 days in culture media containing 10% AB serum with 
recombinant human IL-2 (2 ng/ml) added at day 7. PBMC were harvested at days 0 
(immediately ex vivo), 7 and 14, and labelled with HLA-DR1 tetramers loaded with 
either peptide 26 (p26 tetramer) or an irrelevant control peptide (Phl p 5b peptide 4). 
Cells were counterstained with anti-CD3 and CD4 antibodies to enable gating on the 
live CD4
+
 T cells to evaluate tetramer-positive populations (Figure 4.1). At day 0 and 
day 7 no tetramer-positive populations were detectable. In contrast, substantial tetramer-
positive populations were only detectable at day 14. These data indicate that in vitro 
expansion for 14 days was required for optimal detection of tetramer-positive CD4
+
 T 
cells.  
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Figure 4.1: Time course of in vitro expansion for optimal detection of HLA-DR1, Phl p 5b peptide 26 tetramer-positive populations. 
PBMC were isolated from HLA-DR1, grass-allergic, seasonal allergic rhinitic subjects and cultured with Phl p 5b peptide 26 (p26) for 14 days with 
recombinant human IL-2 added at day 7. PBMC were labelled with anti-CD3-FITC and anti-CD4-PE-Cy5 antibodies, and PE-conjugated-HLA-DR1 
tetramer loaded with p26 (p26 tetramer) or control tetramer loaded with an irrelevant peptide (Phl p 5b peptide 4, p4 tetramer) at days 0, 7 and 14. 
Samples were analysed using flow cytometry. Cells were gated on live lymphocytes according to forward and side scatter and on the CD3
+
CD4
+
 
population in order to detect the p26-specific CD4
+
 T cell population. Numbers are percentage of tetramer-positive gated events in the upper right 
quadrant. Samples processed during Winter 2008/09. 
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Peptide stimulation of cell cultures was more effective at generating tetramer-positive 
CD4
+
 populations from PBMC cultures than whole protein stimulation.  
Having established an appropriate length of time for T cell expansion, the optimal 
stimulus used was investigated by comparing whole protein and peptide stimulation. 
PBMC isolated from allergic subjects were cultured for 14 days, with addition of IL-2 at 
day 7 in the presence of either 10 µg/ml recombinant Phl p 5b or 20 µg/ml p26. 
Tetramer staining was performed at day 14 with p26 and control (Phl p 1 peptide 20) 
tetramers and tetramer-positive CD4
+
 populations compared (Figure 4.2). Small but 
clear discrete p26 tetramer-positive populations were detectable from cultures 
stimulated with Phl p 5b in 2 of 4 allergic subjects. However, for cultures stimulated 
with p26, tetramer-positive populations were clearly detectable in all 4 allergic subjects. 
As a positive control the p26-specific T cells generated from the HLA-DR1 transgenic 
mouse were also labelled with the p26 tetramer at the same time. In future experiments 
peptide stimulation was used to expand T cells rather than whole antigen.  
 
 223 
 
p26 tetramer
p26 stimulated 
PBMC
Control tetramer p26 tetramer
rPhl p 5b stimulated 
PBMC
T
et
ra
m
er
-P
E
CD4- PE-Cy5
URM 018
URM 022
URM 031
URM 044
T
e
tr
a
m
e
r-
P
E
CD4- FITC
p26  HLA-DR1 
transgenic mouse line
1.47 2.600.69
0.28 2.520.19
0.72 2.070.28
0.43 10.430.28
p26 tetramer
9.09
 
Figure 4.2: Stimulation with Phl p 5b peptide 26 produces a larger population of 
tetramer-positive cells than culture with recombinant Phl p 5b protein. 
Whole PBMC isolated from HLA-DR1, grass-allergic, seasonal allergic rhinitic subjects 
were cultured for 14 days with either recombinant Phl p 5b protein (rPhl p 5b) or Phl p 
5b peptide 26 (p26). At day 7 recombinant human IL-2 was added. At day 14 cells were 
labelled with anti-CD3-FITC and anti-CD4-PE-Cy5 antibodies and PE-conjugated-
HLA-DR1 tetramer loaded with p26 (p26 tetramer) or control tetramer loaded with Phl 
p 1 peptide 20. Samples were analysed using flow cytometry. Cells were gated on live 
lymphocytes according to forward and side scatter and on the CD3
+
CD4
+
 population in 
order to detect the p26-specific T cell population. As a positive control the p26 tetramer 
was used to label an HLA-DR1 transgenic mouse T cell line generated against p26. 
Numbers are percentage of tetramer-positive gated events in upper right quadrant. 
Where control tetramer plots are not shown numbers represent percentage of p26 
tetramer-positive gated events with percentage of control tetramer-positive events 
subtracted. Samples were processed outside of the grass pollen season during Winter 
2008/09. 
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Use of serum-free cell culture medium did not enhance generation of tetramer-positive 
CD4
+
 T cell cultures.  
The next culture condition investigated was the use of human AB serum in cell culture 
medium or commercially available serum-free medium AIM-V. Previous groups have 
shown an improvement in the expansion of allergen-specific cells using serum-free 
medium (Upham et al., 1995). PBMC were isolated from allergic subjects as previously 
described and cultured at a density of 2 x 10
6
 per well with 20 µg/ml p26 in either cell 
culture medium containing 10% AB serum or serum-free medium, AIM-V. Cells were 
cultured for 14 days with the addition of IL-2 at day 7. At day 14 cells were harvested 
and labelled with the p26 tetramer or control (Phl p 5b peptide 4) tetramer and the 
number of tetramer-positive CD3
+
CD4
+
 events compared (Figure 4.3). Increased 
numbers of tetramer-positive events were detected when PBMC were cultured with 
medium containing 10% AB serum as compared to those PBMC cultured in AIM-V 
serum-free medium. Cells were therefore cultured in cell culture medium supplemented 
with 10% AB serum for subsequent experiments.  
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Figure 4.3: Cell culture media containing human AB serum enhances expansion of 
tetramer populations in comparison to AIM-V serum-free medium. 
Whole PBMC isolated from HLA-DR1, grass-allergic, seasonal allergic rhinitic subjects 
were cultured with Phl p 5b peptide 26 (p26) in either RPMI medium containing 10% 
human AB serum or AIM-V serum free medium. Recombinant human IL-2 was added 
at day 7 and cells cultured for a total of 14 days. At day 14 cells were labelled with anti-
CD3-FITC and anti-CD4-PE-Cy5 antibodies and PE-conjugated HLA-DR1 tetramer 
loaded with p26 (p26 tetramer) or control tetramer loaded with an irrelevant peptide 
(Phl p 5b peptide 4). Samples were analysed using flow cytometry. Cells were gated on 
live lymphocytes according to forward and side scatter and on the CD3
+
CD4
+
 
population in order to detect the p26 tetramer-specific T cell population. Numbers 
represent percentage of gated events in upper right quadrant. Samples were processed 
outside of the grass pollen season during Winter 2008/09. 
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Culture of whole PBMC gave rise to the greatest tetramer-positive populations. 
The next aim was to determine which cell population to use in primary cultures in order 
to provide the greatest possible expansion of the allergen-specific CD4
+
 T cells. Three 
conditions were compared; whole PBMC, CD4
+
 T cells or CD4
+
CD25
-
 T cells plus 
adherent cells. CD4
+ 
T cells were isolated from whole PBMC samples using negative 
selection magnetic beads. For CD4
+
CD25
-
 T cell cultures, CD25
+
 T cells were removed 
using positive selection magnetic beads. Culture plates were coated with adherent cells 
as described in Chapter 2, Materials and Methods. Cells were cultured for 14 days with 
20 µg/ml p26 and labelled with p26 or control (Phl p 1 peptide 20) tetramer as 
previously described (Figure 4.4). It was found that culture of whole PBMC gave the 
largest tetramer-positive CD4
+
 T cell populations. 
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Figure 4.4: Culture of whole PBMC with Phl p 5b peptide 26 resulted in the best 
tetramer-positive populations. 
Different cell culture conditions were compared to establish the best conditions for 
detection of tetramer-positive cell populations. A) Whole PBMC were cultured with Phl 
p 5b peptide 26 (p26) for 14 days. B) CD4
+
 T cells were isolated by negative selection 
with magnetic beads and columns and cultured in wells coated with adherent cells with 
p26 for 14 days. C) CD25
+
 cells were depleted from isolated CD4
+
 T cells and cultured 
with adherent cells with p26 for 14 days. At day 7 recombinant human IL-2 was added 
to all conditions. 
 
At day 14 cells were labelled with anti-CD3-FITC and anti-CD4-PE-Cy5 antibodies and 
PE-conjugated HLA-DR1 tetramer loaded with p26 (p26 tetramer) or control tetramer 
loaded with an irrelevant peptide (Phl p 1 peptide 20). Samples were analysed using 
flow cytometry. Cells were gated on live lymphocytes according to forward and side 
scatter and on the CD3
+
CD4
+
 population in order to detect the p26-specific T cell 
population. Numbers represent percentage of p26 tetramer-positive gated events in 
upper right quadrants with percentage of control tetramer-positive events subtracted. 
Samples were processed outside of the grass pollen season during Winter 2008/09. 
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CD4
+
 T cells specific to peptides from two major grass pollen allergens, Phl p 5b and 
Phl p 1 can be detected in a number of grass-allergic, seasonal allergic rhinitic donors. 
After determining the optimised conditions for detection of T cells using HLA-DR1 
tetramers, the next aim was to investigate a number of allergic subjects. To this end, 
PBMC were isolated and cultured from the 8 HLA-DR1 positive, grass-allergic, 
seasonal allergic rhinitis donors as characterised in Table 1, outside of the grass pollen 
season during Winter 2008/09. Following 14 day culture and tetramer staining, p26 
tetramer-positive populations were detectable in 7 of 8 allergic subjects indicating that 
this peptide is recognised by CD4
+
 T cells from a number of allergic subjects (Figure 
4.5). Peptide 20 has been highlighted as a potential epitope in the major grass allergen 
Phl p 1 so; Phl p 1 peptide 20 tetramer (p20 tetramer) positive populations were also 
studied (Figure 4.6). In this instance, 6 of 8 allergic subjects had p20 tetramer-positive 
populations following 14 day culture of PBMC stimulated with 20 µg/ml p20. Together, 
these data show CD4
+
 T cell populations that recognise specific peptides within the 
grass pollen allergens Phl p 5b and Phl p 1 can be expanded and detected in a number of 
allergic subjects. 
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Figure 4.5: HLA-DR1 Phl p 5b peptide 26 tetramer-positive populations detected 
in whole PBMC cultures. 
Whole PBMC isolated from HLA-DR1, grass-allergic, seasonal allergic rhinitic subjects 
were cultured with Phl p 5b peptide 26 (p26) for 14 days with recombinant human IL-2 
added at day 7. At day 14 cells were labelled with anti-CD3-FITC and anti-CD4-PE-
Cy5 antibodies and PE-conjugated-HLA-DR1 tetramer loaded with p26 (p26 tetramer) 
or control tetramer loaded with an irrelevant peptide. Samples were analysed using flow 
cytometry. Cells were gated on live lymphocytes according to forward and side scatter 
and on the CD3
+
CD4
+
 population in order to detect the p26-specific T cell population. 
Numbers represent percentage of tetramer-positive gated events in upper right 
quadrants. Samples were processed outside of the grass pollen season during Winter 
2008/09. 
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Figure 4.6: HLA-DR1 Phl p 1 peptide 20 tetramer-positive populations detected in 
whole PBMC cultures. 
Whole PBMC isolated from HLA-DR1, grass-allergic, seasonal allergic rhinitic subjects 
were cultured with Phl p 1 peptide 20 (p20) for 14 days with recombinant human IL-2 
added at day 7. At day 14 cells were labelled with anti-CD3-FITC and anti-CD4-PE-
Cy5 antibodies and PE-conjugated-HLA-DR1 tetramer loaded with p20 (p20 tetramer) 
or control tetramer loaded with an irrelevant peptide. Samples were analysed using flow 
cytometry. Cells were gated on live lymphocytes according to forward and side scatter 
and on the CD3
+
CD4
+
 population in order to detect the p20-specific T cell population. 
Numbers represent percentage of tetramer-positive gated events in upper right 
quadrants. *Control tetramer staining was not performed. Samples were processed 
outside of the grass pollen season during Winter 2008/09. 
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Tetramer-positive CD4
+
 T cells can be detected following 14 day in vitro expansion in 
allergic and non-allergic donors. 
Having identified p26 tetramer-positive cells from allergic individuals outside of the 
grass pollen season, the next experiments aimed to determine the effect of pollen 
exposure and whether tetramer-positive CD4
+
 T cells could be detected in non-allergic 
individuals. Samples were processed during the grass pollen season Summer 2010 and 
whilst p26-specific CD4
+
 T cells were detected in cultures from non-allergic subjects, 
following in vitro expansion with peptide, there were significantly fewer (p = 0.005) 
p26-specific cells as compared to in allergic cultures (Figure 4.7). The flow cytometry 
plots of the samples analysed are shown in Figure 4.8.  
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Figure 4.7: Frequency of Phl p 5b peptide 26 tetramer-positive populations 
following 14 day in vitro expansion of PBMC isolated from allergic and non-
allergic subjects. 
Whole PBMC isolated from HLA-DR1, grass-allergic, seasonal allergic rhinitic subjects 
and non-allergic controls were cultured with Phl p 5b peptide 26 (p26) for 14 days with 
recombinant human IL-2 added at day 7. At day 14 cells were labelled with anti-CD3-
FITC and anti-CD4-PE-Cy5 antibodies and PE-conjugated-HLA-DR1 tetramer loaded 
with p26 (p26 tetramer) or control tetramer loaded with Phl p 1 peptide 26. Samples 
were analysed using flow cytometry. Cells were gated on live lymphocytes according to 
forward and side scatter and on the CD3
+
CD4
+
 population in order to detect the p26-
specific T cell population. Graphical representation of the percentage of p26 tetramer-
positive gated events between allergic and non-allergic subjects with percentage of 
control tetramer-positive gated events subtracted is shown. Statistical analysis was 
performed using the Mann-Whitney U test (bars indicate median values). Samples were 
processed during the grass pollen season Summer 2010. (n = 6 allergic and n = 8 non-
allergic subjects). 
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Figure 4.8: Phl p 5b peptide 26 tetramer populations in in vitro expanded PBMC 
cultures from allergic and non-allergic subjects. 
In vitro expanded PBMC cultures from allergic and non-allergic subjects were labelled 
with Phl p 5b peptide 26 or control (Phl p 1 peptide 26) tetramers and analysed by flow 
cytometry. Cells were gated on live lymphocytes according to forward and side scatter 
and on the CD3
+
CD4
+
 population. Numbers are percentage of tetramer-positive gated 
events in upper right quadrant for allergic (A) and non-allergic (B) subjects. 
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4.2.2. Ex vivo investigation and characterisation of tetramer-positive CD4+ T cells 
Tetramer-positive populations can be detected immediately ex vivo without the 
prerequisite for in vitro expansion with allergen. 
Having established detection of p26 and p20 tetramer-positive CD4
+
 T cells in both 
allergic and non-allergic subjects following in vitro expansion of PBMC, experiments 
were performed to determine whether tetramer-positive cells could be detected and 
characterised immediately ex vivo.  
 
PBMC were isolated from both allergic and non-allergic subjects and labelled with p26 
tetramer. Samples were then analysed by flow cytometry. Discrete populations of 
tetramer-positive CD4
+
 T cells were seen in the majority of allergic and non-allergic 
subjects, although the size varied between subjects. These tetramer-positive populations 
were associated with a high expression of CD4 (CD4
high
), therefore, in order to calculate 
the frequency of tetramer-positive cells the number of tetramer-positive cells per 
10
5
 CD4
high
 T cells was calculated. The control tetramer used for these experiments was 
an HLA-DR1 tetramer loaded with a glutamate decarboxylase 65 (GAD-65) peptide, 
corresponding to an immunodominant epitope in Type I diabetes. The staining observed 
with the control tetramer however, was of a higher intensity than that seen for the test 
tetramers and highly ambiguous, lacking definition of discrete tetramer-positive cell 
populations in all subjects (data not shown). The control tetramer staining was 
determined not to have worked therefore background staining was not subtracted from 
the test tetramer samples. 
 
In order to evaluate seasonal variation in tetramer-positive cell frequency, in season 
samples were processed during the Summer 2009 grass pollen season, and out of season 
samples were processed during Winter 2009/10. Due to the small sample sizes for the 
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out of season analyses, statistical comparisons were performed using unpaired Student‟s 
t-tests. Whilst similar numbers of tetramer-positive cells were detected in allergic and 
non-allergic subjects, a decrease in the number of tetramer-positive cells was observed 
outside of the pollen season (Figure 4.9a). For non-allergic subjects, this was 
statistically significant (p = 0.048). Representative flow cytometry plots are shown of 
the staining of p26 tetramer-positive cells from allergic (Figure 4.9b) and non-allergic 
(Figure 4.9c) subjects. 
 
In addition to the detection of p26 tetramer-positive cells immediately ex vivo from both 
allergic and non-allergic subjects, p20 tetramer-positive cells were also detectable 
(Figure 4.10). Although not significant there was a tendency for the frequency of 
tetramer-positive cells to be lower in non-allergic subjects as compared to allergic 
subjects and the frequency further decreased outside of the pollen season (Figure 4.10a). 
Representative flow cytometry plots are shown from allergic (Figure 4.10b) and non-
allergic (Figure 4.10c) subjects.  
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Figure 4.9: Phl p 5b peptide 26 tetramer-positive populations are detectable 
immediately ex vivo in PBMC from allergic and non-allergic subjects. 
Whole PBMC isolated from allergic and non-allergic subjects were labelled 
immediately ex vivo with Phl p 5b peptide 26 tetramer. A) Tetramer-positive cells were 
detected in both allergic and non-allergic subjects both in (Summer 2009) and out 
(Winter 2009/10) of the grass pollen season. P values were determined by unpaired 
Student‟s t-test, bars indicate mean values. Representative plots of immediate ex vivo 
tetramer staining of whole PBMC from allergic (B) and non-allergic (C) subjects during 
the grass pollen season. Cells were gated on live lymphocytes according to forward and 
side scatter and on the CD3
+
CD4
+
 population in order to detect the p26-specific T cell 
population. Numbers are frequency of tetramer-positive cells.   
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Figure 4.10: Phl p 1 peptide 20 tetramer-positive populations are detectable 
immediately ex vivo in PBMC from allergic and non-allergic subjects. 
Whole PBMC isolated from allergic and non-allergic subjects were labelled 
immediately ex vivo with Phl p 1 peptide 20 tetramer. A) Tetramer-positive cells were 
detected in both allergic and non-allergic subjects both in (Summer 2009) and out 
(Winter 2009/10) of the grass pollen season. P values were determined by unpaired 
Student‟s t-test, bars indicate mean values. Representative plots of immediate ex vivo 
tetramer staining of whole PBMC from allergic (B) and non-allergic (C) subjects during 
the grass pollen season. Cells were gated on live lymphocytes according to forward and 
side scatter and on the CD3
+
CD4
+
 population in order to detect the p20-specific T cell 
population. Numbers are frequency of tetramer-positive cells.   
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Characterisation of the surface phenotype of tetramer-positive CD4
+
 T cells labelled 
immediately ex vivo is suggestive of an effector memory phenotype. 
In order to phenotype the p26- and p20-specific T cells, ex vivo labelled tetramer-
positive CD4
+
 T cells were counter-stained with a number antibodies specific to 
different cell surface makers associated with different CD4
+
 T cell subsets e.g. Th1, Th2 
and also memory and activation status. Cell surface markers evaluated included: CCR4, 
CCR3, CXCR1, CCR5, CXCR3, CCR7, CD62L, CD38 and CD45RA (Table 4.2). The 
expression of these cell surface markers on tetramer-positive CD4
+
 T cells was 
compared to their expression on the total CD4
high
 T cell population. A higher proportion 
of p26 tetramer positive cells expressed CCR4 and CCR3 than the total CD4
high
 
population (p = 0.008) (Figure 4.11). In contrast, expression of CCR7, CD62L and 
CD45RA was lower on tetramer-positive cells as when compared to the total CD4
high
 T 
cell population (p = 0.004, p = 0.008 and p = 0.04 respectively). 
 
Cell surface marker phenotyping was also carried out on ex vivo p20 tetramer-labelled 
CD4
+
 T cells (Figure 4.12). Expression of CCR4, CCR5 and CXCR3 was seen to be 
significantly higher compared to the total CD4
high
 T cell population (p = 0.008, p = 0.02 
and p = 0.02 respectively), whereas expression of CCR7 was significantly lower (p = 
0.004).  
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Table 4.2: Cell surface markers selected for phenotyping analysis. 
 
Cell surface 
marker 
 Phenotype References 
CCR4  Th2 
1,2,3,4 
CCR3  Th2 
1,2,3,5 
CXCR1  Th2 
8,9 
    
CCR5  Th1 
2,3,6,7 
CXCR3  Th1 
2,3 
    
CCR7  Central memory 
10 
CD62L  Central memory 
10 
    
CD38  Activation 
11 
    
CD45RA  Naïve 
12 
1 
(Morgan et al., 2005); 
2
 (Bonecchi et al., 1998);
3
 (Sallusto et al., 1998); 
4
 (D‟Ambrosio 
et al., 1998); 
5
 (Sallusto et al., 1997); 
6
 (Loetscher et al., 1998); 
7
 (Qin et al., 1998); 
8
 
(Francis et al., 2004); 
9
 (Francis et al., 2007); 
10 
(Sallusto et al., 1999); 
11
 (Hercend et al., 
1981); 
12 
(Akbar et al., 1988). 
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Figure 4.11: Phenotyping of Phl p 5 peptide 26 tetramer-positive CD4
+
 T cells from 
allergic subjects. 
PBMC isolated from allergic subjects were labelled immediately ex vivo with Phl p 5b 
peptide 26 tetramer. This was followed by cell surface staining with FL-1 conjugated 
cell surface maker antibodies and an anti-CD4PE-Cy5. A) The expression of a FL-1 
conjugated cell surface maker antibody was compared on total CD4
high
 and CD4
+
 HLA-
DR1 Phl p 5 peptide 26 tetramer-positive cells from HLA-DR1, grass-allergic, seasonal 
allergic rhinitic subjects. Statistical analysis was performed using a Wilcoxon signed 
rank test. B) Representative flow cytometry plots for cell surface marker expression. 
Plots are shown for the expression of the cell surface marker on CD4
+
 and tetramer-
positive cells. Numbers are percentage of gated events in upper left or right quadrant. 
Samples were processed during the grass pollen season Summer 2009. 
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Figure 4.12: Phenotyping of Phl p 1 peptide 20 tetramer-positive CD4
+
 T cells from 
allergic subjects. 
PBMC isolated from allergic subjects were labelled immediately ex vivo with Phl p 1 
peptide 20 tetramer. This was followed by cell surface staining with FL-1 conjugated 
cell surface maker antibodies and an anti-CD4PE-Cy5. A) The expression of a FL-1 
conjugated cell surface maker antibody was compared on total CD4
high
 and CD4
+
 HLA-
DR1 Phl p 1 peptide 20 tetramer-positive cells from HLA-DR1, grass-allergic, seasonal 
allergic rhinitic subjects. Statistical analysis was performed using a Wilcoxon signed 
rank test. B) Representative flow cytometry plots for cell surface marker expression. 
Plots are shown for the expression of the cell surface marker on CD4
+
 and tetramer-
positive cells. Numbers are percentage of gated events in upper left or right quadrant. 
Samples were processed during the grass pollen season Summer 2009. 
 242 
 
4.2.3. Characterisation of peptide-specific CD4+ T cell populations 
PBMC from allergic subjects showed increased IL-5 production as compared to non-
allergic donors when stimulated with Phleum pratense proteins. 
In order to characterise the p20 and p26 epitope-specific CD4
+
 T cells according to 
cytokine production, supernatants were collected from allergic and non-allergic PBMC 
cultures after 7 day stimulation. These were analysed for IL-5 and IFN-γ content by 
ELISA (Figure 4.13 and Figure 4.14). As a positive control PBMC were stimulated by 
10 µg/ml Phleum pratense extract or PPD (1 µg/ml). Cultures from allergic subjects 
produced significantly more IL-5 as compared to non-allergic subjects when stimulated 
with whole Phleum pratense extract (p = 0.0002) or recombinant Phl p 5b (p = 0.009) 
and Phl p 1 (p = 0.001) (Figure 4.13a and b). There were no differences in IL-5 
production between allergic and non-allergic subjects with PPD stimulation (Figure 
4.13a).   
 
Although concentrations of IL-5 produced in response to p20 were generally low, more 
was produced by allergic subjects at both 2 µg/ml (p = 0.009) or 20 µg/ml (p = 0.04) 
concentrations versus non-allergic subjects (Figure 4.13c). The amount of IL-5 secreted 
upon peptide stimulation was less than that observed in response to stimulation with 
whole extract or major allergen, due to the presence of multiple epitopes within the 
whole extract as compared to only one in the peptide. 
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Figure 4.13: PBMC from allergic subjects cultured with Phleum pratense proteins 
showed greater IL-5 production than non-allergic subjects. 
PBMC isolated from HLA-DR1 allergic and non-allergic subjects were cultured for 7 
days in the presence of A) Phleum pratense extract (Phl p; 10 µg/ml ) or PPD (1 µg/ml). 
B)  Phl p 5b (10 µg/ml) or Phl p 5b peptide 26 (2 or 20 µg/ml). C) Phl p 1 (10 µg/ml) or 
Phl p 1 peptide 20 (2 or 20 µg/ml).  Supernatants were then collected and assayed for 
IL-5 using ELISA. Data shown are with background (medium only) subtracted. 
Statistical analysis was performed using the Mann-Whitney U test. Bars indicate 
median values. (n = 9 allergic and 7 non-allergic HLA-DR1 subjects).  
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Production of IFN-γ was not detectable in day 7 supernatants as assessed by ELISA. 
IFN-γ production was also measured in day 7 supernatants by ELISA. When stimulated 
with whole Phleum pratense extract, IFN-γ production was below the limits of detection 
in both allergic and non-allergic subjects (Figure 4.14). Following stimulation with 
PPD, allergic cultures produced more IFN-γ than non-allergic cultures (p = 0.04) 
(Figure 4.14a). However, there was little IFN-γ produced by allergic and non-allergic 
cultures when stimulated with Phl p 5b or Phl 5b p26 at either 2 or 20 µg/ml (Figure 
4.14b). Similarly, Phl p 1 and Phl p 1 p20 (2 and 20 µg/ml) elicited little IFN-γ with no 
difference between the clinical groups (Figure 4.14c).  
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Figure 4.14: IFN-γ production by PBMC isolated from allergic and non-allergic 
subjects was not detectable in day 7 supernatants. 
PBMC isolated from HLA-DR1 allergic and non-allergic subjects were cultured for 7 
days in the presence of A) Phleum pratense extract (Phl p; 10 µg/ml ) or PPD (1 µg/ml). 
B)  Phl p 5b (10 µg/ml) or Phl p 5b peptide 26 (2 or 20 µg/ml). C) Phl p 1 (10 µg/ml) or 
Phl p 1 peptide 20 (2 or 20 µg/ml).  Supernatants were then collected and assayed for 
IFN-γ using ELISA. Data shown are with background (medium only) subtracted. 
Statistical analysis was performed using the Mann-Whitney U test. Bars indicate 
median values. (n = 9 allergic and 7 non-allergic HLA-DR1 subjects). 
 
 246 
 
The frequency of Th2 cytokine-producing cells was greater in allergic than non-allergic 
subjects following stimulation with whole Phleum pratense extract. 
Since the levels of IL-5 production as measured by ELISA were generally low, cytokine 
production was further characterised by dual Fluorospot assays. PBMC were isolated 
from allergic and non-allergic subjects and cultured for 42 hours on PDVF-bottomed 
cell culture plates with positive control antigens- Phleum pratense and PPD and a dose 
response of p26 and p20. The frequencies of cytokine-producing cells per 10
6
 PBMC 
were calculated and compared between allergic and non-allergic subjects. Fluorospot 
analysis of the response to control antigens showed significantly higher frequencies of 
IL-5-producing cells in allergic as compared to non-allergic donors (p = 0.05), when 
stimulated with Phleum pratense but not with PPD (Figure 4.15a). Furthermore, there 
were some IL-5-producing cells in allergic subjects when stimulated with 20 µg/ml p26 
(Figure 4.15a). The frequency of IL-4-producing cells from allergic subjects was higher 
than in non-allergic subjects when stimulated with Phleum pratense (p = 0.004), and no 
difference observed with PPD stimulation (Figure 4.15b). There was no substantial IL-4 
production by p26-stimulated PBMC in allergic or non-allergic subjects (Figure 4.15). 
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Figure 4.15: Frequencies of IL-5 and IL-4-producing cells from allergic and non-
allergic subjects in response to Phl p 5b peptide 26. 
Frequencies of cytokine-producing cells in HLA-DR1 allergic and non-allergic controls 
in response to Phl p 5b peptide 26 measured by IL-5 (A) and IL-4 (B) Fluorospot assay. 
PBMC isolated from HLA-DR1, grass-allergic, seasonal allergic rhinitic subjects or 
HLA-DR1 non-allergic controls were cultured for 42 h in the presence of Phl p 5b  
peptide 26, Phleum pratense extract (10 µg/ml) or PPD (1 µg/ml) at 20 x 10
6
 cells/ml. 
Data shown are numbers of spot forming units per 10
6
 PBMC with background 
(medium alone) subtracted. Statistical analysis was performed using the Mann-Whitney 
U test. Bars indicate median values. (n = 9 HLA-DR1 allergic and non-allergic 
controls).  
 248 
 
When stimulated with PPD, IFN-γ-producing cells were detected from both allergic and 
non-allergic subjects, but no IFN-γ-producing cells were observed following Phleum 
pratense or p26 stimulation (Figure 4.16a).  
 
The frequency of IL-10 producing cells was similar in allergic and non-allergic subjects 
stimulated with PPD and p26. There may be a small increase in allergic subjects 
stimulated with Phleum pratense (Figure 4.16b).  
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Figure 4.16: Frequencies of IFN-γ and IL-10-producing cells from allergic and 
non-allergic subjects in response to Phl p 5b peptide 26. 
Frequencies of cytokine-producing cells in HLA-DR1 allergic and non-allergic controls 
in response to Phl p 5b peptide 26 measured by IFN-γ (A) and IL-10 (B) Fluorospot 
assay. PBMC isolated from HLA-DR1, grass-allergic, seasonal allergic rhinitic subjects 
or HLA-DR1 non-allergic controls were cultured for 42 h in the presence of Phl p 5b  
peptide 26, Phleum pratense extract (10 µg/ml) or PPD (1 µg/ml) at 20 x 10
6
 cells/ml. 
Data shown are numbers of spot forming units per 10
6
 PBMC with background 
(medium alone) subtracted. Statistical analysis was performed using the Mann-Whitney 
U test. Bars indicate median values. (n = 9 HLA-DR1 allergic and non-allergic 
controls). 
 250 
 
Stimulation with Phleum pratense and increasing concentrations of p20 showed an 
increase in the frequency of IL-4- and IL-5-producing cells in allergic compared to non-
allergic individuals (Figure 4.17a and b). No difference in the frequency of IFN-γ- or 
IL-10-producing cells between allergic and non-allergic donors was observed at any p20 
concentration (Figure 4.18a and b).  
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Figure 4.17: Frequencies of IL-5 and IL-4-producing cells from allergic and non-
allergic subjects in response to Phl p 1 peptide 20. 
Frequencies of cytokine-producing cells in HLA-DR1 allergic and non-allergic controls 
in response to Phl p 1 peptide 20 measured by IL-5 (A) and IL-4 (B) Fluorospot assay. 
PBMC isolated from HLA-DR1, grass-allergic, seasonal allergic rhinitic subjects or 
HLA-DR1 non-allergic controls were cultured for 42 h in the presence of Phl p 1  
peptide 20, Phleum pratense extract (10 µg/ml) or PPD (1 µg/ml) at 20 x 10
6
 cells/ml. 
Data shown are numbers of spot forming units per 10
6
 PBMC with background 
(medium alone) subtracted. Statistical analysis was performed using the Mann-Whitney 
U test. Bars indicate median values. (n = 9 HLA-DR1 allergic and non-allergic 
controls). 
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Figure 4.18: Frequencies of IFN-γ and IL-10-producing cells from allergic and 
non-allergic subjects in response to Phl p 1 peptide 20. 
The frequency of cytokine-producing cells in HLA-DR1 allergic and non-allergic 
controls in response to Phl p 1 peptide 20 measured by IFN-γ (A) and IL-10 (B) 
Fluorospot assay. PBMC isolated from HLA-DR1, grass-allergic, seasonal allergic 
rhinitic subjects or HLA-DR1 non-allergic controls were cultured for 42 h in the 
presence of Phl p 1  peptide 20, Phleum pratense extract (10 µg/ml) or PPD (1 µg/ml) at 
20 x 10
6
 cells/ml. Data shown are numbers of spot forming units per 10
6
 PBMC with 
background (medium alone) subtracted. Statistical analysis was performed using the 
Mann-Whitney U test. Bars indicate median values. (n = 9 HLA-DR1 allergic and non-
allergic controls). 
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Production of IFN-γ but no other cytokines tested was shown by intracellular cytokine 
staining of CD4
+
 T cells proliferating in response to p26 or p20. 
Intracellular cytokine staining was attempted. In a pilot experiment, PBMC isolated 
from two allergic and one non-allergic subjects were labelled with CFSE in order to 
monitor antigen-specific proliferation. Following PMA and ionomycin stimulation and 
intracellular cytokine staining, those CD4
+
 T cells that were shown to have proliferated 
by CFSE dilution were analysed for cytokine expression. Using this method neither IL-
4 nor IL-10 were detectable under any culture conditions for allergic or non-allergic 
cells, medium only, PPD (1 µg/ml), p26 (20 µg/ml) or p20 (20 µg/ml) (Figure 4.19 and 
Figure 4.20).  IFN-γ-producing cells were detected in allergic and non-allergic subjects 
in response to Phl p 5 p26 and Phl p 1 p20 stimulation (Figure 4.21).  
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Figure 4.19: Intracellular IL-4 staining of CFSE-labelled PBMC isolated from 
allergic and non-allergic subjects. 
PBMC isolated from HLA-DR1 allergic and non-allergic subjects were labelled with 
CFSE (1 µM) and cultured in medium only or PPD (1 µg/ml) control or in the presence 
of Phl p 5b peptide 26 or Phl p 1 peptide 20 (20 µg/ml) for 14 days with recombinant 
human IL-2 (1 ng/ml, from day 7 onwards). Cells were harvested at day 14 and 
restimulated for intracellular cytokine staining with PMA (10 ng/ml) and ionomycin (1 
µg/ml) in the presence of brefeldin A (1µg/ml) for 4 hours and monensin (1 µg/ml) for 
the final 2 hours. Cells were then surface stained with anti-CD4-PE-Cy5 before 
permeabilisation and staining with anti-IL-4-PE antibody or isotype control. Cells were 
analysed by flow cytometry and were gated on the live lymphocyte gate according to 
forward and side scatter and CD4 positivity. Numbers are percentage of CD4
+
 cells that 
have proliferated as shown by CFSE dilution expressing IL-4.   
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Figure 4.20: Intracellular IL-10 staining of CFSE-labelled PBMC isolated from 
allergic and non-allergic subjects. 
PBMC isolated from HLA-DR1 allergic and non-allergic subjects were labelled with 
CFSE (1 µM) and cultured in medium only or PPD (1 µg/ml) control or in the presence 
of Phl p 5b peptide 26 or Phl p 1 peptide 20 (20 µg/ml) for 14 days with recombinant 
human IL-2 (1 ng/ml, from day 7 onwards). Cells were harvested at day 14 and 
restimulated for intracellular cytokine staining with PMA (10 ng/ml) and ionomycin (1 
µg/ml) in the presence of brefeldin A (1µg/ml) for 4 hours and monensin (1 µg/ml) for 
the final 2 hours. Cells were then surface stained with anti-CD4-PE-Cy5 before 
permeabilisation and staining with anti-IL-10-PE antibody or isotype control. Cells 
were analysed by flow cytometry and were gated on the live lymphocyte gate according 
to forward and side scatter and CD4 positivity. Numbers are percentage of CD4
+
 cells 
that have proliferated as shown by CFSE dilution expressing IL-10.     
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Figure 4.21: Intracellular IFN-γ staining of CFSE-labelled PBMC isolated from 
allergic and non-allergic subjects. 
PBMC isolated from HLA-DR1 allergic and non-allergic subjects were labelled with 
CFSE (1 µM) and cultured in medium only or PPD (1 µg/ml) control or in the presence 
of Phl p 5b peptide 26 or Phl p 1 peptide 20 (20 µg/ml) for 14 days with recombinant 
human IL-2 (1 ng/ml, from day 7 onwards). Cells were harvested at day 14 and 
restimulated for intracellular cytokine staining with PMA (10 ng/ml) and ionomycin (1 
µg/ml) in the presence of brefeldin A (1µg/ml) for 4 hours and monensin (1 µg/ml) for 
the final 2 hours. Cells were then surface stained with anti-CD4-PE-Cy5 before 
permeabilisation and staining with anti-IFN-γ-PE antibody or isotype control. Cells 
were analysed by flow cytometry and were gated on the live lymphocyte gate according 
to forward and side scatter and CD4 positivity. Numbers are percentage of CD4
+
 cells 
that have proliferated as shown by CFSE dilution expressing IFN-γ.    
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4.3. Discussion 
4.3.1. Identification of tetramer-positive populations 
In the previous chapter, regions containing immunodominant T cell epitopes, peptide 26 
of Phl p 5b and peptide 20 of Phl p 1, were identified. The aim of the work described in 
this chapter was to characterise recognition of these epitopes in allergic and non-allergic 
subjects using HLA class II tetramers.  
 
To achieve this, the initial experiments in this chapter were designed to evaluate a 
number of different cell culture methods to allow the optimal in vitro expansion of 
allergen-specific CD4
+
 T cells for their detection using HLA-DR1 tetramers. It was 
found that tetramer-positive populations could be optimally detected following culture 
of whole PBMC isolated from HLA-DR1 grass-allergic seasonal rhinitic donors and 
stimulation with allergen-derived peptide for 14 days with the addition of IL-2 at day 7.  
The protocol in this study varied from a number of published protocols which added IL-
2 earlier to the cultures from day 3 (Wambre et al., 2008) or day 5 (Van Overtvelt et al., 
2008; Wambre et al., 2011). The delay in the addition of IL-2 until day 7 was to 
maximise the selection of activated and proliferating allergen-specific CD4
+
 T cells and 
therefore to minimise bystander proliferation induced by IL-2. As in the study by 
Macaubas et al., (2006), addition of IL-2 at day 7 expanded the tetramer-positive 
population to readily detectable levels by day 14.  Other groups also restimulated their 
cell cultures with irradiated autologous APCs and allergen prior to tetramer staining 
(Macaubas et al., 2006; Wambre et al., 2008; Van Overtvelt et al., 2008; Wambre et al., 
2011) and subsequently cultured isolated cells with allergen for longer than 14 days. 
This approach was not necessary in the current study since tetramer-positive 
populations were readily detectable at day 14 without the need for restimulation. 
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The next objective was to establish the most effective stimulus that would produce the 
largest tetramer-positive populations, thereby improving the sensitivity of detection of 
epitope-specific CD4
+
 T cells. This was carried out by comparing the tetramer-positive 
populations following stimulation with either whole protein Phl p 5b or with Phl p 5b-
derived peptide 26. In this study, peptide stimulation gave the highest percentage of 
tetramer-positive CD4
+
 T cells as compared to stimulation with whole protein. 
Previously Macaubas and co-workers (2006) showed little difference in the size of 
tetramer-positive populations observed following protein or peptide stimulation. In 
contrast, Wambre et al., (2008) found that peptide stimulation was better than whole 
protein stimulation. However, Wambre et al., also showed that peptide stimulation 
could be further enhanced by using a conjugate peptide mix comprising both complete 
and serially truncated versions of their immunodominant peptide coupled to the Ii-Key 
peptide, shown to facilitate peptide exchange and binding on HLA class II molecules. In 
this study the difference in size of the tetramer-positive population between protein and 
peptide stimulated cultures was greater than that observed by Wambre et al., and so it 
was not considered necessary to use additional reagents to boost expansion of epitope-
specific CD4
+
 T cells.  
 
Previously, Upham and colleagues (1995) demonstrated that use of serum-free medium 
substantially improved the expansion and detection of allergen-specific T cells over the 
use of medium supplemented with human AB serum.  For this reason, the effect of cell 
culture medium supplemented with 10% AB serum or serum-free medium upon CD4
+
 T 
cell expansion was compared. In this study, cell culture with serum-free medium, AIM-
V, did not enhance the expansion of tetramer-positive CD4
+
 T cells. Indeed, detection of 
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tetramer-positive cells from these cultures was markedly impaired compared to culture 
in AB serum-containing media.  
 
The final objective of the optimisation experiments was to establish if different starting 
cell populations differentially improved tetramer-positive cells expansion. Three 
conditions were compared: whole PBMC, isolated CD4
+ 
T cells plus adherent cells or 
isolated CD4
+
CD25
-
 T cells plus adherent cells. Since allergen-specific CD4
+
 T cells 
are present at low frequencies in the periphery, it was hypothesised that enrichment of 
the CD4
+
 T cell population prior to in vitro expansion could increase the allergen-
specific precursor cell frequency within the culture well. Adherent cells were included 
in these cultures to act as APCs. Previous studies investigating antigen-specific CD4
+
 T 
cell populations with HLA class II tetramers have successfully expanded allergen-
specific cells by isolating CD4
+
 T cells and culturing with adherent CD4
-
 cells (James et 
al., 2007; Roti et al., 2008). However, in this study, CD4
+
 T cell enrichment did not 
enhance the expansion of tetramer-positive cells. Possible explanations for this include 
inefficient antigen presentation by adherent cells or compromised CD4
+
 T cell viability 
due to the enrichment process.  
 
Removal of regulatory T cells (CD4
+
CD25
+ 
T cells; Tregs) has previously been shown 
to enhance the proliferation of CD4
+
CD25
-
 T cells in studies investigating both 
autoreactive and allergic CD4
+
 T cell responses to antigen (Danke et al., 2004; Ling et 
al., 2004; Yang et al., 2006a). In preliminary experiments performed in this study, 
depletion of Tregs did not enhance CD4
+
 T cell proliferation to peptide. Human T cells 
express CD25 at varying levels and removal of Tregs based on CD25 expression may 
also have depleted activated T cells. Although samples were analysed outside of the 
grass pollen season and allergen-specific CD4
+
 T cells are unlikely to be activated, the 
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difference in CD25 expression alone is insufficient to fully differentiate between 
activated (CD25
intermediate
) and regulatory T cells (CD25
high
). Efficient depletion of Tregs 
cells requires a more stringent isolation protocol relying on additional cell surface 
markers such as CD127 (Skrindo et al., 2008) or CD39 (Mittag et al., 2010).  
 
Having optimised the conditions for in vitro detection of tetramer-positive CD4
+
 
populations the next objective was to determine the extent to which the identified 
epitopes were recognised by grass allergic subjects. The data show that following in 
vitro expansion with Phl p 5b-derived p26, distinct p26 tetramer-positive cells were 
detectable in 7 of 8 subjects.  Furthermore, after in vitro expansion with Phl p 1- derived 
p20, 6 of 8 allergic donors had distinct p20 tetramer populations. This contrasted with 
tetramer guided epitope mapping (TGEM, described and discussed in Chapter 3) where 
only one of three donors showed a positive signal for p26. The two donors, in whom 
TGEM was initially performed and p26 not identified as an epitope, subsequently 
showed detectable p26 tetramer-positive CD4
+
 T cell populations following the in vitro 
expansion protocol used in this study. This illustrates that TGEM may miss important 
epitopes in individual cases as previously discussed in Chapter 3, and highlights the 
importance of screening for epitopes in multiple subjects and HLA class II transgenic 
mouse studies.   
 
Apparent differences in the sensitivity of these approaches may be attributed to various 
factors. Firstly, a cryopreservation step was used before TGEM whereas the samples 
used in this study were cultured immediately following isolation from whole blood. The 
freeze-thawing process might have affected the viability of T cells resulting in epitope-
specific T cell death. Additionally, the culture system for TGEM uses CD4
+
 T cells plus 
adherent cells. As previously discussed, this study has found that optimal expansion of 
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epitope-specific CD4
+
 T cell population was when whole PBMC cultures were used; 
therefore during in vitro expansion for TGEM potential epitope-specific CD4
+
 T cells 
could have been lost. The data illustrate that immunodominant epitopes, once identified, 
have the potential to be recognised by most, if not all HLA-DR1 allergic subjects.  
 
Following identification of epitope-specific T cells in allergic individuals, subsequent 
experiments addressed the presence of epitope-specific T cells in non-allergic subjects. 
In this study, following in vitro expansion, tetramer-positive CD4
+
 T cells were detected 
from both allergic and non-allergic subjects, however, the frequency of these cells was 
significantly lower in non-allergic subjects.  
 
Earlier studies failed to find tetramer-positive CD4
+
 T cells from cultures obtained from 
non-allergic donors (Macaubas et al., 2006). However, other studies (Van Overtvelt et 
al., 2008; Wambre et al., 2008, 2011; Kinnunen et al., 2010) have since demonstrated 
tetramer-positive populations from non-allergic donors following in vitro expansion, 
albeit at a lower frequency than in allergic subjects. Kinnunen et al., (2010) 
demonstrated that whilst detectable, naïve epitope-specific cells from non-allergic 
individuals displayed a lower avidity for tetramer than cells isolated from allergic 
individuals. If epitope-specific CD4
+
 T cells from non-allergic individuals are of lower 
avidity there is the potential for them to be missed by tetramers. When Macaubas et al., 
(2006) failed to identify tetramer-positive cells from non-allergic donors they used a 
comparatively short in vitro expansion protocol. Additionally, Van Overtvelt and 
colleagues (2008) reported that detection of tetramer-positive cells from non-allergic 
donors required a longer, two to three week, in vitro stimulation with allergen as 
compared to allergic donors. Possible explanations for the difference between the 
frequency of tetramer-positive populations between allergic and non-allergic donors 
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could therefore be due to a low frequency of epitope-specific CD4
+
 T cells in non-
allergic donors, a reduced avidity for the tetramer by epitope-specific CD4
+
 from non-
allergic individuals or due to impaired proliferative capacity of these cells in non-
allergic donors (for example due to the presence of functional regulatory T cells).  The 
mechanisms that result in a higher frequency of epitope-specific CD4
+
 T cells in allergic 
individuals after in vitro expansion remain to be elucidated; there is evidence for 
dysfunction of regulatory T cells (Grindebacke et al., 2004; Ling et al., 2004; Thunberg 
et al., 2007) and reduced numbers of regulatory T cells in allergic individuals (Han et 
al., 2010), which may contribute to the different responses observed between allergic 
and non-allergic individuals. 
 
In summary, immunodominant epitopes identified by epitope mapping studies are 
recognised by both allergic and non-allergic individuals following optimised in vitro 
expansion. Tetramer-positive cells were present at a higher frequency in allergic 
individuals as compared to non-allergic individuals which highlights the need for 
further investigation and characterisation in the context of grass pollen allergy.  
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4.3.2. Ex vivo investigation and characterisation of tetramer-positive CD4+ T cells 
Having investigated tetramer-positive populations in allergic and non-allergic subjects 
from PBMC cultures, the next objective was to use HLA class II tetramers to directly 
characterise epitope-specific CD4
+
 T cells immediately ex vivo i.e. without in vitro 
expansion. 
 
MHC class II tetramers have previously been used to enrich antigen-specific CD4
+
 T 
cells. Day et al.,(2003), Lucas et al., (2004) and Scriba et al., (2005) all employed MHC 
class II tetramers to identify and characterise virus-specific CD4
+
 T cells immediately 
ex vivo by staining freshly isolated PBMC with tetramer conjugated to PE, and then 
enriching the tetramer-positive cells using anti-PE magnetic beads in conjunction with a 
magnetic column. Recently this method was used to isolate and characterise allergen-
specific CD4
+
 T cells from cat-allergic subjects (Kwok et al., 2010) and peanut-allergic 
subjects (DeLong et al., 2011). This technique enabled quantification of allergen-
specific CD4
+
 T cells at low frequencies in addition to direct characterisation of surface 
marker expression on the cells.  
 
In this study, attempts to enrich tetramer-positive CD4
+
 T cells were only partially 
successful, because the cell yields obtained after column enrichment were too small to 
enable further characterisation of tetramer-positive cells. However, analysis of a pre-
enrichment sample of tetramer-labelled PBMC led to the unexpected observation that 
discrete tetramer-positive populations were identifiable, albeit at low frequencies. 
Consequently, subsequent analyses of tetramer-positive cells were performed without 
enrichment. 
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Following identification of tetramer-positive CD4
+
 T cells immediately ex vivo, the next 
objective was to perform exploratory studies examining the influence of natural grass 
pollen exposure and allergic status on the frequency of these cells. Detection of 
tetramer-positive CD4
+
 T cells immediately ex vivo in allergic and non-allergic samples 
has been demonstrated for several allergens including Fel d 1(Bateman et al., 2006; 
Kwok et al., 2010), Ves v 5 (Aslam et al., 2010) and Ara h 1 (DeLong et al., 2011) (cat, 
wasp and peanut, respectively). The experiments presented here were undoubtedly 
limited by the low numbers of HLA-DR1 subjects recruited at the time of analyses. 
Nevertheless, these experiments demonstrated in principle that grass pollen-specific 
CD4
+
 T cells are detectable by tetramers directly ex vivo in non-allergic individuals. In 
addition, when allergic and non-allergic subjects were combined, the frequency of p26-
specific CD4
+
 T cells increased during the grass pollen season. These data are broadly 
consistent with previous studies evaluating seasonal effects upon allergen-specific CD4
+
 
T cell frequencies (Wambre et al., 2008).  
 
In summary, although subject to further confirmation in future studies, these data 
suggest that p26- and p20-specific CD4
+
 T cells are present in non-allergic subjects. 
However, in contrast to allergic subjects these cells expand poorly following in vitro 
stimulation with peptide, suggesting that natural tolerance may be particularly 
associated with immunoregulation of allergen-specific T cell responses. Such a concept 
is supported by previously published work showing that grass pollen allergy is 
associated with a relative deficiency of Treg cells as determined in conventional 
proliferation assays (Ling et al., 2004). 
 
Following the identification and evaluation of the frequency of tetramer-positive CD4
+
 
T cells immediately ex vivo, the next aim of the study was to characterise these allergen-
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specific cells according to the expression of cell surface markers correlated with the 
function of CD4
+
 T cells. To date, only three studies have investigated the immediate ex 
vivo phenotype of allergen-specific CD4
+
 T cells, using Ara h 1-peptide loaded 
tetramers in peanut-allergic subjects (DeLong et al., 2011) and Fel d 1-peptide loaded 
tetramers in cat-allergic subjects (Bateman et al., 2006; Kwok et al., 2010). Following 
immediate ex vivo labelling with tetramer, the surface expression of phenotypic markers 
was compared between tetramer-positive CD4
+
 T cells and the whole CD4
high
 T cell 
population. Data presented here are for tetramer-positive CD4
+
 T cells isolated from 
allergic individuals only; further investigations will be required to characterise surface 
phenotype in relation to non-allergic individuals.  
 
In this study, ex vivo p26 tetramer-positive cells exhibited a memory phenotype as 
shown by reduced expression of the naïve cell marker CD45RA. This observation 
agrees with data presented by Kwok et al., (2010) for Fel d 1-tetramer-positive CD4
+
 T 
cells and DeLong et al., (2011) for Ara h 1-tetramer-positive CD4
+
 T cells.  Differential 
expression of CCR7 and CD62L can distinguish between „central‟ and „effector 
memory‟ cell phenotypes (Sallusto et al., 1999). Data presented here suggest decreased 
CCR7 expression on both p26 and p20 tetramer-positive cells and decreased CD62L 
expression on p26 tetramer-positive cells as compared to the whole CD4
high
 T cell 
population. These findings are suggestive of an „effector memory‟ phenotype. Previous 
ex vivo tetramer analyses of Fel d 1-specific CD4
+ 
T cells identified tetramer-positive 
cells as central memory cells  i.e. expressing high levels of CCR7 and CD62L (Bateman 
et al., 2006; Kwok et al., 2010). However, Bateman et al., (2006) also observed a 
smaller percentage of tetramer-positive cells that displayed an effector memory 
phenotype i.e. expressing low levels of CCR7 and CD62L. Effector memory cells are 
characterised by poor proliferative ability but potent effector function (Sallusto et al., 
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2004). Therefore, the tetramer-positive CD4
+
 T cells identified in this study may 
represent a population of circulating allergen-specific cells that may be recruited to the 
site of allergic inflammation, and release effector cytokines in response to activation. In 
a recent study, Wambre et al., (2011) showed differences between the memory 
phenotype of CD4
+
 T cells expanded from birch and house dust mite allergic 
individuals. Persistent, chronic exposure of allergic individuals to house dust mite 
produced CD4
+
 T cells with a central memory phenotype whilst transient, seasonal 
exposure to birch pollen gave rise to an effector memory phenotype. This observation 
may explain the differences between the memory phenotypes determined in previous ex 
vivo analyses of tetramer-positive CD4
+
 memory cells and the current study. Due to 
chronic exposure to cat allergen, tetramer-positive CD4
+
 T cells from cat-allergic 
individuals, display a central memory phenotype (Bateman et al., 2006; Kwok et al., 
2010). Whilst following seasonal exposure to grass pollen, tetramer-positive CD4
+
 T 
cells from grass-allergic individuals, are characterised by an effector memory 
phenotype. 
 
Previous studies of ex vivo tetramer-labelled CD4
+
 T cell phenotypes showed that CCR4 
expression was enriched on tetramer-positive cells isolated from allergic individuals 
(Bateman et al., 2006; Kwok et al., 2010; DeLong et al., 2011). In the current study, 
CCR4 expression was higher on p26 tetramer-positive cells than in the whole CD4
high
 
population. This was not seen with p20 tetramer-positive cells. In addition to CCR4 
expression, higher expression of CCR3 was found on p26 and p20 tetramer-positive 
cells when compared to the whole CD4
high
 population. CCR4 and CCR3 are Th2 cell 
markers known to be over-expressed in allergic disease (Sallusto et al., 1997; Bonecchi 
et al., 1998; Panina-Bordignon et al., 2001; Till et al., 2001; Morgan et al., 2005; 
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Francis et al., 2007) and expression of these chemokine receptors is associated with the 
trafficking of Th2 cells to non-lymphoid sites.  
 
CCR5 and CXCR3 were also expressed at a higher level on p20 tetramer-positive cells 
as compared to the whole CD4
high
 T cell population, in contrast to the data obtained for 
p26 tetramer staining. CCR5 and CXCR3 are classically associated with a Th1 
phenotype (Qin et al., 1998). Both mRNA and protein for Regulated upon Activation, 
Normal T-cell Expressed, and Secreted (RANTES)/C-C chemokine ligand (CCL) 5, a 
ligand for CCR5, have been shown to be up-regulated in the nasal mucosa and skin 
following allergen challenge of grass-allergic individuals (Ying et al., 1995; 
Rajakulasingam et al., 1997). Therefore, the increased expression of CCR5 on p20 
tetramer-positive CD4
+
 T cells may represent a mechanism for recruitment of these cells 
to the site of allergic inflammation. The findings presented in this thesis are novel since 
previous studies have demonstrated reduced CXCR3 expression on tetramer-positive 
cells from allergic individuals following both in vitro stimulation (Van Overtvelt et al., 
2008; Kinnunen et al., 2010) and ex vivo analysis (Kwok et al., 2010). It is also 
possible, however, that p20 tetramer-positive CD4
+
 T cells display a Th1 phenotype 
since epitopes from different allergen groups have been associated with different T cell 
responses (Oseroff et al., 2010). 
 
A limitation of the analyses presented in this thesis is that phenotyping was based on 
analyses of very small numbers of cells. In part this reflects to the technical need to 
divide samples after tetramer staining for cell surface marker counterstaining. To 
circumvent this, the four-colour analysis used in this work could be expanded to include 
more colours. Labelling for multiple cell surface markers per sample would not only 
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reduce the amount of tetramer-labelled sample required but also enable evaluation of 
cell surface marker co-expression. 
 
In summary, allergen-specific CD4
+
 T cells from allergic and non-allergic individuals 
were identified immediately ex vivo, enabling determination of the frequency of 
tetramer-positive cells in the peripheral blood of subjects and characterisation of the 
surface phenotype of these cells in allergic individuals. The data suggest that tetramer-
positive CD4
+
 T cells have an effector memory phenotype although phenotypic 
differences may arise according to the precise grass pollen allergen epitope recognised 
by individual T cells.  
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4.3.3. Characterisation of peptide-specific CD4+ T cell populations 
The aim of this section to was to characterise the cytokine responses of T cells in 
relation to the immunodominant epitopes identified. Stimulation of PBMC with whole 
Phleum pratense grass pollen extract or the major allergens resulted in significantly 
more IL-5 in allergic than in non-allergic subjects, as measured by ELISA. IL-5 was 
selected as it is a prototypical Th2 cytokine, and because it is technically easier to detect 
than IL-4.  In order to minimise effects of antigen concentration on cytokine profile, two 
concentrations of p26 and p20 were selected (Carballido et al., 1992; Secrist et al., 
1995). Nevertheless, there was no substantial IL-5 production detected by ELISA 
following peptide stimulation. The production of the prototypical Th1 cytokine, IFN-γ 
was also measured by ELISA. However, no substantial IFN-γ production could be 
detected from PBMC cultures of allergic or non-allergic subjects, following stimulation 
with peptides or the control antigen, PPD. 
 
Consistent with the findings from ELISA, Fluorospot assays demonstrated that 
stimulation of PBMC with whole Phleum pratense grass pollen extract gave rise to a 
Th2 response with significantly higher frequencies of IL-5- and IL-4-producing cells in 
allergic than in non-allergic subjects.  
 
On stimulation with whole grass pollen extract, the frequency of IL-10-producing cells 
was slightly increased in PBMC cultures from allergic subjects than those from non-
allergic donors. This was unexpected given the inhibitory properties/function associated 
with IL-10. Some previous studies have reported higher expression of IL-10 in non-
allergic than allergic subjects (Jutel et al., 2003; Akdis et al., 2004). Supporting the data 
presented here, Domdey and co-workers (2010) have demonstrated IL-10 production by 
allergic PBMC, but minimal IL-10 production by non-atopic control donors following 
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stimulation with Phl p 1 and Phl p 5. Moreover, blocking IL-10 decreased both allergen-
induced proliferation and cytokine production in allergic but not control cultures. 
Additionally, Robinson and colleagues (1996) observed increased IL-10 mRNA in 
bronchoalveolar lavage cells of asthmatic subjects as compared to controls. They also 
saw that the percentage of IL-10 mRNA-positive cells was increased in asthmatics 
following allergen challenge (Robinson et al., 1996). During the peak grass pollen 
season, Nouri-Aria et al., (2004) observed a low frequency of IL-10 mRNA positive T 
cells in the nasal mucosa of non-allergic subjects. It is possible, therefore, that IL-10 is 
not involved in the regulation of the non-atopic response to allergen and that other 
mechanisms of tolerance dominate in healthy individuals. 
 
In this thesis, ex vivo analyses of cytokine secretion produced signals that were not 
sufficiently robust to enable a detailed differentiation of the allergic and non-allergic 
response to allergen-derived peptide stimulation. A possible reason for the weak signals 
obtained is the paucity of allergen-derived peptide-specific T cells in the periphery. A 
poorly reproducible ex vivo cytokine response to Phleum pratense allergen-derived 
peptides was also observed by Oseroff et al., for whom implementation of an in vitro 
restimulation step enhanced detection of cytokine production (Oseroff et al., 2010). 
Therefore, it is likely that in vitro expansion with peptide, prior to cytokine detection 
would enhance the data obtained in the current study, thus enabling delineation between 
the allergic and non-allergic response to allergen-derived peptide stimulation.   
 
Intracellular cytokine staining was also attempted to explore the cytokine expression 
profiles of CD4
+
 T cells, shown to be proliferating to p26 or p20 by CFSE dilution. 
However, only IFN-γ production was detectable following PPD and p26 stimulation of 
allergic and non-allergic samples. Th2 cytokines were not detected and this approach 
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was therefore not pursued further. Further experiments will be required to investigate 
the differences between the allergic and non-allergic responses to these 
immunodominant allergen-derived peptides.  
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4.4. Summary 
The aim of work carried out in this Chapter was to characterise CD4
+
 T cell responses 
to the immunodominant epitopes identified in Chapter 3 using optimised cultures and 
HLA-DR1 tetramers loaded with peptides. The optimised in vitro expansion conditions 
were peptide stimulation of whole PBMC for 14 days in AB serum-containing medium 
with an expansion in IL-2. Using this method, discrete tetramer-positive populations 
were detected for both Phl p 1 peptide 20 and Phl p 5b peptide 26 in the majority of 
allergic subjects. Tetramer-positive CD4
+
 T cells were also detectable in non-allergic 
subjects although in fewer individuals and at a lower frequency than in allergic subjects.  
 
Using HLA-DR1 tetramers, epitope-specific CD4
+
 T cells were detectable immediately 
ex vivo from both allergic and non-allergic donors. However, small sample sizes 
preclude direct comparison of the frequency of tetramer-positive cells between allergic 
and non-allergic subjects. The surface phenotype of tetramer-positive CD4
+
 T cells was 
characterised immediately ex vivo in allergic subjects. Both p20 and p26 tetramer-
positive populations displayed characteristics of an effector memory phenotype with 
low CCR7 and CD62L expression. Expression of CCR4 and CCR3 on p26 tetramer-
positive cells also indicated a Th2 phenotype. 
 
Finally, cytokine expression profiles following stimulation with p20 or p26 in allergic 
and non-allergic cultures were determined. Data obtained were weak; however, they 
suggest that whilst PBMC from non-allergic donors were unresponsive to peptide 
stimulation, PBMC from allergic donors displayed increased frequencies of Th2 
cytokine-producing cells and Th2 cytokine production. Together, these data highlight 
p20 and p26 epitope-specific CD4
+
 T cells as potential therapeutic targets in HLA-DR1
+
 
individuals with grass pollen allergy.  
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5. General Discussion 
5.1. Designing a grass pollen-derived peptide-based vaccine for 
immunotherapy 
Grass pollen allergy is associated with exposure to numerous grass species, each 
containing multiple allergens and isoallergens (Chabre et al., 2010). Although 
conventional immunotherapy with a single grass species such as Phleum pratense is 
effective (e.g. (Frew et al., 2006)) this may reflect extensive cross-reactivity of 
immunotherapy-induced IgG for major allergens (Hejl et al., 2009). In contrast, 
although Hejl and colleagues also demonstrated extensive T cell cross-reactivity for 
Pooideae Group 1 and 5 allergens, the extent of post-immunotherapy Treg cell cross-
reactivity has not been tested. Although T cell peptide vaccines can induce IL-10-
producing Tregs (Campbell et al., 2009), the extent of IgG4 induction by such vaccines, 
if any, has not been reported. Therefore, implicit in the development of a T cell-vaccine 
based on a limited number immunodominant epitopes is the hypothesis that these 
selected epitopes will induce sufficiently robust Treg responses to confer 
immunological tolerance towards multiple whole allergen proteins. Such mechanisms, 
called „linked suppression‟ or „bystander tolerance‟, have been described in both human 
and animal models of peptide-induced tolerance towards a range of allergens (Briner et 
al., 1993; Hoyne et al., 1993; Bauer et al., 1997; Astori et al., 2000; Campbell et al., 
2009). The data presented in this thesis provides the foundation for testing these 
concepts in a grass pollen allergy model. 
 
Insufficient published data is currently available on the identity of grass allergen T cell 
epitopes to design a peptide vaccine for testing. T cell epitope identification is an 
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essential step in testing the hypothesis that administration of limited immunodominant 
epitopes will induce „linked suppression‟ or „bystander tolerance‟ to whole grass pollen. 
A number of different approaches have been developed in order to identify 
immunodominant T cell epitopes. T cell epitopes for Phl p1 and Phl p 5 have previously 
been described following analysis of T cell lines and T cell clones derived from grass 
allergic individuals (Schenk et al., 1995; Müller et al., 1998b; Oseroff et al., 2010).  In 
this thesis, complementary methods were employed for epitope identification. These 
included in silico HLA-DR epitope prediction algorithms, HLA-DR tetramer guided 
epitope mapping and analysis of an HLA-DR transgenic mouse model. The major 
advantage of using a combination of methods is that identification of an epitope by all 
approaches considerably strengthens the evidence for that being epitope being truly 
immunodominant.  
 
The majority of experimental epitope mapping approaches are expensive and time 
consuming. Use of in silico prediction algorithms complements experimental studies 
and enables the downsizing of experimental approaches thus accelerating the epitope 
identification process. The prediction algorithms used in this thesis were selected 
according to recent performance reviews of HLA class II prediction programs therefore 
represent the most reliable in silico predictions currently available (Lin et al., 2008; 
Wang et al., 2008, 2010). 
 
The need for complementary approaches towards epitope identification is highlighted 
by epitope mapping studies of the major mugwort allergen, Art v 1. Initial in silico 
prediction did not highlight the single immunodominant epitope within this allergen as a 
high-affinity HLA-DR1-binding peptide. However, following analyses of T cell 
responses in vitro, HLA-DR1 was shown to be the major restricting allele for this 
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epitope (Jahn-Schmid et al., 2002, 2008). Additionally, HLA-DR4 was shown by in 
vitro analyses to present the same epitope but in silico prediction algorithms indicated 
that the epitope would not bind HLA-DR4 (Jahn-Schmid et al., 2011). This example 
clearly demonstrates that whilst effective tools for initial epitope prediction, in silico 
prediction algorithms are not sufficient to identify all biologically relevant epitopes and 
highlights the requirement for experimental identification and validation of disease 
relevant epitopes.   
 
Epitope mapping with PBMC cultures is intrinsically complex due to the low precursor 
frequency of allergen-specific CD4
+
 T cells in the periphery. Whilst T cell lines or 
clones from atopic individuals can be generated in order to screen panels of allergen-
derived peptides, in vitro expansion may introduce a bias in the T cell response to 
allergen due to the selection of T cell clones during the cloning process (van Neerven et 
al., 1996). Use of the HLA-DR1 transgenic mouse model in this study provided a 
abundant source of allergen-specific T cells following immunisation with Phl p 1 or Phl 
p 5, thereby enabling immediate ex vivo analyses of T cell responses to allergen-derived 
peptides without in vitro expansion. 
 
A major limitation of using T cell epitope-containing peptides for immunotherapy is the 
prerequisite of HLA-restriction for T cell activation and the polymorphism of the HLA 
class II peptide-binding groove. Unlike previous epitope mapping studies for Phl p 1 
and Phl p 5, the current study was designed to only identify HLA-DR1-restricted 
epitopes. Limiting epitope identification to one individual restricting HLA allele 
enabled a streamlined approach to epitope mapping and the application of allele-specific 
reagents. The use of HLA-DR1 tetramers enabled the identification and characterisation 
of immunodominant T cell epitopes on a single cell level.  Additionally, epitope 
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identification was further enhanced by the HLA-DR1 transgenic mouse model which 
enabled the analysis of T cell responses in the context of one individual HLA allele, 
24% of the population express HLA-DR1 (Meyer et al., 2007; Gonzalez-Galarza et al., 
2010). This approach should be expanded to encompass all HLA-DR molecules so 
epitopes for grass pollen disease that are not HLA-DR1-restricted are not missed. It is a 
long term objective of Boyton/Till to do this, but was not possible during the timescale 
of this PhD. 
 
5.2. Should a peptide-based vaccine comprise an individual peptide 
with HLA binding promiscuity or peptides tailored to each HLA? 
Due to polymorphism of the HLA class II peptide-binding groove and the diverse 
expression of HLA class II alleles within the population, there is a degree of 
heterogeneity in the patterns of T cells epitopes recognised by different individuals. 
Thus an epitope that is immunodominant in one individual may not be 
immunodominant in another individual with an alternative HLA genotype. Conversely, 
some epitope sequences show inherent promiscuity, displaying the ability to bind a 
number of different HLA molecules. Therefore, in order to target as broad a population 
as possible a peptide-based vaccine could either contain 1) a small number of highly 
promiscuous epitopes that may bind to multiple HLA alleles or 2) a larger number 
epitopes, each able to bind to separate HLA alleles, but with less of an emphasis on 
promiscuity. To date, peptide vaccines for cat and bee venom allergy have included 
multiple peptides, often encompassing the majority of the allergen sequence (Müller et 
al., 1998a; Oldfield et al., 2002). Initially these peptides were selected without 
considering HLA-restriction. However, using data from HLA binding assays, these 
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preparations have undergone some refinements to include only those peptides providing 
the best population coverage (Texier et al., 2000; Worm et al., 2011). 
 
The data obtained in this study suggest that peptide 20 of Phl p1 and peptide 26 of Phl p 
5b are HLA-DR1-restricted epitopes. However, it was not determined whether these 
peptides demonstrate alternative HLA-restriction. Analyses of HLA-binding studies by 
Sidney et al., (unpublished) suggest that peptide 20 and peptide 26 would likely display 
promiscuous binding to additional HLA-DR haplotypes. However, as discussed in a 
previous chapter, high-affinity binding to HLA is insufficient alone to prove T cell 
recognition. Thus in vitro validation of this promiscuity will be required using in 
models employing T cells responses as readouts. The work in this thesis focused on 
HLA-DR1-restricted T cell epitopes, reflecting the hypothesis that peptide vaccines will 
likely focus on promiscuous epitopes for reasons of pragmatism. This rationale is also 
supported by Oseroff  and colleagues, who observed that promiscuous HLA-binding 
capacity is associated with the more prevalent Phleum pratense epitopes i.e. that it is the 
promiscuous nature of an epitope which determines its dominance in the immune 
response (Oseroff et al., 2010). The host lab has now obtained peptide binding data for 
peptide 26 across the human class II and confirmed that is a promiscuous binder across 
several HLA class II molecules. 
 
5.3. Refining the epitopes 
The candidate immunodominant HLA-DR1-restricted CD4
+
 T cell epitopes identified in 
this study overlap with epitope regions identified by previous epitope mapping studies 
(Schenk et al., 1995; Müller et al., 1998b; Oseroff et al., 2010). However, the minimal 
peptide and amino acids that are essential for T cell activation have yet to be described. 
The identification of these residues, using truncated peptide or alanine scanning 
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mutagenesis techniques, will enable the fine characterisation of the interaction between 
peptide 20 and peptide 26 with the TCR, as previously been performed for Art v 1 and 
Lol p 5 (Burton et al., 1999; Jahn-Schmid et al., 2005). Identification of the core 
residues for peptide/HLA-TCR interaction may assist in the design of immunodominant 
peptide analogues that induce specific T cell responses and enable peptide binding to 
multiple HLA haplotypes (Texier et al., 2002). 
 
Altered peptide ligands (APLs), i.e. peptides in which amino acids substitutions have 
been introduced in to native sequence, have the potential to modify T cell responses by 
altering T cell proliferation and cytokine expression profiles (Sloan-Lancaster and 
Allen, 1996). APLs can act as agonists, partial agonists, superagonists or antagonists to 
TCR signalling (Sloan-Lancaster and Allen, 1996). In vitro studies have demonstrated 
that administration of APLs modulates T cell responses to allergen. Faith and colleagues 
investigated the effect of APLs on bee venom-specific T cell responses (Faith et al., 
1999). When compared to natural peptide, stimulation of PLA2-specific T cell clones 
with certain APLs led to reduced proliferation and cytokine production (Faith et al., 
1999). In addition, APL stimulation could induce IgG4 production in PBMC cultures. In 
a study evaluating the potential of APL-based immunotherapy for an immunodominant 
T cell epitope of Bos d 2 (a major cow allergen), Kinnunen and colleagues 
demonstrated immune deviation towards a Th1/Th0 T cell phenotype upon T cell line 
stimulation with an APL, as compared to a Th2/Th0 T cell phenotype following natural 
peptide stimulation (Kinnunen et al., 2007).  T cells recognising the APL were also 
cross-reactive to the natural peptide. The authors proposed that APL-specific T cells 
may potentially mediate bystander suppression following activation by the natural 
peptide upon secondary allergen exposure (Kinnunen et al., 2007). They also suggested 
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that APL immunisation may lead to induction of Treg populations that would also 
modulate the immune response (Kinnunen et al., 2007).  
 
In the clinic, administration of an APL of an immunodominant epitope of myelin basic 
protein was evaluated for the treatment of multiple sclerosis (Bielekova et al., 2000; 
Kappos et al., 2000). However, due to reports of adverse events and hypersensitivity 
reactions, the trial was terminated before demonstration of any clinical efficacy 
(Bielekova et al., 2000; Kappos et al., 2000). There are also examples of unwanted 
complications from animal models: Smith and colleagues reported induction of fatal 
anaphylaxis following administration of a peptide-based vaccine against pneumococcal 
disease in mice (Smith et al., 2011). In that study, peptide-specific IgE antibodies were 
generated during primary immunisation. Together these studies demonstrate that the 
administration of synthetic epitopes can elicit immune response that are damaging to the 
recipient and thus serves as a caution for future similar peptide-based immunotherapy 
strategies.  
 
5.4. Possible approaches to reduce the IgE-mediated side-effects of 
specific immunotherapy - alternatives to allergen-derived peptides 
 Chemically or genetically-modified allergens that reduce IgE binding but which 
preserve T cell epitopes represent an alternative strategy for reducing IgE-mediated 
side-effects. Denaturation of allergens with aldehydes is used to generate allergoids 
(Marsh et al., 1970), which are commercially available for immunotherapy in the 
European Union (Walker et al., 2011). Grass pollen allergoids are clinically effective 
when given as pre-seasonal immunotherapy (Drachenberg et al., 2001; Corrigan et al., 
2005) and induce grass pollen allergen-specific IgG antibodies, indirectly implying the 
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induction of IL-10 producing Tr1 cells. Increased adverse events were reported in the 
actively-treated groups compared to placebo by both studies. Treatment efficacy with 
allergoid immunotherapy was assessed by measurement of symptom and medication 
scores. Drachenberg and colleagues reported improved symptom scores for the actively-
treated group after a month of treatment however, no difference was observed between 
the two groups for medication scores (Drachenberg et al., 2001). Corrigan and 
colleagues reported improved combined symptom and medication scores for the two 
grass pollen seasons investigated furthermore, scores for the second season were higher 
than those observed in the first (Corrigan et al., 2005). Improvements in symptom and 
medication scores following conventional SIT are well-documented and furthermore 
have been shown to be long-lasting (Durham et al., 1999; Walker et al., 2001; Frew et 
al., 2006).  
 
Local adverse events were recorded in 80% (Drachenberg et al., 2001) and 19% 
(Corrigan et al., 2005) of patients, whilst systemic adverse events experienced by 17% 
(Drachenberg et al., 2001) and 7% (Corrigan et al., 2005) of patients.  These were at a 
frequency comparable to adverse events reported in trials with SCIT with whole 
allergen extract (Varney et al., 1991; Walker et al., 2001; Frew et al., 2006) suggesting 
little, if any, additional safety benefit. The allergoid preparation therefore retained the 
potential to initiate IgE-mediated systemic reactions most likely due to incomplete 
disruption of IgE epitopes following grass pollen allergen exposure to aldehydes. The 
degree of allergen modification following aldehyde exposure is dependent upon the 
primary amino acid sequence of the protein since only N-terminal lysine resides are 
modified. In contrast, allergen-derived peptides would be selected such that they 
completely lack IgE epitopes, thus obviating the possibility of IgE-mediated side-
effects.   
 283 
 
To date, clinical studies comparing conventional SIT and allergoid immunotherapy have 
not been performed. However, Henmar and colleagues recently compared the 
allergenicity, immunogenicity and dose-relationships of whole allergen extract and 
allergoid vaccines for grass pollen immunotherapy (Henmar et al., 2008). Whilst the 
allergoid vaccines mostly demonstrated reduced allergenicity measured by IgE-
inhibition and basophil activation assays, this was correlated with reduced 
immunogenicity investigated by human T cell line proliferation and specific IgG-titres 
following murine immunisation. Thus the preparation of allergoids may compromise 
their ability to induce Treg responses, unlike with the peptide approach. 
 
Recombinant DNA technology has also been employed to reduce the allergenicity of 
allergen extracts generating recombinant hypoallergenic allergen derivatives (Focke et 
al., 2010). Reduction of the IgE binding capacity of these recombinant hypoallergens is 
achieved though modification of allergen-encoding cDNA sequences by site-directed or 
random mutation, deletion, fragmentation, oligomerisation, chemical modification and 
fusion of allergen variants (Focke et al., 2010). Recombinant hypoallergens have been 
investigated clinically for treatment of birch pollen allergic disease in only a few small 
trials (Niederberger et al., 2004; Purohit et al., 2008) Unfortunately these data do not yet 
allow us to compare the efficacy and safety profile of this approach to whole extract 
immunotherapy (Niederberger et al., 2004). 
 
5.5. Can B cells alone be targeted for efficient induction of antigen-
specific tolerance? 
The relative contributions of T cell- and B cell-driven mechanisms to the efficacy of 
immunotherapy are still unknown. Accordingly, the value of targeting T or B cell 
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responses individually is also open to speculation. Whilst immunotherapy targeting 
allergen-specific T cells may be associated with delayed adverse events (Haselden et al., 
1999; Purohit et al., 2008), vaccines solely targeting B cell epitopes may have the 
potential to induce IgE-mediated side-effects. Wallman and colleagues designed an 
allergen vaccine based on a single B cell epitope of Phl p 5 (Wallmann et al., 2010). The 
peptide selected acted as a mimotope, mimicking the three-dimensional B cell epitope. 
Drawing on the concept of the hapten-carrier principle, the B cell mimotope is coupled 
to a carrier molecule which contains T cell epitopes, thus driving T cell help for 
generation of a mimotope-specific B cell response (Katz et al., 1970; Paul et al., 1970). 
Immunisation of mice with the mimotope vaccine led to the development of Phl p 5-
specific IgG antibodies but did not stimulate T cell responses from Phl p 5-sensitised 
mice.  The therapeutic capacity of the mimotope vaccine to modulate the allergic 
response was demonstrated in an experimental model of allergic asthma. Following 
immunisation, a reduction in eosinophilic airway inflammation and mucus 
hypersecretion was observed (Wallmann et al., 2010). However, the functional blocking 
activity of the IgG antibodies against IgE was not assessed but clearly requires 
investigation.  Although this approach holds some promise, a further important issue to 
address is the number of mimotopes that will required for effective treatment of disease 
driven by whole pollen containing numerous IgE epitopes. 
 
5.6. Characterisation of epitope-specific CD4+ T cells 
The second aim of this thesis was to characterise grass pollen epitope-specific CD4
+ 
T 
cells according to both cell surface phenotype and cytokine expression profiles. 
Attempts to characterise the phenotype immediately ex vivo were hampered by the low 
frequency of allergen-specific T cells in peripheral blood of allergic and non-allergic 
donors. Although epitope-specific CD4
+
 T cells could be detected immediately ex vivo 
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using HLA-DR1 tetramers, attempts to enrich the tetramer-positive CD4
+
 T cell 
populations, as per previous studies by Kwok and colleagues, were only partially 
successful (Kwok et al., 2010; DeLong et al., 2011). As a result, evaluation of cell 
surface antigen expression was performed on very small cell numbers and should 
therefore be interpreted with caution. Further work will be needed to optimise the 
technology required for enrichment of tetramer-positive CD4
+
 T cell populations prior 
to analysis of cell surface antigen expression.  
 
Characterisation of the cytokine profile of epitope-specific CD4
+
 T cells was performed 
by analysis of cytokines produced following in vitro expansion of PBMC with the 
candidate epitope-containing peptides. Whilst only the allergen-specific T cells should 
be activated in response to allergen-derived peptide stimulation, it is possible that 
bystander activation of non-allergen specific T cells may occur in such cultures. 
Although the cytokine data presented is this thesis supports the biological importance of 
the epitopes identified, an ideal approach for characterising cytokine expression profiles 
of epitope-specific CD4
+
 T cells in this study might involve combining HLA-DR1 
tetramer staining with intracellular cytokine staining. However, mitogenic stimulation 
of T cells is required to boost cytokine production to levels where staining can be 
performed and such stimulation is associated with reductions in surface TCR levels, and 
therefore tetramer staining.  An alternative approach under development is the use of 
plate-immobilised HLA class II tetramer together with monoclonal anti-CD28 to 
provide co-stimulation. This technology has shown some promise in preliminary studies 
(personal communication, Professor W Kwok). Finally, epitope-specific CD4
+
 T cells 
have been characterised by sorting tetramer-positive T cell populations followed by 
analysis for gene expression relating to T cell polarisation using quantitative PCR or 
gene arrays (Van Overtvelt et al., 2008; DeLong et al., 2011). 
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5.7. Investigating the phenotypic and functional differences between 
epitope-specific CD4
+
 T cells isolated from allergic and non-allergic 
individuals 
Data were presented in this thesis regarding the identification and frequency of epitope-
specific CD4
+
 T cells in allergic and non-allergic individuals. One of the shortcomings 
of these data are the limited numbers of subjects studied. Consequently, it is not 
possible to draw firm conclusions regarding the differences of the epitope-specific 
CD4
+
 T cells between allergic and non-allergic individuals. Such data might be of value 
in further highlighting the disease-relevance of these potentially therapeutic epitopes. 
However, these experiments did provide evidence for recognition of these epitopes by 
CD4
+
 T cells in non-allergic individuals, consistent with previous tetramers studies of 
other allergens (Bateman et al., 2006; Van Overtvelt et al., 2008; Kwok et al., 2010). 
Verification of the differences between the characteristics of epitope-specific CD4
+
 T 
cell between allergic and non-allergic donors may provide further insight into the 
mechanisms of allergen-specific „natural‟ tolerance and regulation of the allergic 
response. 
 
5.8. Identification of epitope-specific CD4+ T cells in situ 
An additional use of HLA-DR1 tetramers loaded with candidate epitopes identified in 
this study could be the visualisation of epitope-specific CD4
+ 
T cells in situ. Both HLA 
class I and class II tetramers have previously used to visualise antigen-specific cells in 
live tissue sections of draining lymph nodes and central nervous system tissue of mice 
with EAE and from cryosections of human tissue from melanoma patients (Bischof et 
al., 2004; De Vries et al., 2007). Tetramer staining of biopsies from allergic subjects 
would enable some fundamental questions to be addressed about the properties of the 
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allergen-specific T cell response at the site of disease. Unfortunately, pilot experiments 
performed in our laboratory were unsuccessful at staining nasal biopsies of hay fever 
subjects (in season) with HLA class II tetramers (personal communication, Dr Stephen 
Till), since a degree of non-specific staining was also observed with negative control 
tetramers. In theory, specific tetramer staining of non-live and fixed tissue could also be 
compromised by the loss of plasma membrane fluidity, since generation of high avidity 
tetramer binding may require aggregation of surface TCRs.  
 
5.9. Is administration of a single immunodominant epitope from the 
major grass pollen allergens, Phl p 1 and Phl p 5 sufficient to induce 
tolerance to whole grass pollen?  
Having identified the HLA-DR1-restricted candidate CD4
+
 T cell epitopes it will be 
important to investigate whether administration of these epitopes is sufficient to induce 
tolerance to whole allergen and whole grass pollen extract. Phl p 1 and Phl p 5 have 
been shown to dominate the immune response in grass allergic individuals on the basis 
of IgE binding in sensitised individuals (Vrtala et al., 1993b; Laffer et al., 1994b). 
However, the relative contributions of Phl p 1 and Phl p 5 in eliciting the T cell 
responses to grass pollen are unknown. As a result it is not possible to know whether 
peptides from only Phl p 1 or Phl p 5 would be sufficient to induce tolerance if used in a 
therapeutic vaccine. In order to evaluate induction of tolerance to whole allergen, 
similar experiments to those performed by Hoyne and colleagues are warranted (Hoyne 
et al., 1993, 1997). Induction of tolerance could be investigated by analysing T cell 
proliferative responses to antigen following intranasal administration of peptide 20 or 
peptide 26 to HLA-DR1 transgenic mice and subsequent challenge with the peptide, 
whole protein or whole grass pollen extract. Furthermore, it would be possible to use 
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HLA-DR1 tetramers to isolate and compare the peptide-specific T cells from tolerised 
and non-tolerised mice. Using the HLA-DR1 transgenic model, it will be possible to 
analyse induction of tolerance to administered peptide, the individual protein and whole 
grass pollen extract and to address whether Phl p 1- or Phl p 5-derived peptides are 
sufficient to induce tolerance individually or whether a cumulative effect is observed 
following joint administration. If induction of tolerance to whole grass pollen extract is 
successful, the model could also be employed to evaluate cross-reactivity of the Phl p 1- 
and Phl p 5-mediated immune response to whole grass pollen extract from additional 
species.   
 
The tolerance induction experiments described above are already in progress in the lab 
and will determine whether the identified candidate epitopes can induce tolerance in 
naïve mice and previously sensitised animals (Hoyne et al., 1993). 
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5.10. Conclusions 
In this thesis HLA-DR1-restricted CD4
+
 T cell epitopes of the major grass pollen 
allergens, Phl p 1 and Phl p 5b, have been identified. CD4
+
 T cells specific to these 
candidate epitopes have been identified in both allergic and non-allergic individuals 
immediately ex vivo and following in vitro expansion. Thus, both Phl p 1-derived 
peptide 20 and Phl p 5-derived peptide 26 appear to be important epitopes for grass 
pollen allergic responses in HLA-DR1-positive individuals. Characterisation of the 
epitope-specific CD4
+
 T cells suggests that in allergic individuals these cells represent 
an effector memory, Th2-like T cell population. The ability of such epitopes to induce 
tolerance in grass pollen allergic disease remains to be established. However, these 
epitopes are now testable in a humanised transgenic mouse model and are strong 
candidates for inclusion in a peptide-based vaccine for treatment of grass pollen allergic 
disease. 
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